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Abstract 
 
 This work describes the development and the optimisation of microfluidic 
radiolabelling by using an Eckert & Ziegler device remotely controlled by a computer to 
perform the multistep synthesis of [18F]-fluoro-2-deoxy-D-glucose ([18F]-FDG). This device 
was then modified to control the fluidic transfers via flow of nitrogen and vacuum with the 
aid of a new one-way cassette system by using different concentrations of water for the 
Kryptofix solution. A new route was also explored to perform florbetaben ([18F]-BAY94-
9172), a potent Alzheimer’s disease PET tracer. 
 
Chapter 1 is an overview of positron emission tomography techniques to synthesise 
tracers. 
 
Chapter 2 is a brief introduction of the PETIC centre (Wales), where the fluoride-18 
was delivered to produce [18F]-FDG. 
 
Chapter 3 describes the reaction of the [K+⊂2.2.2]18F− complex on mannose triflate 
and the variety of products formed. The Eckert & Ziegler platform was furnished with a 
cassette module and a microfluidic tubing to perform the radiolabelling fluorination of 
mannose triflate to the tetraacetate [18F]-deoxy-D-glucose and [18F]-FDG. 
 
Chapter 4 is focused on the modifications on the Eckert & Ziegler modules by using 
1-way cassettes to limit the use of mechanical valves. [18F]-FDG was synthesised via a semi-
automated procedure by limiting the number of modules present in the hot cell. 
 
Chapter 5 is an investigation for the preparation of several triethylene glycol 
derivatives following the syntheses of Kryptofix [2.2.2]. The use of triethylene glycol chain 
will be essential for the synthesis of the Florbetaben precursor. 
 
The Chapter 6 is the exploration of a new synthetic route leading to the precursor of 
florbetaben.  
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Chapter 1: Introduction 
Introduction   
 
 
1 
 
 
 
Marginalised in the past, clinical diagnosis received over recent decades a huge interest. It has 
been growing with the development of combined techniques to improve disease detection, early 
treatment response and therapy monitoring. The fusion between usual anatomical techniques like X-
ray (CT) or magnetic resonance imaging (MRI)[1], associated with high sensitive molecular imaging 
techniques such as single-photon emission tomography (SPECT) or positron emission tomography 
(PET) offered an essential method for biomedical research and clinical diagnosis. The fused PET-CT 
method is specially used for cancer patient management, in particularly for oncology, cardiology and 
neuropsychiatry.[2-4] 
 
1.1 Tracer principle 
 
The Chemistry Nobel prize winner in 1943, George Charles de Hevesy[5, 6] performed studies 
on the diffusion of radioactive elements in metabolic processes. Using bean plants he studied the 
absorption of radioactive molecules at low-concentrations. Radioactive sites were located with 
accuracy and precision using a Geiger counter. This was offering a new non-invasive diagnostic 
method which was able to analyse the emission of γ-rays with high sensitivity.[3, 7] This technique 
avoided the use of excessive doses of radioactive agents and so the potential toxicity risk for the 
metabolism. 
The use of radioactive molecules as markers or tracers of biological non-radioactive processes 
of a metabolism is the foundation of SPEC and PET imaging.  
 The design of new tracers, in this case radiotracers or radiopharmaceuticals, and technologic 
improvements have developed better sensitivity and better specificity for PET images.[3, 8] Two types 
of imaging tracers are commonly synthetised: inorganic chemicals with radioactive metals and 
coordinated ligand(s), or organic compounds, which are small molecules almost similar to the 
biological active molecule with a radioactive atom. Today, a large variety of labeled molecules[9, 10] 
are routinely produced to detect biological modification within the metabolism, to predict or follow 
the progression of diseases and for the discovery of new drugs.[11-13] 
 
1.2 Positron Emission Tomography 
 
To obtain a high-resolution picture of the distribution of a tracer molecule within a body, the 
PET method is using the physical properties of positrons combined with an efficient and selective 
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detection of antiparallel γ-rays.[3, 13, 14] Radioactive proton-rich nuclei decay to more stable atoms by 
converting a proton to a neutron.[2, 8, 15] The new nature of this element induced the release of three 
entities: a positron (β+), the emission of a neutrino (ν) and loss of one electron (e– or β–). The emitted 
positron annihilates immediately after collision with an electron present in its environment, producing 
two diametrically opposed γ-rays of 511 keV each (see Figure 1). 
 
 𝑋!! → 𝑌!!!! +    𝛽!!! +   𝜈 +   𝑒– 
 
Figure 1: Illustration of annihilation process with the formation of two anti-parallel quanta (γ) 
identified simultaneously by two γ-cameras (present in red) parts of the ring scanner.[9] 
 
The γ-camera also known as Anger scintillation camera, named from its inventor Hal 
Anger[16], can be described as a multitude of very small detectors. Usually forming a circle around the 
body or the object, PET cameras are designed to detect the paired photons generated from the same 
annihilation event. Starting from the closest of the annihilation, the main parts of these detectors are 
the collimator, a large area of scintillation crystal and an array of photomultiplier tubes (PMT).[7, 8, 17] 
The received gamma rays, which are not visible to the eye, are converted into flashes of light 
by the scintillation crystal, usually made of (sodium iodide with thallium doping) (NaI(Tl)) or 
bismuth germinate (BGO). Face to the crystal, the collimator also known as the parallel-hole 
collimator consists in a lead plate full of small holes parallel to each other. Only photons travelling 
along the hole axis will pass into the scintillation crystal, the others (oblique angles) will be absorbed 
by the collimator. Acting as an efficient filter only 0.1% of the gamma rays will reach the scintillation 
crystals, which means 99.9% of emitted photons will not be treated. At the rear of the crystal, the light 
is transformed into electronic pulses by the PMTs and amplified (factor of 107) to offer a reliable 
current able to be treated by a computer. Signals are then analysed and (x;y) coordinates are generated 
Introduction   
 
 
3 
to give a 2 D image. The energy received by the crystal will determine the coordinate z and will then 
provide 3D PET images. 
 
 
Figure 2: Schematic components and basic principles of a PET camera. 
 
Generally combined with a CT scanner, fused PET-CT images offer the advantages of the 
two techniques (see Figure 3). The CT pictures are appreciated for their morphological details and 
PET images for the detection of low-level radiotracers inside the subject. 
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Figure 3: A standard PET-CT acquisition for a patient.[7] 
 
1.3 PET radionuclides 
 
Usually chosen for suitable physical properties, PET nuclei possess a long enough half-life (t½) 
to encompass the synthesis of the tracer and the biologic process studied (see Table 1). The desired t½ 
ranged from 20 minutes to 7 days. Another important factor is its decay mode. The radioisotope must 
decay completely or nearly by emission of positrons (β+). This is to avoid other nuclear reactions able 
to generate equivalent energy γ-rays and contaminate the calculation to determinate the source of the 
annihilation event. 
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Table 1: Characteristics and production reaction of the most common PET radioisotope.[3, 9, 18] 
Nuclide Half-life 
[min] 
Maximum 
energy 
[MeV] 
Decay mode 
[%] 
Nuclear reactiona 
Decay 
product 
   C!!!  20 0.97 β+ [100] N(p, α) C!!!"  B!!  N!!"  10 1.20 β+ [100] O(p, α) N!"!"  C!"  O!!"     2 1.74 β+ [100] N(d, n) O!"!"  N!"  F!!"       110 0.64 β+ [97]        Ne d, α F!"!"  O(p, n)!"!" F  O!"  
Ga!"!"  68 1.90   β+ [89] 
ECc [11] 
Ge − Ga  generator!!"!"  Zn        !"  
a) nuclear reactions will be explain in Section 1.4; b) production of Ga!" : Ga(p, 2n) Ge!"!" , generator: Ge!" t! ! = 271  d →    Ga!" ; c) electron capture 
 
The 11C and 18F nuclides are by far the most used isotopes for PET labeling. Despite a short 
half-life (20 min), carbon-11 offers an incredible advantage, the possibility of synthesising 
radiotracers identical to the non-radioactive analog, such as replacement of a carbon-12 by a carbon-
11. However fluorine-18 is the positron-emitting isotope of choice for several reasons. Its long half-
life (see Table 1) allows multistep radiosynthesis and the transport of doses to other clinical sites for 
all day patients. By emitting the lowest energy of all nuclei previously mentioned, it offers high 
spatial resolution for PET imaging. Hence the most routinely produced PET tracer used over the 
world is [18F]-fluoro-2-deoxy-D-glucose also named [18F]-FDG 1. 
 
 
1.4 Production of nuclides 
 
In nuclear medicine the most frequent way to produce nuclides is the cyclotron, an accelerator 
of particles (see Figure 4). The production of radionuclides demands a high frequency electric field 
applied to an ion beam, generated via the source present at the middle of the machine. The electrical 
field increases the energy of the particles in raising their celerity through two electrodes named 
“dees”. It forms excited particles with reasonable high energy (around 20 MeV) able to perform the 
OHOHO
18F
OH
OH
1
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desired reaction in practical yield. The magnetic field, perpendicular to the electrical one, leads 
particles to travel in spiral orbits. This acceleration chamber is continuously under high vacuum 
(around 10−5 and 10−7 mm of Hg) to accelerate effectively the ions. When the level of energy is 
reached, the particles exit the chamber and are deflected into the target. The bombardment of the 
particles to the atoms of the target provides the energised desired nuclei.[19] 
 
 
Figure 4: Illustration of a cyclotron accelerating particles with electro-magnetic fields to offer 
energised atoms, used for PET images.[20] 
 
This allows the reactions previously mentioned (see Table 1) to be explained further. For 
example if an [20Ne] atom is irradiated with a deuteron beam (one proton and one neutron) to produce 
a nucleus of [18F] with the emission of an alpha particle ( He!! ), the reaction is written Ne d, α F!"!" . 
This method forms [18F]-F2 gas for electrophilic fluorination. Similarly, if [18O] nucleus is bombarded 
with a proton to form [18F] atom and neutron, the nuclear reaction can be abbreviated O(p, n)!"!" F. 
With this reaction, electrophilic fluorine ([18F]-F2) and nucleophilic fluoride ([18F]-F–) can be 
respectively produced using a gas or liquid target. 
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1.5 Notion of specific activity 
 
The specific activity (SA) is defined as the amount of radioactivity (MBq, mCi) per unit mass 
of a radionuclide or a labeled tracer (g). Low SA occurred with the presence of “cold” isotopes of the 
radioactive atoms (carrier-added). The formation of non-radioactive tracers competes with the 
radioactive ones and provides lower RCY. This deteriorates the PET signal-noise ratio by saturating 
the binding sites of the reactive tracer and causing by sizeable mass, pharmacological and toxic risks 
for the patient.[21] The SA reaches its maximum value when the labeled atoms in the sample are free 
of its isotopes (carrier-free). The SA can be calculated by using the physical properties of the 
radionuclide, such as the number of atoms of the radioactive element (N) divided by the 
corresponding half-life (t1/2), and by Avogadro’s number (NA) to convert grams to moles (Equation 
1).[17, 22] 𝐒𝐀  (𝐌𝐁𝐪/𝐦𝐨𝐥) =    𝐥𝐧𝟐𝐭𝟏 𝟐    ∙    𝐍𝐍𝐀                                  Equation 1 
 
For a same number of atoms (N), SA is the highest for the element having the shortest half-
life. Therefore [15O] has the highest theoretical specific activity with a half-life of 2 min (see Table 1).  
 
1.6 Radiolabelling with [18F]  
 
In spite of a definite interest for [18F]-labeling, fluorine atoms are rarely present in molecules 
with biological activity. Therefore the effect of the fluoro-substituent on the organism has to be 
studied to offer at least similar activity than the non-fluorous parent molecule.[23] Atoms generally 
substituted by fluorine atoms are hydrogen or hydroxyl moieties and their protected derivatives. The 
replacement by fluorine leads to a modification of the electron density of the molecule due to the 
strong electronegativity of the fluorine atom (4.0, 2.1 for hydrogen and 3.5 for oxygen in Pauling 
scale). However steric parameters of the biotracer are almost unchanged, indeed van der Waal’s radii 
of fluorine, hydrogen and oxygen are 1.35, 1.20 and 1.52 Å respectively. Recent studies have shown 
some benefits by the incorporation of fluorine atom in biologically active drugs[24, 25] by improving 
their safety and efficiency for the patient.[23] Indeed fluorine substitution can influence the 
distribution, the selectivity to the receptors and extend drug metabolism. 
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1.6.1 Electrophilic [18F] 
 
Electrophilic [18F] can generally be produced by two different nuclear reactions Ne d, α F!"!"  and O(p, n)!"!" F with a preference for the latter.[26] Electrophilic fluorinations proceed 
with the use of a carrier, for example 19F2 gas, which, when mixed with 18F (see Scheme 1) forms the 
radioactive [18F]-F2 used for the reaction.  
 
 
Scheme 1: Preparation of the diatomic molecule 18F−19F. 
 
Due to the presence of one radiolabelled atom the theoretical radiochemical yield can reach a 
maximum of 50%. The powerful oxidizing activity of the difluorine gives an unspecific labeling 
leading to a mixture of products. This makes this method difficult to use for a routinely large-scale 
production. Mild and more selective reagents were developed such as [18F]-acetyl hypofluorite[27] or 
[18F]-xenon difluoride[28] and, more recently, N-fluorobenzenesulfonimide[29, 30] and selectfluor®[31, 32] 
leading to a large range of electrophilic reactions with fluorine-18. One of the first reported synthetic 
route of [18F]-FDG 1 was proposed by Ido and co-workers[33] in 1978. The synthesis was carried out 
with the electrophilic specie [18F]-F2; 6 years later the reaction was improved by the use of [18F]-
acetyl hypofluorite (see Scheme 2).[34] 
 
 
Scheme 2: Preparation of [18F]-FDG 1 via electrophilic 18F fluorination using [18F]-acetyl 
hypofluorite. 
 
Other clinically used PET tracers still rely on electrophilic [18F]-fluorination for example by 
addition to allylic moiety. [18F]-EFS or [18F]-2-(2-nitro-1[H]-imidazol-1-yl)-N-(2,2,3,3,3-
pentafluoropropyl)-acetamide 4, used to detect tissue hypoxia, is obtained in 17% radiochemical 
yield[35] as shown in Scheme 3. 
 
18F 19F2+ 19F+18F 19F
OHOHO
18F
OH
OH
O
HO
HO
OH
1. [18F]-CH3COOF
    H2O
2. HCl (aq)
2 1
RCY = 40%
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Scheme 3: Electrophilic [18F]-fluoro labeling of 3 to [18F]-EFS 4. 
 
Another known routinely produced PET tracer, 6-[18F]-fluoro-L-DOPA 6, can probe cerebral 
dopamine metabolism for the diagnosis of Parkinson’s disease. The fluorination by electrophilic 
carrier ([18F]-F2 or [18F]-AcOF) is achieved by initial incorporation of protecting groups and leaving 
group, here the trimethylstannyl precursor 5. This approach limits the presence of labile hydrogen and 
so, increases the selectivity of the radiolabelling. The tracer 6 was provided in a reasonable 
radiochemical yield (a maximum of 25%) after HPLC purification (see scheme 4).[36] 
 
 
Scheme 4: [18F]-fluoro labeling of [18F]-fluoro-L-DOPA 6 by direct electrophilic substitution. 
 
Labeling a molecule with [18F]-F2 has a huge drawback. Electrophilic aromatic substitution 
has a maximum value of SA of about 0.6 to 16 GBq/µmol[37] whereas no-carrier-added nucleophilic 
pathway has a theoretical SA of  6.3 x 104 GBq/µmol.[38] 
 
1.6.2 Nucleophilic [18F−] 
 
Carbon-fluorine bond formations can be effectively performed by direct nucleophilic 
substitution of an aliphatic carbon or unsaturated system like aryl groups following a SNAr-
mechanism. Owing to the highest electronegativity, the [18F]-fluoride ion is very sensitive to hydrogen 
bonding and can be easily solvated by protic solvent such as water or alcohols due to the basic 
properties of the anion. To increase the nucleophilicity, the fluoride-18 must be under anhydrous 
N
N
NO2
HN
O
F
F
F
N
N
NO2
HN
O
F
F
FF
18F
[18F]-F2
3 4
RCY = 17%
1. [18F]-F2
2. HI (aq)
5
COOEt
SnMe3
BocO
OBoc
NHCHO
COOH
18F
HO
OH
NH2
6
RCY = 25%
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conditions and exposed via the coordination of the potassium cation by a cryptand (bicyclic 
aminopolyether), or associated with an ammonium salt (see Section 1.7.2). 
 As electrophilic pathway, precursors should not own labile hydrogens to avoid side reactions 
within the incorporation of fluoride-18. 
Nucleophilic aliphatic substitution 
 
The [18F]-Florbetaben or [18F]-BAY94-9172 (8) is a promising PET imaging tracer 
delineating the presence of β-amyloid (Aβ) plaques in the brain, which are a significant factor 
associated with the development of Alzheimer’s disease (AD). The labeling was performed at 120 °C 
to provide after deprotection and semi-preparative HPLC purification the desired tracer 8 in 30% 
decay-corrected yield for a total synthesis of 90 min. The radiochemical purity was reported to be 
excellent (>99%).[39-41] 
 
 
Scheme 5: Radiosynthetic route for [18F]-Florbetaben 8 by SN2 mechanism. 
 
  
7
8
1. [K+⊂2.2.2]18F−,
    DMSO
2. HCl (aq)
RCY = 30%
N
(E)
Me
Boc
O OMs3
HN
(E)
Me
O
18F
3
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Nucleophilic aromatic substitution 
 
Following the literature, nucleophilic aromatic substitution with fluorine-19 was developed 
63 years ago by Burnett et al.[42] More interest emerged with the growth of fluorine-18 labeling. 
Several reactions were performed with activation of arenes by electron-withdrawing moieties, in 
ortho or para position, associated with a leaving group (LG). These reactions include the Balz-
Schiemann reaction, the Wallach reaction and reactions with standard leaving group for SNAr (–NO2, 
–Me3N+, halogen).[43] 
Achieved under harsh conditions and poor efficiency, functionalised substrates offered low 
radiochemical yield and new strategies have appeared by using hypervalent iodine compounds and/or 
using new devices (see section 1.7.2). 
 
1.7 Preparation of fluorine-18 for SN2 reaction following the example of [18F]-FDG 1 
 
The routine production of clinical PET tracers requires a high degree of reproducibility. The 
presence of impurities in consumables or in aqueous [18F]-fluoride solution has a detrimental effect on 
the radiolabeling. However, automation and standardisation have optimised the conditions such as 
time reaction (between 20 and 30 min) and RCY (≈60%, activity corrected, almost double than 
manual procedure).[44] 
 
 
 
OHOHO
18F
OH
OH
2. NaOH (aq)
9 1
1. [K+⊂2.2.2]18F−
    MeCN, 100→85 °C
RCY = 67%
OAcOAcO
OAc
OAc
OAc
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Figure 5: Nucleophilic nca pathway for [18F]-FDG 1 performed by a General Electric (GE) medical 
system: TracerLab MXFDG, a single-use cassette synthesiser. 
 
 TracerLab platform is the most used synthesiser over the world for routine [18F]-FDG 
production. This example will illustrate the different steps for a direct radiofluorination synthesis, 
accompanied with progress achieved in the literature. 
 
1.7.1 Step 1: Trapping and elution 
 
After irradiation of [18O]-water by protons in the cyclotron, the aqueous [18F]-fluoride solution 
is transferred to the synthesiser unit or module present inside the PET laboratory. The fluoride-18 is 
separated from the [18O]-water by an anion exchange cartridge (preconditioned with NaHCO3, 8.4%, 
5 mL)[45] and by using a pressure of helium or nitrogen gas. Trapped by a Sep Pak QMA light 
cartridge (Waters, USA) with quaternary ammonium chloride at the edge (see Figure 5); [18F]-fluoride 
is eluted using 0.6 to 1 mL of a solution of acetonitrile/water (50/50 or more recently 4/96, v/v). It 
contains weak base associated with cryptand (K2CO3 or KHCO3 and Kryptofix [2.2.2]), or 
tetrabutylammonium salt such as Bu4NHCO3 or Et4NHCO3[46]. 
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Figure 6: Conventional trapping of [18F]-fluoride by Sep Pak QMA light cartridge[47]. 
 
1.7.2 Step 2: Azeotropic drying 
 
The evaporation of the solvents is commonly carried out by a succession of three dry 
acetonitrile vials, at around 95 °C in the reactor vessel under reduced pressure and nitrogen or helium 
flow.[10] Within the evaporation process (8.5 minutes), TracerLab procedure involves 240 µL of 
acetonitrile (3 x 80 µL). 
 
 
Scheme 6: Distilled Kryptofix [2.2.2]/potassium cation complex with “naked” [18F]-fluoride ion for 
nucleophilic reaction; m << n.[22] 
 
 Even if more vigorous conditions may accelerate the drying process, higher temperature or 
too strong negative and positive pressure will provoke an uncontrolled splattering of solvents and will 
be accompanied with a loss of activity. This iterative azeotropic distillation looses more than 30% 
(activity corrected) of the radioactivity present in the vessel. Different alternatives and studies were 
performed over the last 20 years to limit the loss of radioactivity and to improve the time-consuming 
process.[48] 
 The use of low water concentration,[49] (96/4, v/v, MeCN/water) solution to elute the fluoride-
18 may dry the [K+⊂2.2.2]18F− complex after one distillation with a loss of activity of less than 4%. 
Other alternatives were described such as anhydrous [K+⊂2.2.2]OH− or strong organic bases such as 
phosphazene base (P4tBu)[50, 51] in dry acetonitrile. Electrochemical separations associated with 
microfluidic apparatus are able to catch the [18F]-fluoride on an electrode. After washing out the water 
QMA
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with acetonitrile, fluoride-18 is considered dried and directly conditioned for the labeling without 
azeotropic distillation.[52, 53] 
  Another strategy using hypervalent iodine and microreactor has been developed leading to a 
[18F]-labelling of unreactive iodonium salt[54] or [18F]-labelling with a low concentration of water 
(<0.3% v/v) and without cryptand/base complex. Reactions led to a reasonable RCY (see Scheme 8). 
 
 
Scheme 7: Radiofluorination of diaryliodonium tosylates salt in DMF/[18O]-water (72/28, v/v). 
 
Lee et al.[55] recently reported the influence of the radiochemical yield per amount of 
precursor for another common PET tracer, the [18F]-fluorothymidine also named [18F]-FLT. For 
similar radiolabelling conditions half of precursor leads to a significant drop of incorporation of 
fluorine-18 (for 20 and 10 mg of precursor, the RCY is: 90 and 50%, respectively). The Chromafix® 
PS-HCO3 and QMA cartridges, ion exchange columns are usually washed with strong bases such as 
OH− or KCO3−. These anions might involve side reactions such as elimination and hydroxylation to 
the precursor and leading to multiple separation steps.[56] The use of inert anions such as −OTf or –
OMs, owing to weak nucleophilic properties, doesn’t interfere with [18F]-fluoride labeling and carries 
out [18F]-incorporation independently to the amount of precursor. 
 
1.7.3 Step 3: Radiolabeling and deprotection 
 
The incorporation of fluorine-18 usually takes place in aprotic and polar solvents like 
acetonitrile, DMSO or DMF at relatively high temperature in a sealed reactor or in a microfluidic 
system. The labeling by nucleophilic aromatic substitution can be performed at up to 200 °C instead 
of approximately 85-100 °C used for aliphatic substitution. 
Alternative solvents have been described to be efficient for [18F]-fluorination. Protic tertiary 
alcohols (tert-amyl alcohol, tBuOH) led to [18F]-FDG 1 in up to 77% RCY.[56, 57] 
The possibility of [18F]-fluorination in the presence of traces of water was elaborated 13 years 
ago by using an ionic liquid, 1-butyl-3-methylimidazolium trifluoromethanesulfonate (BMI(OTf)), to 
form the labeled FDG 1 in 59% RCY.[58] 
 
MeO
I
CN
RCY = 50%
200 °C, 3 min
OTs
CN
18F18F– in [18O]-water
DMF
10 11
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1.7.4 Step 4: Deprotection/hydrolysis 
 
The cleavage of the four acetyl moieties of 2-[18F]-fluoro-1,3,4,6-tetra-O-acetyl-D-glucose 
([18F]-TAG) is performed under basic or acid conditions. In contrast to the acidic hydrolysis (HCl(aq), 
1 N, 120 °C, 5 minutes), basic deprotection occurs almost instantaneously under mild conditions 
(NaOH(aq), 2 N, 40 °C). Another basic method is performed by the TracerLab MXFDG (see Figure 5). 
The deprotection occurs with 800 µL of 2 N NaOH at room temperature through the first tC18 Sep 
Pak cartridge (Waters). Both tC18 columns were conditioned with 3 mL of ethanol and 22 mL of 
water within the synthesis. The tC18 resin holds back all nonpolar molecules such as [18F]-TAG or 
Kryptofix [2.2.2] and polar substances are eluted through the resin with water (10 mL) such as [18F]-
FDG 1. 
 
1.7.5 Step 5: Purification 
 
For the basic deprotection at 40 °C, three cartridges are used before to collect [18F]-FDG 1. 
The first cartridge is based on ion-exchange resin (SCX, Grace or IC-H, Alltech), which neutralises 
the pH of the solution to physiological pH. Then neutral alumina column (Waters) removes the 
unreacted fluorine-18 and finally tC18 Sep Pak cartridge removes the nonpolar molecules. 
For TracerLab process the ion-exchange cartridge is replaced by tC18 Sep Pak column (2nd), 
to provide the solution at physiological pH. The mixture elutes through the neutral alumina column 
and a sterile filter (Millex-GS, 0.22 µm) to purify the [18F]-FDG 1 solution. 
 
Even if these solid phase extraction (SPE) methods using cartridges are reliable and easy 
implementable into the equipment, side products such as glucose or 2-chloro-2-deoxy-D-glucose 
remain inside the product vial. Only HPLC purification can proceed to a complete removal of 
impurities. The disadvantages of this technique are time consuming to perform purification step 
compare to SPE columns and the requirement of specific HPLC conditions for each PET probe. 
 
1.7.6 Step 6: dispensing 
 
The product vial is then diluted and divided in several smaller vials by a dispensing module, 
which is generally comparable to the size of the production synthesiser. One vial is analysed to check 
the purity of the reaction solution produced (quality control, QC). When confirmed, the [18F]-FDG 
solution can be injected to patient. 
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1.8 Automation and new methods 
 
Fully-automated or semi-automated synthesisers are the most used devices in the world for 
clinical productions of radiolabeled compounds and in academic researches. The RCY between the 
original methodology and automated version can almost double.[10, 59] It facilitates the innovations of 
new synthesis techniques already used in conventional chemistry (cold chemistry) to make the 
radiolabeling syntheses faster and more efficient with the desire to simplify and reduce the price of 
the synthesisers. 
 
1.8.1 Automated apparatus for routine production of PET radiopharmaceuticals 
 
Automated synthesis carries out basic operations as heating, cooling, injecting gas pressure, 
negative pressure, filtration, reagents transfer etc. The transfer of reagents is commonly performed by 
pressure gradients. The use of inert gas pressure and vacuum pump associated with multiple check 
valves (stopcocks) guide liquids inside modules. It can as well be completed by some motor-driven 
syringe pumps. Reactions take place in a vial or in channels, for microreactors. Controlled by a 
computer, the interface software generates in real time the common parameters useful of the 
radiolabelling such as pressure, level of radioactivity, empty or full vials, temperature etc (see Figure 
7). The interface generally offers the possibility to manually interfere in the reaction in case of 
problems (not for the Synthera Interface). 
 
 
 
Figure 7: Interface software of Synthera [18F]-FDG synthesiser (IBA, Belgium) used for routine 
production in the Cardiff PET centre. 
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 Two categories of automated or semi-automated apparatus will be described: the cassette-
based synthesisers and the modular system, with however an exception for modularLab system which 
combine both methods (Eckert & Ziegler, Germany). 
 The cassette-based systems (see Figure 8) are subject to sterile one-use consumables 
(cassette, reagents etc.) to comply with the GMP regulations and reproducibility from run to run. 
However, it is generally limited to two reactions. Recently, new type of cassette-based synthesiser has 
been developed to achieve the synthesis of different PET tracers with the same apparatus and the 
possibility to realise 3 chemical reactions in one cassette.[60] 
 
A B 
 
 
C D 
  
 
 
Figure 8: the most widespread cassette-based automated modules: A) Fastlab, GE Health Care; B) 
NEPTIS synthesiser, Ora; C) Synthera, IBA cyclotrons solutions; D) GRP module, SCINTOMICS.[60] 
 
Modular automated systems generally need more space inside the hot cell but offer flexibility 
by allowing a large range of chemical operations with radionuclides. The complexity of multi-stage 
syntheses is to avoid the contamination with other solvents or accumulate impurities from stage to 
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stage and not to loose chemicals or radioactivity inside the large surface of tubing used in such 
devices (see Figure 9). 
 
 
 
Figure 9: ModularLab standard (Eckert & Ziegler, Germany). 
 
1.8.2 New techniques for [18F]-radiolabelling 
 
The field of microreactor devices and capillary loop system for radiolabelling has grown over 
the last decades mainly with the apparition of new materials (polymers)[61, 62] and the reduction of 
quantity of tracer needed per dose for chemical or biochemical assays. The miniaturisation of 
microfluidic systems is ideal to control small amount of reagents and can lead to portable devices to 
enable radiosynthesis remote from the production site.[63, 64] 
 Reducing space between molecules allows a rapid homogeneous mixing (in the order of 
microseconds) compare to batch mixing (the order of seconds or longer). The temperature distribution 
is considerably improved in microfluidic systems by high surface to volume ratio. The flow of the 
solutions can be perfectly controlled by syringe pumps. All these factors can influence yield and 
selectivity of reactions in a shorter time which is convenient for short life nuclides.[61] 
In 2005, Lee and co-workers described a multistep synthesis of [18F]-FDG in a microfluidic 
device[65] inspiring the development of automated radiolabelling processes on the microscale.[66] The 
synthesis of other PET tracers[63, 67-70] carried on with an interest for aromatic nucleophilic substitution 
(see Figure 10). 
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Scheme 8: Radiolabelling for aryl groups activated in ortho, meta or para position by an electron 
withdrawing group.[71] 
  
 The use of microreactors or hypervalent iodine (III) were not the only improvements. Several 
chelated metals were investigated such as Ni[72], Al([73]), Pd[74] and Cu[75, 76] as a co-catalyst to perform 
fluorination with fluorine-18 in practical yield. 
 Promising techniques with a particularity were also recently reported for radiolabelling. A 
compact and semi-automated synthesis platform[77] was designed to perform reaction under high 
pressure (up to 1.4 MPa) in a sealed reactor vessel. The advantages of such condition are the shorter 
reaction times, the enhancement of radiochemical yields and the use of volatile species such as 
reagents and precursors. The tight reaction system also avoids the loss of radioactive reagent over the 
labeling process by maintaining each chemical inside the vessel. The second apparatus[78] was 
provided with stepper motors, which were able to remove tubing from the reaction vial and so limited 
the contamination of reagents over the different steps of the radiolabelling. The syntheses occurred in 
a pressurised reactor vessel (up to 1 MPa) where, removed tubing was replaced with a stopper prior to 
reaction conditions such as heating or flow of nitrogen to avoid loss of radioactivity. 
 
Ar NO2
[K+⊂2.2.2]18F−
DMF or DMSO
120-210 °C
Microreactor (100 mm x 2 m)
less than 5 min
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 With an aging worldwide population and a life span tending to increase, Alzheimer’s 
disease (AD) and cancer have become two of the most important public healthcare problems 
over the world. Many governmental projects have been in charge of studying and diagnosing 
these diseases.[79] 
 Cardiff (Wales, UK) has not been an exception. Operational in 2010, the PET centre 
(PETIC[80]) has performed the routine production of [18F]-FDG for clinical diagnoses and 
studies. New synthetic methods have also been processed for [18F]-FLT and for different 
radioactive nuclei such as the [89Zr] production and purification. A large range of PET 
isotopes (11C, 13N, 15O, 18F, 124I, 64Cu) have been produced onsite and can be directly 
delivered to the three hot cells (Gravatom Engineering Systems Ltd, UK) located in the 
research laboratory (see Figure 10). 
The dose calibrator probe inside the hot cell is linked to the digital reading placed 
outside the hot cell. This permits an instant radioactivity measurement of several different 
radionuclides with accuracy and constancy.[20] Before use, each instrument are checked and 
calibrated. 
  
2 PETIC centre and aims 
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Figure 10: A) The hot cell in PETIC research laboratory, furnished with tongs and windows 
at each side of the cell to respectively manipulate goods inside and visually follow the 
reaction process. B) The inside of the hot cell with the Eckert & Ziegler kit next to the dose 
calibrator lead sleeves and the delivery lines. C) Digital reading of the dose calibrator 
instrument located outside the hot cell (CRC®-25PET, Capintec Inc., USA). 
 
 The aim of this work was to setup and explore different methods for [18F]-FDG 
production using the E&Z platform in this new environment. Most of the synthetic routes for 
PET tracers are 20 years old (25 years old for FDG[59]). The development of new techniques 
already known in non-radioactive chemistry was the first objective, such as using 
microfluidic syntheses. Another aspect was the achievement of a more compact synthesis 
unit to restrict the exposure of the electronic devices to radiation.  
The development of a potassium salt soluble in anhydrous solvents was investigated 
to reduce the time consumed by the azeotropic distillation for radiopharmaceutical syntheses.  
Then we were focused on the development of mono or bis-protected triethylene 
glycol derivatives via the synthetic routes leading to K[2.2.2]. 
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The last perspective was the optimisation of a new synthetic route of the precursor 7 
leading to the florbetaben 8 (see Scheme 9), a phase 3 study PET probe for Alzheimer 
disease (Bayer company, Germany).[41] 
 
 
Scheme 9: Radiolabelling to [18F]-Florbetaben 8 via SN2 mechanism.  
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3.1 Incorporation of fluoride-19 to mannose triflate 9 
 
As previously discussed in Chapter 1, the most frequent route for synthesising [18F]-
FDG is the no-carrier-added fluorination of 1,3,4,6-tetra-O-acetyl-2-trifluormethanesulfonyl-
β-D-mannopyranose 9. The procedure involves the presence of a phase transfer agent such as 
the 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane also named Kryptofix 
[2.2.2]. Associated with [18/19F]-fluoride and a weak base (K2CO3 or KHCO3), the 
[K+⊂2.2.2]18/19F− complex allows the [18/19F]-fluorination, as reported by Hamacher and co-
workers.[59] 
More recently, Brown and co-workers depicted the chemical yield of this reaction and 
identified side products and their ratio (see Scheme 10).[81]  
 
 
Scheme 10: Characterisation of products formed by reacting a "naked" fluoride salt with 
mannose triflate 9. 
 
 Brown et al. pointed out the extremely low conversion (< 5%) to the fluorinated 
[19F]-deoxy-glucose 14; and the predominant formations of side products such as the enone 
12 (42%) and the pentaacetate β-D-glucose 13 (29%) with some unreacted tetra-O-acetyl-2-
O-trifluoromethanesulfonyl D-mannose 9 (> 26%). After hydrolysis under basic or acidic 
conditions of [19F]-14, [19F]-FDG 1 is usually obtained in quantitave yield.[59, 81] 
9
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 As mentioned in Section 1.7, the radiochemical yield is around 60% (decay 
corrected) for the [18F]-FDG synthesis by using an automated synthesiser. The significant 
difference between chemical yield (< 5%) and RCY (≈60%) are mainly due to the amount of 
fluoride used for the fluorination. On one hand the preparation of [19F]-FDG is achieved with 
a fluoride source (KF, TBAF…) approximately or exactly equivalent to the mannose triflate 
9. On the other hand [18F]-fluoride is produced in picomole scale (Equation 2) whereas the 
mannose triflate 9 is present in µmole scale (25 mg, 52 µmol). 
 n = !!! ∙    !! !!"  (!)                                                 Equation 2 
 
The number of moles of the radioactive element can be calculated by using the 
radioactivity of the sample in Becquerel (A), the Avogadro’s number (NA) and the half time 
of the radioactive atom (s). For example for 100 GBq of [18F]-fluoride the number of mole 
for [18F] is 1 nanomol. The amount of radioactivity used for each experiment in this work 
(entries 1 to 39) is 50 times less radioactive. 
The RCY (%) is the quotient between the radioactivity delivered by the cyclotron 
(A0, in mCi) and the amount of radioactivity of the pure radiolabeled product collected at the 
end of the experiment (Aexp in mCi). Because of [18F] decays (half of the radioactivity is 
consumed after 110 minutes), the latter value must be adjusted (At in mCi) to be able to 
compare with the initial activity (A0) as shown in Equation 3.  
 RCY =    !!!!    ∙ 100 =   !!"#.!!!.!!"#  .    !!!      ∙   100                              Equation 3 
 
The 0.0063 coefficient is the quotient between ln(2) and the half time (min) of the 
radioactive nucleus. The t parameter is the time spent in minutes between the measurement of 
the activity received from the cyclotron and the measurement of the vial product by using a 
dose calibrator. 
Along this work the notion of RCY was not used due to the analysis of a product 
mixture mixing [18F]-fluoride and fluorinated [18F]-deoxy-glucose 1 or 14. The term 
radiochemical conversion was preferred. Radiochemical conversion (%) is the ratio of these 
fluorinated [18F]-deoxy sugars (1 and 14) inside the mixture. It was monitored by radio-TLC. 
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3.2 Investigation of the Hamacher method 
 
The [19F]-fluorination of tetraacetylated D-mannose 9 occurred in batch-mode 
following the work of Hamacher et al.[59] (see Scheme 11). The reaction was performed with 
25 mg (52 µmol, 19 times less than Hamacher) of mannose triflate 9 and was monitored by 
TLC analysis. 
 
 
 i. K19F (1 equiv), K[2.2.2] (1.2 equiv), K2CO3 (0.15 equiv), CH3CN, reflux, 20 min. 
 
 
Scheme 11: Pentaacetate glucose formation from mannose triflate 9 using fluorination agent. 
 
 The product mixture was analysed by 1H and 19F NMR spectroscopy at the end of the 
process. A sample of pentaacetylated glucose 13 present in the laboratory was used to 
identify this molecule in the crude product mixture. The 19F NMR did not confirm the 
presence of the desired [19F]-deoxy-glucose 14. 
 
The reaction was then transferred to microfluidic conditions, so they can be 
compared with the batch process. Using PC remote syringes and Peltier reactor module from 
the Eckert & Ziegler platform (see Figure 12), the microfluidic fluorination of mannose 
triflate 9 was performed in a capillary loop tubing linked to two syringes. The PEEK loop 
(Vici, Switzerland) was a 3 m long tubing shaped as a double helix with an internal diameter 
of 0.5 mm (total volume 589 µL) forming a cylinder of 30 mm of diameter. One syringe was 
filled with mannose triflate in MeCN (3 mL) (blue) and the other one (red) was filled with a 
fluorinated agent (TBAF) soluble in organic solvent (MeCN, 3 mL). The software 
(ModularLab) was configured to proceed the reaction with an overall flow rate of 14 µL/s (7 
µL/s each syringe, minimum speed). Mixed with a T-mixer, the combined solutions were 
heated at different temperatures (70, 85 and 95 °C). The different conditions afforded the 
same product mixture: elimination product 12 and the protected β-glucose 13, inseparable by 
flash chromatography. 
 
OAcOAcO
OAc
OAc
OAc
9
OAcOAcO
OTf
OAc
OAc
13
i
15%
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Scheme 12: Microfluidic reaction with mannose triflate 9 and TBAF in MeCN. 
 
 To identify the possible presence of the deoxy-glucose 14, the crude mixture was 
monitored by 19F NMR. Unfortunately no relevant peaks were observed. The reaction 
conditions (9: 25 mg, 52 µmol) might not be suitable for the detection of the [19F]-product 14 
by NMR spectroscopy. However, for an equivalent amount of starting material 9, [18F]-
fluorination can be analysed by radio-TLC (Canberra, Belgium) and radio-HPLC (agilent 
system, Germany). 
 
3.3 Generalities about radio-detection 
 
The detection of radiolabelled substances is generally performed by radio-HPLC and 
radio-TLC. The high performance liquid chromatography (HPLC) is one of the most widely 
used analytical techniques. The addition of a radio-detector allows the analysis of radioactive 
samples. The sensitivity of this detector is higher than the usual UV and refractive index 
detectors. The full setup is controlled via specific software (in PETIC, Laura software). The 
analysis of the mixture of the [18F]-FDG reaction was performed with a phenomenex column 
(Resex, RHM-Monosaccharide H+) in 30 minutes. The other method, radio-TLC, has the 
advantage to be fast (5 minutes). It is the same principle than thin layer chromatography 
(TLC), a drop (≈5 µL) of the radioactive crude mixture is applied on the bottom edge of a 
silica gel plate. The TLC plate is then placed inside a developing chamber with solvent 
mobile phase. For [18F]-FDG, the mixture of solvents used was 5% (v/v) of distilled water 
(millipore, USA) in acetonitrile. After complete development of the chromatogram, the plate 
is placed on the rack as shown in Figure 11. The computer, with the control of Laura 
software, moves the probe (NaI crystal) along the plate and detects the spots of radioactivity. 
In these conditions (5% distilled water in acetonitrile), the free [18F]-fluoride stays on the 
bottom edge of the TLC plate and [18F]-FDG 1 and the protected [18F]-deoxy-glucose 14 
9
TBAF
12 & 13
14 µL/s
≥ 70 °C
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migrate. The use of the second method (radio-TLC) was preferred to the first one (radio-
HPLC) due to its convenient time consuming (5 minutes). 
 
 
 
Figure 11: Radio-TLC apparatus (left picture) and radio-TLC chromatogram (right picture). 
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3.4 E&Z platform performed for [18F]-fluorination of mannose triflate 9 
 
 
 
i. [K+⊂2.2.2]18F−, MeCN,Δ. 
 
Figure 12: The first setup used for the tetraacetate [18F]-deoxy-glucose 14 synthesis. 
 
 The synthesiser was setup in a shielded hot cell as shown in Figure 12. The entire 
reaction process was controlled outside the cell by a computer with ModularLab software.  
This interface is able to control all actions: heating, cooling, turn valves etc. It is an 
automated or manual programing system with interactive scheme of the devices (see Figure 
13). The modules are daisy-chained together with connections to the source of inert gas 
(nitrogen) and to the power supplier placed outside the hot cell. Daisy-chaining minimises 
the number of cables passing through the hot cell to link the power supply. The two sensors 
(see Figure 12 and Scheme 13) monitored the pressure (bar) and radioactivity (no units) in 
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real time. The main part of the platform was the Peltier reactor module, which allows 
temperature control to 150 °C and water cooling. Connections for liquid and gas transfers 
were allowed by tubing constructed out of polytetrafluoroethylene (PTFE). The loop reactor 
was designed to heat double helix capillary loop system (length = 3 m, Ø = 0.5 mm,), which 
forms a cylinder of 30 mm of diameter. Each [18F]-fluorination reaction was using 25 mg of 
mannose triflate (52 µmol) in dry acetonitrile (1.1 to 2 mL). 
 
 
 
Scheme 13: ModularLab control panel developed for protected [18F]-deoxy-glucose 14 using 
a twelve 3-way valves cassette. 
 
 The reaction process commenced with the elution of the aqueous [18F]-fluoride to the 
synthesiser. The radioactive solution was transferred from the cyclotron (cyclone® 18/9, 
IBA, Belgium) to the intersection 6 (see Scheme 13) via the [18F]-line present inside the hot 
cell.  
The valves 6, 7, 8 and 9 were configured by ModularLab software to allow the 
aqueous [18F] to pass through the QMA cartridge. The cartridge was loaded with the [18F]-
fluoride and the [18O]-water was collected into a waste vial (O18 water, intersection 9). Dried 
with a flow of nitrogen, the [18F]-fluoride was then eluted into the reactor vial from the 
cartridge by using a Kryptofix solution (ABX, Germany) containing K2CO3 (4.2 mg, 30.4 
µmol) and Kryptofix [2.2.2] (22.6 mg, 60.0 µmol) in 600 µL of water/MeCN (50/50 v/v). 
The liquid transfer into the 5 mL V-shape reactor vial (Alltech, Grace Discovery Sciences, 
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USA) was allowed by the negative pressure performed by the vacuum pump (see Scheme 
13). 
The drying process was first carried out at 90 °C with both positive and reduced 
pressure within 2 minutes. The simultaneous use of negative and nitrogen flow allowed the 
acceleration of vapor removal over the evaporation steps. 
The azeotropic drying sequence was carried out with acetonitrile (2 x 1 mL). The 
acetonitrile (1 mL) was transferred to the heated reactor vessel (55 °C) via the vacuum pump. 
The Peltier reactor heated the mixture at 95 °C under reduced pressure and flow of nitrogen. 
This sequence was repeated once to remove residual traces of water. The whole azeotropic 
sequence was achieved over 4 minutes. 
The Peltier module was cooled to 35 °C. The 2 mL of acetonitrile (MeCN 3) were 
drawn by syringe A (sA) and injected to the reactor vial. The [K+⊂ 2.2.2]18F− solution was 
then contained in sA. The mannose triflate 9 dissolved in dry acetonitrile (2 mL) was 
transferred inside syringe B (sB). The mixing of the two solutions was performed with a T-
mixer (PTFE) at 14 µL/s as overall flow rate. 
The radiolabelling reaction took place in a PEEK loop (double helix, length: 3 m,  ∅: 
0.5 mm) in continuous flow at 80 °C. Only a small amount of radioactivity was recovered (< 
30%, entries 1 to 3, Table 2). 
 
Table 2: Radiolabelling proceeded in a 3 m PEEK loop tubing. 
Entry 
Activity received 
(GBq) 
Process time  
(min) 
Recovery of activity, decay-
corrected (%) 
1 1.5 34 19 
2 1.5 30 27 
3 1.5 30 23 
 
 The experiment 1 was longer (34 instead of 30 minutes) due to a problem of elution 
of the vial at the intersection 3 (MeCN 1, Scheme 13). The vial was replaced and the reaction 
occurred normally. The three reactions (experiment 1 to 3) were performed by the same 
method described above Table 2. 
 A part of the loss of radioactivity was detected for the synthesis 3. The vacuum trap 
(liquid trap, Scheme 13) was placed in the sleeve of the dose calibrator to detect online the 
presence of radioactivity inside this one. Within the azeotropic sequence, the dose calibrator 
detected 27 MBq after the evaporation of the first vial of acetonitrile at 90 °C under reduced 
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pressure. The value increased to 147 MBq after evaporation of the second vial of acetonitrile 
under the same conditions. 
 
Table 3: Azeotropic distillation performed at 90 °C instead of 95 °C. 
Entry 
Activity received 
(GBq) 
Process time  
(min) 
Recovery of activity, decay-
corrected (%) 
4 1.8 34 30 
5 1.5 30 37 
 
 The reactions 4 and 5 (Table 3) were performed with a different azeotropic 
distillation process. The acetonitrile (2 x 1 mL) injected to the reactor vessel was evaporated 
at 55 °C for 30 seconds and then at 90 °C (instead of 95 °C) over 90 seconds. No presence of 
activity was detected inside the vacuum trap. The recovery of activity was collected up to 
37%. However after the azeotropic distillation was achieved, the [K+⊂ 2.2.2]18F− complex 
was not dry and solvents were still inside the reactor vessel. So water residuals might be 
present in the reactor vial, which can decrease the efficiency of the [18F]-fluorination. Higher 
temperature (>90 °C) should be used to complete the evaporation of solvents inside the 
reactor vessel. 
 The experiment 4 was stopped step by step to check the efficiency of each process, 
which can explain the delay of 4 minutes compared to the reaction 5. 
 
 The reactor vial was still radioactive after elution of the [K+⊂ 2.2.2]18F− complex by 
syringe A. At the experiment 4, 50 % (decay-corrected) of the initial radioactivity was 
present in the reactor vial. The cassette was highly radioactive at the end of the synthesis. 
Some drops of the reaction mixture remained inside the cassette. In order to rinse the 
cassette, the modularLab program was modified to perform the synthesis of [18F]-FDG 1 by 
adding the NaOH solution (1 M, 1 mL) and 3 mL of distilled water. 
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3.5  E&Z synthesiser configured for [18F]-FDG 1 synthesis 
 
 
 
Figure 13: New configuration of the modules with the new shortened cassette module. 
 
This method integrated the new cassette module (12 mechanical valves instead of 18) 
and the addition of a three 3-way valves module (see Figure 13). The addition of this latter 
module (see Scheme 14) was required to transfer automatically the reaction mixture inside 
the loop (radiolabelling process) to the reactor vial for the hydrolysis step. The deprotection 
step was accomplished in the reactor vial with a solution of NaOH. The organisation of the 
modules was modified due to the addition of these new modules. 
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Scheme 14: Configuration of the E&Z platform used for the radiosynthesis of [18F]-FDG 1. 
 
 After the loading of the QMA cartridge with [18F]-fluoride, the cartridge was dried 
under nitrogen pressure for 80 seconds. 
 The Kryptofix solution (ABX) was eluted through the QMA cartridge and then to the 
reactor vial under reduced pressure at room temperature. The [K+⊂ 2.2.2]18F− complex was 
heated at 70 °C for 50 seconds and for an additional 70 seconds under pressure of nitrogen. 
 The azeotropic solution was performed with one vial of acetonitrile (1 mL, see 
MeCN 1, Scheme 14) at 55 °C under negative pressure. The reactor vial was heated to 95 °C 
for 50 seconds under reduced pressure and nitrogen flow and for an additional 20 seconds 
under nitrogen. 
 The reagent mixtures were more concentrated; the volume of solvent was 0.5 mL 
less than the experiments 1 to 5 (2 mL). The [K+⊂ 2.2.2]18F− complex heated at 39 °C was 
transferred into syringe A via 1.5 mL of dry acetonitrile present at the intersection 13. 
Syringe B withdrew the mannose triflate solution dissolved in 1.5 mL of dry acetonitrile.  
 The solutions were driven to the T-mixer. The resulting mixed solution was then 
eluted to the loop tubing to achieve the [18F]-fluorination. The reaction was carried out at 85 
°C instead of 80 °C (reactions 1 to 5) and collected in the reactor vial. The vacuum line was 
opened within this sequence to ventilate the reactor vial.  
QMA$
6" 5" 4"
7" 9"
13"
12"11"10"
3" 2" 1"
8"
14" 15"
loop$
reactor$
mannose$$
triﬂate$$
in$MeCN$
MeCN$2$
pressure$
ac6vity$
Kryptoﬁx$
solu6on$
MeCN$1$ NaOH$ dis6lled$water$
sA$ sB$
liquid$$
trap$
vacuum$$
pump$
alumina$
CC18$
16" 17" 18"
pel6er$
reactor$module$
Chapter 3   
 
 
34 
 The deprotection step occurred at 50 °C for 50 seconds prior to the elution of NaOH 
(1 M, 1 mL, ABX) in the reactor vessel under reduced pressure. 
 After the addition of 3 mL of distilled water (3 mL) into the Peltier module, the 
reaction mixture was collected inside sA. The solution was then injected through the 2 
cartridges (alumina & C-18, see Section 1.7.5) for purification. The purified mixture was 
collected in the product vial. 
 
Table 4: Study of the recovery of activity for [18F]-FDG preparation. 
Entry 
Activity received 
(GBq) 
Process time  
(min) 
Recovery of activity, decay-
corrected (%) 
6 3.0 38 10 
7 2.4 34 18 
8 1.5 36 14 
 
 The process time for the experiment 6 was longer than the experiment 7 and 8 due to 
a mistake on modularLab at the elution of the reaction mixture in the loop to the reactor vial. 
To complete the synthesis of [18F]-FDG 1, the deprotection step and elution to the product 
vial was performed manually. The deprotection step for the reaction 8 proceeded in 100 
seconds instead of 50 seconds. 
 The recovery was low for each reaction (below 20 %, Table 4). Following the 
reaction 8, 10% (decay-corrected) of the initial radioactivity was trapped by the alumina 
cartridge. The alumina cartridge generally used to trap the [18F]-fluoride indicated the 
presence of unreacted fluoride-18 in the reaction mixture.  
 
 The alumina and C-18 cartridges were removed for the experiments (9 to 11). The 
PEEK tubing connecting the several modules were shortened and the reactor vial was 
replaced by a 7 mL PEEK flat vial. The larger capacity of the vial (7 instead of 5 mL), its 
material (PEEK instead of glass) and its shape (flat instead of V-shape) improved the 
recovery of the radioactivity (see Table 5) by containing the splashes inside the reactor vial. 
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Table 5: Study of the recovery of activity after achievement of the [18F]-FDG preparation in 
a flat PEEK reactor vial. 
Entry 
Activity received 
(GBq) 
Process time  
(min) 
Recovery of activity, decay-
corrected (%) 
9 1.1 30 68 
10 1.85 33 52 
11 1.1 30 64 
 
3.6 Segmented flow in capillary tubing 
 
To our knowledge no radiolabelling by using segmented flow has been described in 
literature. The strength of segmented or biphasic system in a micro-channel is a rapid and 
efficient mixing comparing to continuous flow. The droplets immiscible with its neighbour 
phases (liquid/liquid or liquid/gas), generate an internal vortex for both phases due to a 
difference of viscosity and surface tension (see Figure 14).[82, 83] The drops containing the 
reagents react faster and more efficiently due to their small volume. 
 
 
Figure 14: Schematic mixing phenomenon involved in microfluidic segmented flow.[82] 
 
3.7 Formation of the [18F]-deoxy-glucose 14 by using ionic liquids for the segmented 
flow procedure 
 
A series of 15 reactions was performed to obtain a percentage of conversion of the 
[18F]-deoxy-fluoride 14 superior to 0%. The maximum temperatures used for the drying 
process and the azeotropic distillation increased by at least 20 °C. The sequence time for 
these processes was also longer to enhance the removal of solvents and to obtain better 
conversion. 
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As mentioned in the Section 1.7.3, the use of an ionic liquid such as BMI(OTf) can 
perform in batch the [18F]-fluorination with presence of water in reasonable RCY (lit.[58] 
59%). Two attempts were performed by using 300 µL of the ionic liquid (see Table 6). 
 
Table 6: Radiolabelling achieved with the presence of an ionic liquid by using segmented 
technique. 
Entry 
Activity 
received 
(GBq) 
Process time  
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
12 3.3 38 69 5 
13 1.3 30 — 54 
 
 
Scheme 15: Radiolabeling of mannose triflate 9 in the presence of ionic liquid. 
 
The aqueous [18F]-fluoride from the cyclotron was transported to the QMA cartridge 
where the [18F]-fluoride was trapped. The cartridge was dried for 50 seconds over a nitrogen 
flow. 
The commercial Kryptofix solution (ABX) was eluted into the reactor vial under 
reduced pressure. The elution carried on for an additional 1 minute under reduced pressure 
and flow of nitrogen. 
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The evaporation of the solvents performed with an azeotropic distillation (1 mL of 
acetonitrile) occured with a maximum of temperature of 120 °C for approximatly 6 minutes 
under vacuum and nitrogen stream. 
The mannose triflate with the ionic liquid (300 µL, 1.6 µmol) in acetonitrile (1.5 mL) 
was added into the heated reactor vial (43 °C) by using syringe A. The solution was then 
withdrawn to syringe A and syringe B filled with the nitrogen gas. 
The segmented flow was performed via the simultaneous addition of the substrates to 
the loop at 14 µL/s overall flow rate. The [18F]-incorporation for the experiment 12 was 
carried out at 95 °C. 
The recovery of activity for this experiment (see Table 6) was obtained in 69% but the 
incorporation of [18F] was very low (5%). This percentage of incorporation was improved for 
the experiment 13 (54%) by increasing the maximum temperature over the solvent 
evaporation step (125 instead of 120 °C) and by decreasing the temperature of the 
segmented-based reaction from 95 °C to 85 °C. This enhancement of [18F]-incorporation was 
not fully understood. But the temperature (125 °C) established for the removal of solvents 
might perform a better [18F]-fluorination even without the ionic liquid. The choice was made 
to find better conditions to remove the water present in the commercial Kryptofix solution 
and to not use an ionic liquid, which is also toxic.[84] 
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3.8 New configuration system of [18F]-fluorination of mannose triflate 9 performed in 
segmented flow. 
 
 
Figure 15: New line connections for the segmented flow method. 
 
 The good recovery of activity with high radiochemical conversion was the main 
issue for each attempt. Under reduced and nitrogen pressure, a high temperature (>110 °C) 
will transport the radioactivity away from the reactor vial with the withdrawing of the solvent 
vapor. At low temperature (<90 °C) under reduced and nitrogen pressure, the presence of 
water might remain inside the reactor vial and the [18F]-fluorination will not occur as 
described in Section 1.7.2. 
 
 The possible presence of water inside the cassette for the elution of [K+⊂2.2.2]18F− 
complex with the mannose triflate solution might be a source of contamination. This water 
might remain from the solvent evaporation steps by condensing inside the cassette. Syringe A 
(intersection 14 in Scheme 16) was hence connected directly to the reactor vessel, which 
should minimise the presence of water inside the reaction mixture.  
The mannose triflate 9 usually provided by Sigma-Aldrich in a vial was purchased 
from ABX, in a sealed vial routinely used by PET centres. 
 
 
!
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Scheme 16: New configuration of the segmented flow procedure for the formation of [18F]-
deoxy glucose 14. 
 
 Following similar steps than the reactions achieved previously (see Section 3.7), the 
drying process occurred with an increasement of 10 °C of the temperature. A single 
azeotropic drying sequence was achieved. The solvent removal commenced at 120 °C under 
reduced pressure over 50 seconds and for an additional 70 seconds under reduced pressure 
and nitrogen flow. The addition of the dry acetonitrile (MeCN, valve 4) into the reactor 
vessel heated to 80 °C was performed under reduced pressure. The reaction mixture was 
heated to 110 °C for 80 seconds and for an additional 1 minute at 130 °C under reduced 
pressure. The evaporation process carried on over 80 seconds at 130 °C under reduced and 
nitrogen pressure.  
 The mannose triflate solution (1.5 mL) was injected into the heated reaction mixture 
(43 °C) via syringe A. The combined solution was then withdrawn by the same syringe (A). 
The syringe B was filled with nitrogen gas. 
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Table 7: Radiolabelling synthesis using segmented flow in loop tubing. 
Entry 
Activity 
received 
(GBq) 
Process time  
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
Loop tubing 
14 1.2 35 40 54 3 m 
15 1.2 102 21 74 2 x 3 m 
16 1.2 36 27 62 5 m 
 
 The segmented flow applied for the radiolabeling process of the experiment 14 was 
performed at 100 °C with an overall flow rate of 14 µL/s. The recovery of activity was 
obtained in 40% with an [18F]-incorporation of 54% (see Table 7). It was the best 
incorporation obtained with such recovery of activity (40%). 
 
 The concentration to dryness of the [K+⊂2.2.2]18F− complex for the reaction 15 was 
performed in identical conditions than the experiment 14. The [18F]-labeling was performed 
in 2 identical loops (length =3 m, ∅ = 0.5 mm, each). The first loop was heated in the loop 
reactor at 100 °C and the second was heated in a water bath at 75 °C. Comparing to the 
reaction 14, the [18F]-incorporation was better (74% vs 54%) but the recovery of activity was 
lower (21% vs 74%) (see Table 7). 
 
 A longer and smaller PEEK capillary tubing (length = 5 m, Ø = 0.01 mm) was used 
for the radiolabelling of mannose triflate 9 (see Table 7). The reaction was performed at 100 
°C at 14 µL/s. The results obtained for the experiment 156 (see Table 7) were comparable to 
those performed with two loops (15, Table 7). 
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3.9 Conclusion 
 
An automated radiolabeling synthesis was setup to perform the [18F]-fluorination of 
mannose triflate 9 in a continuous or segmented microfluidic strategy. The recovery of 
activity in this Chapter was low and showed the difficulties of these techniques. However the 
development of a segmented flow method allowed the synthesis of the tetraacetylated [18F]-
deoxy-D-glucose 14. The achievement of the [18F]-fluorination in small size tubing was 
abandoned but the desire to produce [18F]-FDG 1 in a compact synthesiser was promoted. 
 
 
  
 
 
 
 
 
 
  
Chapter 4:  Synthetic routes to 
radiopharmaceuticals using fluidic devices  
Chapter 4   
 
 
42 
 
 
4.1 Compact E&Z platform using tee luers  
 
 
Figure 16: The configuration of E&Z modular platform for [18F]-FDG 1 production. 
 
In collaboration with the Eckert & Ziegler company, we decided to study the 
substitution of the cassette and its modules by luer adapters (connectors) (see Figure 16 and 
Figure 17) to perform a compact synthesiser. The exposure of radioactivity to electric devices 
can possibly damage them over time. All previously used modules contain electronic circuit 
broads. It was suggested to keep the number of modules inside the hot cell to a minimum. 
Two modules could already be outside the hot cell: the vacuum pump and the nitrogen gas 
controller (Hamilton device). The first attempt commenced with the use of tee luers (internal 
volume = 0.35 mL), which fit together and form a chain (see Figure 16). The setup required a 
reactor vessel (5 mL flat bottom glass vial) for performing the different steps of the synthesis. 
The use of such flat reactor vial is the same than the ones provided by TracerLab MXFDG and 
Synthera (see Figure 6 and 7, respectively) for [18F]-FDG 1 production. 
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Figure 17: Picture of the setup using luers for [18F]-FDG 1 synthesis. 
 
 Once all reagents were placed, the liquid transfers were performed by using the 
Hamilton module and a vacuum pump (see Figure 16). The full control of liquid transfers 
required the use of check valves. These connectors were constructed out of polyethylene 
(PE). They prevent backflow under positive pressure permitting gases and liquids to flow 
through it only in one direction (see Figure 17, the way of black arrows and Scheme 17, 
green arrow). Furthermore a reduced pressure can also afford the movement of liquids or 
gases as shown in Scheme 17. 
 
 
Scheme 17: Illustration of the check valve working as a door system (red arrow the valve is 
closed, green arrow the valve is open). 
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 Liquid directions were controlled by vacuo and nitrogen pressure or 
nitrogen/nitrogen pressure. For each liquid transfer, a positive pressure of nitrogen (1.5 bar) 
was added into the desired vial to push the solution through the system to reach its 
destination. For example, at the intersection 8 (see Figure 17) the aqueous [18F]-fluoride from 
the "F18 in" vial was pushed straight to the QMA cartridge via a pressure of nitrogen applied 
on the top of this vial. The horizontal check valve, at the intersection 8, restricted the access 
of the aqueous [18F]. Therefore, this mixture did not contaminate the Kryptofix solution. The 
[18O]-water passed through the QMA cartridge and the [18F]-fluoride was trapped by this one. 
 The applied pressure of nitrogen delivered at the crossing 6 allowed the [18O]-water 
to flow to the [18O]-water vial. The reactor vessel was hence not contaminated by this water. 
The QMA cartridge was then dried under pressure of nitrogen. The horizontal check valves 
positioned at the intersection 7 did not allow the backflow of the [18O]-water to the reactor 
vial under reduced pressure. 
 The Kryptofix solution was transported to the QMA cartridge to form the 
[K+⊂2.2.2]18F− complex and eluted into the reactor vial. This achievement was controlled by 
using simultaneously nitrogen and vacuum pressure. The nitrogen and vacuum flow were 
directly applied from the Kryptofix solution vial and the reactor vial, respectively.  
 The challenge of this technique was to avoid the transfer of the other reagents within 
the use of the vacuum pump. Indeed, an applied reduced pressure from the reactor vessel 
performed the transport of the solutions present in the intersections 4 and 3 (see Scheme 17). 
A stream of nitrogen was required at the intersection 5 to neutralise the effect of the vacuum. 
The solutions in position 1 and 2 were not affected due to the proximity with the ventilated 
product vial, which weakened the vacuum. 
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Figure 18: First configuration of fluidic transfers with one mechanical valve. 
 
 The reaction occurred with the [18F]-incorporation of mannose triflate 9 to form the 
protected [18F]-deoxy-glucose 14. To elute the reaction mixture from the reactor vessel to the 
product vial, a positive pressure of nitrogen was added. A mechanical valve (blue square in 
Figure 18) was added to close or open the line connected to the vacuum pump. The 
advantage was the enhancement of the drying process under nitrogen pressure to the 
ventilated reactor vial. The [K+⊂2.2.2]18F− complex was dried at 95 °C within 270 seconds. 
The azeotropic distillation was achieved with 1 mL of acetonitrile at 95 °C for 5 minutes. The 
radiolabeling was performed at 90 °C over the same time (5 minutes). The recovery was 
better than the experiments achieved in the Section 3.8 but the percentage of incorporation 
was relatively low (36%, Section 3.8: up to 72%). This result can be explained by the lower 
temperatures used for the whole process (up to 95 °C), comparing to the 130 °C as maximum 
temperature for the experiments of the Section 3.8. 
 
Table 8: First reaction achieved with three modules. 
Entry 
Activity 
received 
(GBq) 
Process time  
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
17 1.5 36 67 36 
 
The major drawback of this approach was the inner diameter of the tee luers (∅ = 3 
mm). Its relatively large diameter led to small droplets being lost inside the tubing. Another 
issue was the exposure of the PE check valves to acetonitrile which damaged them over time. 
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4.2 Reducing internal volume of the fluidic devices and new check valves 
 
To obtain more efficient liquid transfers, E&Z provided more suitable consumables 
(see Figure 19). The first one was a 1-way cassette also named cube constructed out of 
polymethylpentene (TPX®, blue square), with an inner diameter of 0.9 mm and composed of 
five inputs/outputs. Each entry/exit was screwed with an adapter thread to luer female 
constructed out of polypropylene (PP) and a plastic join placed between both to avoid leaks. 
Solvent resistant, PP check valves were fitted to solve the problem of blockage and allow 
their reuse. Some of the tee luers were replaced by a low pressure Tefzel® tee which has a 
smaller dead volume (2.9 µL instead of 0.35 mL). For the first complete [18F]-FDG 1 
synthesis with induced fluidic transfers, the 3 M solution of NaOH (3 mL) was injected 
manually inside the reactor vessel for the hydrolysis step. 
 
 
Figure 19: First try of radilabelling using fluidic components without valves. 
 
 The QMA cartridge was placed to the input 7 (see Figure 19) to ease the removal of 
[18O]-water to the intersection 8. Nitrogen pressure was applied into the "F18 in" vial and at 
the input 5 to perform an efficient removal of water to the [18O]-water waste vial. The 
transport of the [K+⊂2.2.2]18F− complex to the reactor vial was performed by simultaneous 
nitrogen pressure, applied into the Kryptofix solution, and a reduced pressure used into the 
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reactor vial. The whole pressure of nitrogen was reduced to 1 bar (1.5 bar in Section 4.1) and 
a syringe filter (0.22 µm, Miller GV) was added to weaken the pressure of nitrogen applied 
into the Kryptofix vial to control the transfer of [K+⊂2.2.2]18F− complex. Similar to the 
Section 4.1, nitrogen pressure was also added at the intersection 3 (see Figure 19) to avoid 
the elution of reagents such as mannose triflate solution and dry acetonitrile (outputs 1 and 2, 
Figure 19). 
 
 The temperature of each step was increased to improve the incorporation of [18F]-
fluoride. Therefore the removal solvents were evaporated for 10 minutes at 110 °C as 
maximum temperature. The labeling of mannose triflate was performed at 100 °C for 5 
minutes. Both processes were under consecutive flow of nitrogen and reduced pressure or 
both. Afterwards the deprotection step was achieved at 40 °C for 1 minute. 
 
Table 9: Experiment was performed with a 1-way cassette 
entry 
activity 
received 
(GBq) 
process time 
(min) 
recovery of activity, 
decay-corrected 
(%) 
Radiochemical 
conversion 
(%) 
18 1.5 109a 85 19 
19 0.9 32 44 91 
a) measurement of radioactivity. 
 
The aim of this experiment was focused on the efficiency of the recovery of activity 
by monitoring the amount of activity present after the deprotection step under usual labeling 
conditions. The measurement was performed after the radioactivity decayed to a quarter of 
the initial value for safety concerns. The reactor vial was then introduced to the sleeve of the 
dose calibrator with the aid of long tweezers. The measurement of the radioactivity was also 
preformed for the cube, which presented traces of radioactivity. The cube seemed to be 
suitable for fluidic transfers and for not becoming contaminated with radioactivity. 
 
 The high recovery of activity (85%, see Table 9) led to the complete synthesis of 
[18F]-FDG 1 with deprotection step (NaOH, 3 M, 5 mL). At the end of the process, the crude 
mixture was driven to the product vial (see Figure 21) to determine the radioactivity present 
inside the vial. 
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Figure 20: two Tefzel® tees used for [18F]-FDG synthesis. 
 
 The setup was again minimised by the association of the two Tefzel® tees. This 
method provided the [18F]-FDG 1 in 91% conversion (see Table 9). The quite low recovery 
of activity (44%) was explained with the presence of drops in the luer tees after transfer of 
the reaction mixture to the product vial and with the aqueous solution of NaOH and inside 
the IC-H cartridge (up to 35%, decay corrected). 
 
 The nitrogen flows at the edges of the two tees (input 1 and 5, Figure 20) were 
necessary to perform the synthesis. The nitrogen pressure (intersection 1, Figure 20) was 
used to guide fluidic transfers of reagents to the reactor vial and the second (intersection 5) to 
neutralise the negative pressure provided by the vacuum pump. 
 
 The next method limited again the number of luer tees by using only two of them. 
One on the top of the QMA cartridge and the other one connected to a low pressure Tefzel® 
cross (see Figure 21). Check valve for the reactor vial were placed to the reactor vial to 
improve the confinement of this vial. 
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Figure 21: Reliable control of fluid sequences by using a Tefzel® cross. 
 
 The recovery of activity was again the parameter to focus on. Therefore no 
acetonitrile was used for the azeotropic distillation. The drying process still took 10 minutes 
at 110 °C as maximum temperature. Unfortunately the radioactivity present in the product 
vial was low (37% (see Table 10) instead of 85% in Table 9). 
 
Table 10: Reaction achieved with a Tefzel® cross. 
entry 
activity 
received 
(GBq) 
process time 
(min) 
recovery of activity, 
decay-corrected 
(%) 
Radiochemical 
conversion 
(%) 
20 1.4 26 37 74 
 
The residual radioactivity was mainly located in the IC-H cartridge (21%, ion 
exchange cartridge) and in the vacuum trap (vacu-guard 150, Whatman, UK). For this latter 
no value can be provided due to the size of the vacuum trap being larger than the sleeve of 
the dose calibrator. Nevertheless the removal of activity was observed with the activity 
sensor present inside the Peltier reactor module. The sensor was not calibrated and had no 
unit. However, the multiple reaction runs allowed the detection of an important loss of 
radioactivity when the sensor decreased by one unit. Before the addition of the solution of 
mannose triflate in acetonitrile (0.6 mL), the instrument indicated 15. After a series of 
vacuum and nitrogen flow at reasonable temperature (between 90 and 110 °C), the level 
dropped to 13-12 over the labeling process. 
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 To sum up, the loss of radioactivity did not happen, or just a little, within the drying 
process but over the [18F]-incorporation. A new procedure of labeling must be found to 
simultaneously minimise the loss of activity and enhance the percentage of [18F]-
incorporation. The check valve placed on the top of the reactor did not allow the transport of 
liquid from the reactor vial to the cube on the Peltier reactor module (see Figure 23) and so 
loss of radioactivity was avoided in this path. 
 
4.3 Development of a semi-automated fluidic transfer by using two cubes 
 
 
Figure 22: ModularLab platform for [18F]-FDG synthesis using two plastic cubes. 
 
 The Tefzel® tee replaced the tee luer at the intersection 1 (see Figure 22) for the 
reasons mentioned previously (section 4.1 and 4.2). Under the QMA cartridge, the new cube 
constructed out of polypropylene (PP) with similar dimensions than the cube located at the 
right (TPX®, inputs 7 to 9). The program operating the synthesis was the same as in the 
previous setup (Section 4.2).  
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Table 11: Radiolabelling synthesis performed in a polypropylene vial. 
entry 
activity 
received 
(GBq) 
process time 
(min) 
recovery of activity, 
decay-corrected 
(%) 
Radiochemical 
conversion 
(%) 
21 1.2 29 20 26 
 
 However the glass vial was replaced by a flat bottom plastic vial (PP, 5 mL). The 
desired [18F]-FDG 1 was obtained in 26% conversion (see Table 11). The difficulty was to 
reach the required temperature with plastic vial than glass vial due to a bad thermal 
conduction of the polypropylene. Plastic vial did still have some advantages. Its price 
(cheaper than glass vial) and had less affinity with fluoride ions. So removing the 
radioactivity with a minimum of solvent was easier (30 Bq left). A smaller flat bottom plastic 
vial (PP, 2.5 mL) was also used but the percentage of conversion was lower (6%). No 
explanation was found. The efficiency of the drying and radiolabelling in a small volume 
should provide better conversion.  
 
 An estimation of the amount of radioactivity present in each major part of the 
synthesiser, able to enter in the sleeve of the dose calibrator, was monitored (see Table 12). 
The delivery of the [18F]-fluoride from the cyclotron into a vial instead of a straight delivery 
to the system was the reason of the first loss of activity (2.6%). The analyses were achieved 
without the precursor (mannose triflate 9) and the ion exchange cartridge but with the same 
amount of solvents. Therefore 1 mL of dry acetonitrile (labeling process), 4 mL of NaOH (3 
M) (hydrolysis) and 4 mL of water (washing reactor vial) were used to recover the activity 
inside the product vial. To obtain relevant results, flat bottom glass vial was chosen instead of 
a plastic one for their better thermal conduction. 
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Table 12: Investigation of the repartition of radioactivity. 
location 
recovery of activity, 
decay-corrected 
(%) 
[18F]-vial (from cyclotron) 100 (633 MBq) 
QMA cartridge 96 
product vial 42 
QMA cartridge (after elution) 0.8 
[18F]-vial (after transfer) 2.6 
reactor vial (glass, 5 mL) 4.8 
vacuum pipe 0.4 
[18F]-waste vial ≈ 0 
cube (PP) (end of synthesis) 0.6 
 
 The radioactivity of the QMA cartridge was determined before and after the elution 
of the captured [18F]-fluoride. All the others parts were monitored at the end of the procedure. 
In total only 51% of the radioactivity initially present inside the [18F]-vial were 
found, which means 49% were lost inside the vacuum trap. 
 
Therefore the majority of the solvents were evaporated at 95 °C as maximum 
temperature instead of 110 °C (see Section 4.2). However the drying process was performed 
in 11 minutes instead of 10 minutes (see Section 4.2) in the 5 mL plastic vial (PP). The 
nitrogen applied into the reactor vial over the drying process was introduced on the top of the 
vial (see Figure 22, intersection 9) and not by the longest tubing present in this one (see 
Figure 21). This modification allowed the reduction of the splattering over the drying 
process. 
A mechanical valve was added between the reactor vial and the cube having the 
reagents such as mannose triflate solution and NaOH solution (see Figure 23). The objective 
was to heat the reactor vial, at the end of the azeotropic distillation, at 100 °C under reduced 
pressure only. As mentioned in Sections 4.1 and 4.2 the use of reduced pressure was always 
associated with a pressure of nitrogen to avoid the uncontrolled flow of the reagents to the 
system. The volume of the mannose triflate solution was reduced to 1.2 mL (instead of 1.5 
mL) to minimise the loss of radioactivity by the evaporation of the acetonitrile solvent over 
the radiolabelling (97 °C for 5 minutes under negative pressure and nitrogen pressure). 
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Table 13: Procedures with nitrogen pipe connected directly to the reactor vial. 
Entry 
Activity 
received 
(GBq) 
Process time  
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
22 1.1 32 59 20 
23 1.0 27 57 32 
 
 The low conversion (see Table 13) of the experiment 22 was explained by a loss of 
the mannose triflate solution within its transfer into the reactor vial. The reaction 23 was 
performed with no significant problems. The achievement at lower temperature for drying 
and labeling sequences in the plastic reactor vial (PP) performed reasonable recovery (59 and 
57%) but low conversion (20 and 32%). Therefore maximum temperatures, for drying and 
labeling steps, were increased by around 10 degrees. 
 
 
Figure 23: Final configuration for the production of [18F]-FDG using the E&Z platform. 
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Table 14: Radiolabelling proceeded at 110 °C in 5 mL plastic vial. 
Entry 
Activity 
received 
(GBq) 
Process time 
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
24 1.2 28 35 72 
 
Experiment 24 was focused on the loss of the radioactivity over the drying and 
radiolabelling process via the sensor present inside the Peltier module. After elution of 
[K+⊂2.2.2]18F− complex, the activity collected inside the reactor was 11. Over the first part of 
the drying step (95 °C for 6 minutes) the value decreased to 8 due to the presence of liquid 
inside the tubing (see Figure 23). Then the dry acetonitrile (500 µL) used for the azeotropic 
distillation (110 °C for 5 minutes under consecutive nitrogen pressure and reduced pressure) 
rinsed this tubing and allowed the recovery of the initial value (11). The mannose triflate in 
1.2 mL of dry acetonitrile was added into the reactor vial. The labeling process occurred at 
105 °C as maximum temperature for 5 minutes under consecutive positive and negative 
pressure. The activity inside the reactor vessel decreased to 9. The deprotection step with a 
solution of NaOH (3 M, 4 mL) was performed at 55 °C for 1 minute with no change of 
radioactivity. The crude mixture was eluted through the IC-H cartridge and into the product 
vial. The IC-H cartridge trapped 21% of the radioactivity (decay corrected) and explained the 
low recovery of the activity (35%, Table 14). However in the product vial, 72% of the [18F]-
fluoride was incorporated to the mannose triflate 9 to form the desired [18F]-FDG 1. To avoid 
the trapping of the free [18F]-fluoride by the IC-H cartridge, this one should react longer over 
the radiolabelling sequence. 
 
Table 15: Reduction of the amount of MeCN for the azeotropic distillation and use of less 
water for the Kryptofix solution. 
Entry 
Activity 
received 
(GBq) 
Process time 
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
25 1.1 32 50 66 
26 1.5 32 59 70 
27 1.6 30 59 79 
28a 0.9 29 54 50 
a) radiosynthesis of [18F]-FDG 1 without azeotropic distillation. 
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The experiments 25 to 28 were performed with a different Kryptofix solution. The 
concentration of water was reduced (17 instead of 50%, v/v). The solution was prepared with 
4 mg of K2CO3 and 24 mg Kryptofix in dry acetonitrile (500 µL) and deionised water (100 
µL). The drying process was performed in 7 minutes at 105 °C as maximum temperature 
under negative and positive pressure. The radiolabelling occurred with a 7 minute sequence 
heated at 105 °C. The deprotection step was achieved with a 3-minute sequence at 55 °C 
using a solution of NaOH (3 M, 4 mL). To obtain better recovery of activity 4 mL of distilled 
water was used to rinse the reactor vial and the IC-H cartridge. The recovery of activity was 
better than in the Table 13 with good radiochemical conversion (up to 79%, experiment 27). 
The difference of radiochemical conversion was achieved by shortening the time of the 
radiolabelling process for the experiment 25 (100 s). It was the same experiment for the 
reactions 26 and 27. The only explanation found was the use of the damaged Hamilton 
device, which leaked. 
After replacement of the Hamilton device by a new one, a similar program was used 
but without the azeotropic distillation. The aim was to evaluate the efficiency of the drying 
process without the addition of dry acetonitrile. The experiment was performed in lower 
incorporation (50%, entry 28) than the reaction runs achieved in Table 15. 
 
4.4 Two cube method with anhydrous Kryptofix solution. 
 
4.4.1 Development of various anhydrous potassium salts to elute radioactivity from QMA 
cartridge 
 
The presence of water in the Kryptofix solution is one of the main reasons of the time-
consuming process of no-carrier-added [18F]-fluoride incorporation. The azeotropic 
distillation generally requires a minimum time of 5 minutes.[10]  
 
Attempts were carried out to understand the elution process in more detail. An aqueous 
solution of [18F]-fluoride was eluted through a preconditioned QMA cartridge. The [18F]-
fluoride was trapped on the cartridge and the [18O]-water was recovered in a beaker. 
Deionised water (1 mL) was manually injected through the cartridge by using a syringe. The 
activity sensor placed near the cartridge did not detect any change of radioactivity inside the 
ion exchange cartridge. After drying over airflow, a solution of Kryptofix [2.2.2] (24 mg, 
63.7 µmol) dissolved in dry acetonitrile was added through the cartridge by using a syringe. 
The radioactivity inside the cartridge remained the same than before the transfer of the 
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Kryptofix mixture. A solution of K2CO3 (4 mg, 29 µmol) dissolved in 1 mL of deionised 
water was injected through the ion exchange cartridge. The [18F]-fluoride ions were eluted 
from the cartridge into the beaker. The potassium carbonate salt is the active substrate able to 
remove the radioactive anions from the cartridge via anion exchanges ([18F]-fluoride replaced 
by carbonate). 
 Therefore, several potassium salts dissolved in anhydrous solvents were investigated 
as replacement for the K2CO3 salt to elute the [18F]-fluoride from the QMA cartridge (see 
Table 16). 
The reactions took place in a plastic reactor vial and mannose triflate 9 was still 
dissolved in acetonitrile (1.1 mL). 
 
Table 16: List of potassium salts used for fluoride-18 elution. 
Entry Salt Solvent (µL) 
elution of activity 
from the QMA 
cartridge 
1 potassium sorbate MeOH (825) yes 
2 potassium hexanoate  MeOH (825) no 
3 potassium acetate MeOH (400) partially 
4 
trans-4-hydroxy-L-
proline potassium  
MeOH (400) no 
5 K2CO3 MeOH (500) yes 
 
 
The potassium salts were prepared with the same method. Potassium hydride (30 wt 
% in dispersion oil) was added dropwise to a stirred solution of a carboxylic acid (1 g) in a 
dry solvent (diethylether) under an inert atmosphere. The resulting solid was filtered off and 
wash with 20 mL of petroleum ether (PE) and placed under vacuum overnight. 
Dissolved in anhydrous methanol the potassium solutions (24 mg) were injected 
through a [18F]-fluoride loaded QMA cartridge. The radioactivity sensor connected to the 
E&Z platform was placed near the cartridge to determine the level of radioactivity present 
inside the cartridge (see Scheme 18). 
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Scheme 18: Setup for elution of [18F]-fluoride present in the QMA cartridge via potassium 
salts with radioactivity sensor connected to the E&Z kit. 
 
 Most of the synthesised salts did not remove the activity from the cartridge (see 
Table 16, entries 1 to 4). The sorbate salt (entry 1) was an exception. No explanation was 
provided but in comparison of the hexanoate and sorbate salts, the presence of a conjugated 
C–C double bonds system might allow the elution of the [18F]-fluoride from the QMA 
cartridge. However sorbic acid and sorbate salts are toxic[85] so, it cannot be used for clinical 
studies. 
 
The exploration of an anhydrous solvent able to dissolve the K2CO3 salt was 
investigated. Several dry solvents were used such as DMSO, DMF, ethanol, i-PrOH, 3-
pentanol, triethylene glycol and methanol. The potassium carbonate salt was only soluble in 
methanol after 2 minutes in an ultrasonic bath. 
The prepared Kryptofix solution (K[2.2.2] (24 mg, 63.7 µmol), K2CO3 (4 mg, 28.9 
µmol) in anhydrous MeOH (600 µL)) passed through the [18F]-loaded cartridge. The 
radioactivity was removed from the cartridge. 
 
In conclusion, an anhydrous Kryptofix solution was used as an alternative to the 
commercial Kryptofix solution (ABX). Even if methanol is toxic, it can be removed at lower 
temperature (65 °C) than water and acetonitrile (100 and 82 °C, respectively). 
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4.4.2 Radiosynthesis in anhydrous Kryptofix solution 
 
Table 17: Use of an anhydrous Kryptofix solution. 
Entry 
Activity 
received 
(GBq) 
Process time 
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
29 1.6 28 33 73 
30 1.2 30 39 50 
31 1.6 34 55 32 
 
A new method was performed for the use of the anhydrous Kryptofix with a shorter 
drying process. The anhydrous Kryptofix solution (see Chapter 5) was prepared with K2CO3 
(4 mg), K[2.2.2] (24 mg) and dry MeOH (600 µL). After elution of the Kryptofix solution, 
the [K+⊂2.2.2]18F− complex was flowed to the heated reactor vial (65 °C) with applied 
nitrogen pressure. That sequence was common to the three reactions (29 to 31). The drying 
process of the experiment 29 was performed at 105 °C for 160 seconds under nitrogen 
pressure and 220 seconds at 110 °C with both negative and positive pressure. The mannose 
triflate solution in dry acetonitrile (1 mL) was transferred in the heated reactor vessel (50 °C, 
reactions 29 to 30). The labeling process occurred at 105 °C under reduced pressure and 
nitrogen flow for 260 seconds. The basic solution of NaOH (3 M, 3 mL) was eluted to the 
reactor vial at 50 °C. The deprotection step was performed at 55 °C for 40 seconds. The 
reaction was eluted to the IC-H cartridge and then to the product vial (common step for 
reactions 29 to 31). The conversion to [18F]-FDG 1 was high (73%) but the recovery of 
activity relatively low (33%). The radioactive sensor present inside the Peltier module 
detected a loss of activity over the radiolabelling sequence (15 to 8). 
To obtain a better recovery of activity, the radiolabelling of reaction 30 was 
performed under milder conditions (95 instead of 110 °C) for a similar time (260 seconds). 
The drying process proceeded at the same temperature than in experiment 29 but over a 
longer period. The reactor vial was heated to 105 °C under nitrogen pressure for 180 seconds, 
and 160 seconds at 110 °C under consecutive negative and nitrogen pressure. The crude 
mixture in the product vial contained less [18F]-FDG 1 (50% conversion) but the recovery of 
activity increased by 6% (39 instead of 33%). 
The third experiment (31) proceeded with a drying step at 95 °C (160 seconds) and 
then at 105 °C (120 seconds) under negative pressure and nitrogen flow. The labeling process 
was similar than the reaction (29). The recovery was better (55 instead of 39%) but the 
labeling process was worse (32 instead of 50%). The 34-minute reaction time involved a leak 
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with the cube above the Peltier module after elution of the [K+⊂2.2.2]18F− complex in the 
reactor vessel. 
 
4.4.3 The anhydrous Kryptofix solution performed the formation of [18F]-FDG 1 (see 
Radiosynthesis in anhydrous Kryptofix solution 
 
Table 17). However the residual activity after elution of the Kryptofix solution was 
higher with MeOH than with a MeCN/water mixture (800 instead of 400 decay per seconds 
(dps)). It could be explained by the lower density of MeOH (d = 0.79) compared with water 
(d = 1). The dry Kryptofix solution might be transferred faster through the QMA cartridge 
than the aqueous mixture. The exchange between the carbonate anions and [18F]-fluorides 
might not happen as much as in the aqueous Kryptofix solution leading to the loss of activity. 
The protocol using anhydrous Kryptofix solution stopped due to a possible nucleophilic 
attack of the methanol to the carbon of the mannose triflate 9 having the leaving group (—
OTf). 
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4.5 Low concentration of water for Kryptofix solution 
 
Figure 24: Semi-automated radiolabelling synthesis of [18F]-FDG 1 by using low water 
concentration for Kryptofix solution. 
 
The reactions of Table 18 were performed with 50 µL of distilled water and 450 µL of 
dry acetonitrile within the Kryptofix solution (in ABX solution: 300 µL of water, 300 µL of 
MeCN). The amount of the other reagents remained similar than in Section 4.4 (4 mg of 
K2CO3, 24 mg K[2.2.2]). The azeotropic distillation took place with 1 mL of dry acetonitrile. 
 
Table 18: [18F]-FDG synthesis prepared with 50 µL of water for the Kryptofix solution. 
Entry 
Activity 
received 
(GBq) 
Process time  
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
32 1.6 32 ⎯ 82 
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33 1.5 28 48 8 
34 1.7 29 53 67 
35 0.4 26 20 84 
36 2.0 28 56 77 
37 1.5 33 89 25 
 
For experiment 32, the [K+⊂2.2.2]18F− complex was transferred to the heated reactor 
vial (65 °C). The drying process started at 95 °C within 250 seconds under nitrogen flow. 
The azeotropic distillation occurred at 90 °C with the addition of 500 µL of dry acetonitrile 
under positive pressure for 15 seconds. The reaction mixture was heated to 105 °C under 
nitrogen pressure for 160 seconds. At 110 °C the vacuum was applied to the reaction mixture 
with nitrogen flow over 140 seconds.  
The addition of the mannose triflate solution in 1 mL of acetonitrile was performed 
in the reactor vial heated to 50 °C. The labeling process started at 95 °C under nitrogen 
pressure for 160 seconds. The reactor vial was then heated to 105 °C for 140 seconds under 
nitrogen flow and reduced pressure.  
At 55 °C, the aqueous solution of NaOH (3 M, 3 mL) was added to the reaction 
mixture. After 40 seconds, the reactor vial was emptied by transfer of the reaction mixture to 
the IC-H cartridge and then into the product vial (1 minute). A vial of 4 mL of deionised 
water replaced the empty vial of NaOH and water was transferred to the reactor vial to rinse 
this one and the IC-H cartridge (160 seconds). 
The flows of nitrogen applied in position c and e (see Figure 24) within the 
hydrolysis, transported a part of the radioactivity to the vacuum trap. Therefore, the product 
vial was not monitored by the dose calibrator. Having a high conversion (82%) for the 
reaction 32, the next experiment (33) was followed the same protocol with the use of only 
one input of nitrogen pressure (c). 
The reaction 35 afforded an unexpected low conversion (8%) but the new hydrolysis 
program using only one input of nitrogen pressure for the mixing was efficient. The 
radioactivity collected in the product vial was 48% (decay corrected). A loss of radioactivity 
was monitored in the Peltier reactor module over the radiolabelling process (24 to 17).  
The experiment 36 was performed with the same method than the reaction 35. The 
results were rather different. The recovery of activity was relatively similar (53% for 36 and 
48% for 35) but the incorporation was significantly different (67% for 36 and 8% for 35). No 
explanation was found. Nevertheless, the loss of activity over the labeling process was also 
noticed in the Peltier module for the reaction 36 (18 to 12).  
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The radiolabelling process for the reaction 37 commenced at 90 °C instead of 95 °C 
(reactions 34 to 36). The mannose triflate in acetonitrile (1 mL) was still transferred to the 
heated reactor vial (50 °C). The reactor vial was then heated to 90 °C for 1 minute under flow 
of nitrogen. The temperature increased by 5 °C for 100 seconds and by 10 degrees to 105 °C 
with both nitrogen flow and vacuum for an additional 100 seconds. Unfortunately two check 
valves leaked over the synthesis (F18 and mannose triflate). The conversion of [18F-FDG] 1 
in the product vial was monitored by radio-TLC (82%) but the recovery of activity was not 
analysed due to the leaks. 
 
Reaction 38 was performed with a new program. In order to increase the conversion, 
the QMA cartridge was dried under nitrogen flow but also with 1 mL of acetonitrile.  
The transfer of the aqueous [18F]-fluoride present from the "F18 in" vial was 
performed under nitrogen flow for 1 minute. The pressure of nitrogen stopped and dry 
acetonitrile (1 mL) was added manually with a syringe into the "F18 in" vial. An additional 3 
minutes of nitrogen flow was applied to the "F18 in" vial and at the intersection 3 (see Figure 
21). The Kryptofix solution was eluted through the QMA cartridge to the reactor vessel 
heated to 65 °C for 30 seconds. The drying process started at 105 °C for 250 seconds under 
nitrogen pressure (intersection 3). The solution was cooled to 90 °C and 500 µL of 
acetonitrile were added for the azeotropic distillation (15 seconds). The reactor vial was 
heated to 110 °C for 160 seconds under reduced pressure and nitrogen flow. At the end of he 
drying process, the Peltier radioactive sensor detected a loss of activity of 4 units from the 
transfer of the [K+⊂2.2.2]18F− complex into the reactor vial. 
The radiolabelling process had also a loss of activity (2 units). This step commenced 
by heating the crude mixture at 90 °C for 1 minute under nitrogen flow and an additional 100 
seconds at 95 °C. The labeling carried on at 105 °C for 100 seconds under vacuum and 
nitrogen pressure. 
Cooled at 55 °C, the deprotection step carried out for 160 seconds by using NaOH 
solution (3 M, 3 mL) followed by distilled water (3 mL).  
The radioactivity collected in the product vial was 59% and [18F]-fluoride was 
incorporated to mannose triflate 9 in 77% conversion (Table 17, experiment 36). 
The last reaction (37) had leaks with the cube connected to the reagents such as 
mannose triflate solution. Therefore the results (82% conversion, 25% recovery) cannot be 
compared with the experiments 35 and 36. Nevertheless, the drying and radiolabelling 
process provided loss of activity of 3 units.  
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The first reaction had no recovery because of the loss of the aqueous KOH solution 
with the radioactive reaction mixture within the vacuum trap. The pressure of nitrogen eluted 
the solution into the vacuum line and then to the trap. 
 
The second attempt (33) had a similar program, except for the labeling process; only 
one check valve was placed differently. Instead of being attached to the TPX® cube, it was 
placed at the [18O]-waste vial. The result was significantly lower. 
 
The third experiment (34) had no obvious leaks or issues over the process. It offered 
a relatively good recovery of activity (53%) and practical [18F]-incorporation (67%). By 
following the radio-detector inside the reactor module, the notable loss of activity was again 
recorded within the azeotropic distillation (2 at 70 to 95 °C and 2 more at 105 °C under 
vacuum). 
Some changes were performed for the next experiment (35): a step at 80 °C for 1 
minute was added to minimise the loss of activity and the QMA cartridge after [18F]-trapping 
was washed with 1 mL of dry acetonitrile to remove the possible residual traces of [18O]-
water. 
The recovery was increased and the [18F]-incorporation also (56% and 77%, 
respectively, see Table 18). 
The last experiment got a leak with the stopcock manifold over the synthesis, which 
explains the low recovery. 
 
4.6 Conclusion 
 
The intensive optimisation of the radiolabelling with 5 modules offered at the end 
(experiment 32 and 37) reasonable recovery (56%) and good [18F]-incorporation (77%). The 
production of [18F]-FDG was achieved with 5 modules instead of 8 for the microfluidic 
method (Chapter 3). Also the Hamilton device and the vacuum pump can be placed outside 
the hot cell. To our knowledge no synthesis of [18F]-FDG 1 has been described was 
performed with only three mechanical valves. The efficiency of the cubes was crucial. They 
were not contaminated by the radioactivity and they can be produced by a workshop at 
different sizes and with any required number of inputs/outputs. The PP check valves were 
also important in the development of this technique. They blocked efficiently one direction 
under positive pressure and were resistant to acetonitrile. 
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Described in chapter 1 as one of the pathways to perform the [18F]-fluorination, 
Kryptofix [2.2.2] was used in this work for each radiolabelling process. This macro bicyclic 
phase transfer is generally synthesised over several days in low yields (see below). But there 
are commercial suppliers such as Merck Millipore (Germany), which sell this cryptand. 
 
5.1 Synthetic routes for Kryptofix [2.2.2]  
 
5.1.1 Multistep synthesis 
 
The synthesis of Kryptofix [2.2.2] 20 was performed for the first time in 4 steps (see 
Scheme 19).[86, 87] The synthetic route was performed under high dilution conditions for 
several steps. The first cyclisation occurred in benzene (concentration of the diamine 15: 
0.045 M) by the nucleophilic reaction between the diamine 15 and the diacid chloride 16 (0.5 
equiv, must be prepared[87]). The formed monocyclic aza-crown ether 17 was reduced by 
LiAlH4 in THF (concentration of 16: 0.1 M), to form the tetraoxadiamine macrocyclic 
compound 18 in 75% yield. Another equivalet of diacid chloride 16 was added to condense 
with the monocycle 17 in toluene (concentration:  9.10-3 M). Obtained in 45% yield, the 
bicyclic compound 18 was then reduced by borane agent (1 M in THF). The formed diamine 
borane derivative was then hydrolysed with HCl (6 M) under reflux to form the desired 
Kryptofix [2.2.2] in quantitative yield. 
 
5 Exploration of cryptand [2.2.2] syntheses and polyethylene glycol 
derivatives   
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i. dry benzene, r.t., 8 h, 75%; ii. LiAlH4 (6.7 equiv), dry THF, reflux, 24 h, 75%; iii. 15 (1 equiv), TEA 
(2.2 equiv), dry toluene, r.t., 10 h, 45%; iν . step 1: BH3•THF (4 equiv), dry THF, 0 °C→reflux, 2.5 h 
and step 2: HCl (6 M), reflux, quantitative yield. 
 
Scheme 19: Multistep synthesis of Kryptofix [2.2.2] 20. 
 
 This 4 step preparation provided the desired Kryptofix in 25% overall yield. The first 
optimisation was reported by Kulstad and Malmsten.[88] They provided the desired aza-crown 
ether 20 in one step as shown in Scheme 20. 
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5.1.2 One-step synthesis 
 
 
i. Na2CO3 (2 equiv), CH3CN, reflux, 3 d, 6%. 
 
Scheme 20: Direct synthesis of the bicyclic diaza-crown ether 20.[88] 
 
 The nucleophilic attack of the diamine 15 to two equivalents of 1-chloro-2-(2-(2-
iodoethoxy)ethoxy)ethane 21 (must be prepared[88]) formed the intermediate 21. The halogen-
halogen exchange permits the ring-closure and the formation of the Kryptofix [2.2.2] 20 in 
6% yield. The driving force of the reaction is the presence of the iodide, a good leaving group 
(pka = –10 in water) and more reactive than the chlorine moiety (pka = –7 in water).  
The same group (Kulstad and Malmsten) investigated under the same conditions the 
use of the 1,2-bis(2-iodoethoxy)ethane 23. Kryptofix [2.2.2] 20 was not isolated, only the 
monocyclic 1,10-diaza-18-crown-6 was synthesised together with byproducts not described 
in the paper (see Scheme 21).[88]  
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i. Na2CO3 (2 equiv), CH3CN, reflux, 3 d, yield not mentioned. 
 
Scheme 21: Monocyclic diaza-crown ether 18 formation from 1,2-bis(2-iodoethoxy)ethane 
23.[89] 
 
A straightforward method for Kryptofix [2.2.2] 20 was reported by Krakowiak and 
co-workers 21 years ago.[90] The cryptand [2.2.2] was synthesised by using the ditosylate 
derivative of triethylene glycol and a large excess of a base (Na2CO3, 19 equiv) (see Scheme 
22). The reaction mixture was refluxed for 6 days and then filtered at room temperature. The 
solid was dissolved in a stirred solution of dichloromethane. After filtration, the filtrate was 
concentrated and purified through an alumina column to remove the inorganic sodium salt 
coordinated by the ligand. The mixture was then chromatographed on silica gel column to 
isolate the final product 20 in 36% yield. 
 
 
i. Na2CO3 (19 equiv), CH3CN, reflux, 6 d, 36%. 
 
Scheme 22: Reliable one-spot synthesis of Kryptofix [2.2.2] 19. 
 
The ditosylated triethylene glycol 25 is generally preferred to the dimesylated 
triehylene glycol 26 as it is commercially available. However, both glycol derivatives 
generate the Kryptofix [2.2.2] with a similar yield.  
 
In conclusion, this method provided the Kryptofix [2.2.2] 19 in the highest yield 
(36%). Others advantages were the one step synthesis and the commercially availability of all 
reagents. 
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This reaction was performed in the laboratory. Unfortunately no significant product 
was collected at the end of the purification step (alumina and silica columns). The Kryptofix 
[2.2.2] synthesis could not be repeated. The requirement of a long reaction time (6 days) 
favored the purchase by suppliers. 
 
 However the ditosylate was synthesised successfully by using two methods (see 
Scheme 23). 
 
 
i. TsCl (2 equiv), KOH (4.3 equiv), THF/water (20/7, v/v), 0 °C→r.t., 4 h, 43%; ii. TsCl (3 equiv), 
TEA (3 equiv), DMAP (5 mol%), CH2Cl2, overnight, 87%. 
 
Scheme 23: Preparation of the ditosylate triethylene glycol 25. 
 
 The first method had the advantage of a 4 hour reaction time but suffered from low 
yield (43%).[91] This route was proposed for the synthesis of ditosylates tetraethylene and 
pentaethylene glycols and offered 35% and 96% yield, respectively. The second procedure[92] 
was catalysed by a nucleophilic base (DMAP) and produced the desired product 25 in 87% 
yield (lit. 88%).  
 
An alternative synthesis of the monocycle 18 was explored to perform the synthesis 
of Kryptofix [2.2.2] 20. The procedure started with the condensation of the previous diamine 
with [2-(2-oxo-ethoxy)-ethoxy]-acetaldehyde 27 with the diamine 15 to form the monocycle 
18 after reduction (see Scheme 24). 
 
 
 
Scheme 24: Route to the aza-crown ether 18 from the dialdehyde 27. 
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The triethylene glycol was oxidised[93] with a catalytic amount of 2,2,6,6-
tetramethylpiperidine-N-oxide 28 (TEMPO) and trichloroisocyanuric acid 29 (TCCA, 2 
equiv) as a a co-oxidant following the mechanism shown in Scheme 25[94]. After 20 minutes, 
the reaction mixture was filtered through Celite and the solvent was removed under vacuo. 
The product was analysed by 1H NMR but no aldehyde signal could be identified. To avoid 
any polymerisation, the solution must be kept in a solution of water (20 mL) with traces of 
trifluoroacetic acid. The reaction was repeated and the diamine was added just after the 
filtration, but no monocycle 18 was observed in 1H NMR. 
 
 
Scheme 25: Proposal mechanism for TEMPO-catalysed alcohol oxidation to corresponding 
aldehyde. 
 
5.2 Investigation into protection of triethylene glycol 
 
The interest of triethylene glycol derivatives was not limited to the synthesis of the 
Kryptofix [2.2.2]. The preparation of florbetaben 7 also required the incorporation of a 
triethylene glycol chain as shown in Scheme 26. 
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Scheme 26: Incorporation of monotosylated side chain to Florbetaben precursor 7. 
 
 Following the work on Kryptofix [2.2.2], the tosylate group seems to be the most 
reliable leaving group, more efficient than halogens. The other protecting group (PG) should 
have some characteristics such as resistance to basic media and, being able to deprotect under 
mild conditions e. g. a benzyl group.[95] 
 
5.2.1 Preparation of monobenzylated and monotosylated triethylene glycol 
 
The selective protection of only one of the two hydroxyl groups was performed by 
the addition of benzyl moiety.[91] To a stirred solution of triethylene glycol (4 equiv) in a 
basic medium (NaOH, 50%, 4 equiv), one equivalent of benzyl chloride was added and the 
reaction mixture was stirred under reflux for 20 hours (see Scheme 27). The crude mixture 
was not distillated with Kugelrohr, as mentioned in the reference, but just placed under 
vacuum to remove the solvents and triethylene glycol. The next step was carried out at 0 °C 
in the same flask, with addition of TsCl (1.5 equiv) and KOH (3.3 equiv) in 1.6 mL of water. 
The reaction was heated to room temperature over two hours and quenched with a saturated 
solution of ammonium chloride. After extraction and dried over Na2SO4, the residue was 
purified by flash chromatography to yield the glycol 31 in 40% yield over two steps (lit. 
60%[91]). 
 
 
i. BnCl (1 equiv), NaOH (4 equiv), H2O, reflux, 20 h; ii. TsCl (1.5 equiv), KOH (3.3 equiv), H2O, 0 
°C→r.t., 2 h, 40% overall yield. 
 
Scheme 27: Selective protection of the monobenzylated and monotosylated glycol 31. 
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 Despite an excess of base and triethylene glycol for the first step, the reaction, which 
was followed by TLC, did not offer significant results, even under reflux (40% overall yield).  
 
5.2.2  Preparation of monosilylated triethylene glycol 
 
Tert-butyldimetylsilyl moiety is a possible protecting group resistant to basic conditions, 
with a deprotection commonly carried out under mild conditions via a fluoride agent such as 
TBAF.[95, 96] Two relatively similar methods have been described in the literature, one 
provided by Zhang et al.[40] (catalysed) and another one performed by Jose et al.[97] (non-
catalysed) (see Scheme 28). 
  
 
Scheme 28: Reported procedure for monosilylated triethylene glycol 32. 
 
These two reactions afforded the monosilylated glycol 32 in 51 and 42% yield (see 
Scheme 28). An alternative synthetic route was found to prepare the monotosylated and 
silylated glycol in better yield. 
 
5.2.3 Preparation of monotosylated and silylated triethylene glycol 
 
To our knowledge no mechanism was suggested for this reaction, only an 
intermediate was proposed. [98, 99] The coordination of the triethylene glycol around the silver 
cation, acting as a Lewis acid, increases the lability of the hydrogen especially the one not 
involved in the intramolecular bonding (see Scheme 29). The effect is proportionally stronger 
to the number of oxygen atoms chelating the silver cation. The reaction is not performed 
under basic conditions but with the use of a catalytic amount of potassium iodide, which 
accelerates the sulfonylation. Following the reaction,[100] the monotosylated triethylene glycol 
was prepared in dichloromethane (HPLC grade). The yield dropped significantly to 60% 
instead of 95% in the literature with distilled dichloromethane. An attempt was performed by 
Method 1: TBSCl (1.1 equiv)
                  TEA (1.1 equiv) 
                  DMAP (10 mol%)
                  CH2Cl2, 0°C →r.t., 12 h
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simply degas the dichloromethane (HPLC grade) over 10 minutes before to commence the 
reaction. It is possible than the molecules of oxygen present inside the dichloromethane 
might interfere with the silver oxide reagent. The monosulfonylation was afforded in 90% 
yield. 
 
 
i. KI (0.1 equiv), Ag2O (1.2 equiv), TsCl (1 equiv), Ar, degassed CH2Cl2, r.t., overnight, 90%. 
 
Scheme 29: Selective silver oxide mediated monosulfonylation. 
 
Afterwards, the silylated group was incorporated based on the strategy of Zhang and 
co-workers[40] (see Scheme 30). 
 
 
i. TBSCl (1.2 equiv), TEA (1.2 equiv), DMAP (1 mol%), CH2Cl2, 0 °C→r.t., overnight, 82%. 
 
Scheme 30: Formation of the side chain for florbetaben precursor 7. 
 
The tosylated and silylated triethylene glycol 35 was obtained in 74% overall yield. In 
the literature,[97] the same molecule was synthesised by Jose and co-workers in 48% yield. 
 
5.3 Conclusion 
 
The different routes used to provide the Kryptofix [2.2.2] promoted the tosylate 
moiety as a suitable leaving group for a nucleophilic reaction into triethylene glycol 
derivative. Two bis-protected triethylene glycol were prepared (31 and 35) for the synthesis 
of the florbetaben precursor 7. The second (35) was obtained in high yield (74%) and will be 
used in section 7.3.2 with 4-nitro-4’-hydroxystilbene. The benzylated and tosylated glycol 31 
will be not used for two reasons. Its formation was performed in lower yield than the 
tosylated and silylated glycol 35 (40% vs 74% yield). The deprotection of benzyl chloride is 
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commonly achieved with palladium on charcoal and hydrogen gas, which can reduce the C–
C double bond present in the stilbene. 
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6.1 Florbetaben: a possible β-amyloid PET tracer for Alzheimer desease. 
 
 Alzheimer's disease (AD) is a neurodegenrative disease, which gradually worsens 
over time[101]. Its causative agents have not been yet well estblished. Nevertheless, the 
abondant number of β-amyloid (Aβ) peptide aggregates and highly phosphorilated tau 
proteins identified post-mortem in the patient brain could be cytotoxic to the neuronal cells 
and could indirectly lead to the dementia[102]. An early non-invasive diagnosis of AD could 
be established by monitoring the progression of theses aggregates. Imaging PET tracers 
targetting Aβ plaques have been developped based on histological amyloid staining agents 
such as Congo red, Thioflavin T and on styryl groups[103]. One of the PET tracers is the 
florbetaben 8, which can be binding with Aβ aggregates as shown in Figure 25. 
. 
 
 
Figure 25: Representative stuctures of the florbetaben cluster binded to the β-amyloid 
aggregated (grey arrows). The PET tracer has been colored following the free energies 
calculated for the tracer, light green (lower) and dark green (higher). The left picture is a 
view of the top layer and the right picture of the bottom layer. The atoms of oxygen, 
nitrogen and hydrogen at the edge of the β-proteins are shown in red, blue and white, 
respectively. 
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6.2 Synthesis of stilbene 7 as precursor for Florbetaben 8, a potential β-amyloid 
PET tracer 
 
To our knowledge, only a few papers have described the preparation of the 
polyethylene glycol stilbene 7. The first steps were reported by Ono and co-workers (see 
Scheme 31).[104] The nitro stilbene 37 was obtained via the Horner-Emmons-Wadsworth 
(HEW) reaction[105] by coupling the phosphonate 36 with p-anisaldehyde. Prior to this 
coupling, the nitro organophosphorus was synthesised following the Arbuzov reaction.[106] 
The advantage of using these conditions, compared to the Wittig reaction, was the synthesis 
of the E-isomer without formation of the Z-isomer. The nitro moiety was then reduced to 
the amine by a large excess of tin chloride (6 equiv). The N-monomethylation was 
performed via reductive amination of formaldehyde. The last step was the removal of the 
O-methyl group to form the corresponding phenol 40. 
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i. p-anisaldehyde (1 equiv.), NaOMe (25% w/w in methanol), reflux, 16 h, 90%; ii. SnCl2 (6 equiv), 
EtOH, 70 °C, 2 h, 94%; iii. step 1: (CH2O)n (1.4 equiv), NaOMe (25% w/w in methanol), MeOH, 0 
°C and step 2: NaBH4 (1.5 equiv), reflux, 1 h, 69%; iν . BBr3 (10 equiv), CH2Cl2, -78 °C→ r.t., 
overnight, 48%. 
 
Scheme 31: Synthesis of (E)-4-methylamino-4’-hydroxystilbene 40. 
 
The other route provided the  (E)-2-(2-(2-(4-(4-((tert-
butoxycarbonyl)(methyl)amino)styryl)phenoxy)ethoxy)ethoxy)ethyl methanesulfonate 7 by 
incorporating the triethylene glycol chain and by the replacement of protected groups (see 
Scheme 32). This sequence was achieved by Zhang and co-workers.[40] To perform the 
ether linkage, the commercially available 2-(2-(2-chloroethoxy)ethoxy)ethan-1-ol was 
coupled with stilbene 40 to form stilbene 41. The hydroxyl moiety was silylated (step ii) 
and the amine protected with a Boc group (step iii). Fluorine agent (TBAF) allowed the 
replacement of the TBS group by a mesylate (iν and ν). The presence of the mesylate or 
tosylate will permit an efficient incorporation of the [18F]-fluoride and the absence of 
silicon atom will not contaminate the labeling by bonding to the fluoride-18. 
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i. 2-(2-(2-chloroethoxy)ethoxy)ethan-1-ol (1.3 equiv), K2CO3 (5 equiv), dry DMF, 100 °C, 
overnight, 95%; ii. TBSCl (1.5 equiv), imidazole (2 equiv), CH2Cl2, r.t., 2 h, 95%; iii. (Boc)2O (1.9 
equiv), dry THF, N2, reflux, overnight, 86%; iv. TBAF (2 equiv), THF, r.t., 2; ν . MsCl (3 equiv), 
TEA (4.9 equiv), CH2Cl2, r.t., 4 h, 86% over two steps. 
 
Scheme 32: Synthetic route for preparation of 7 from 4-methylamino-4’-hydroxy stilbene 
40. 
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 To sum up, the stilbene 7 was prepared in 9 steps with an overall yield of 19%. The 
aim of this chapter will be to identify other routes to perform the desired precursor of 
Florbetaben 7. The different key steps were the formation of the stilbene (C-C double 
bond), the reduction of nitro group, the monomethylation, the deprotection of the O-methyl 
and the incorporation of the polyethoxy chain. The new route should reduce the number of 
steps and improve the overall yield. 
 
6.3 Formation of C-C bond for stilbene synthesis 
 
6.3.1 The Wittig reaction 
 
A well known method for the formation of C-C double bond is the Wittig reaction 
as shown in Scheme 33. The coupling between a phosphorus ylide and an aldehyde or a 
ketone generates an olefin and a phosphine oxide (driving force of the reaction). The 
stereoselectivity of the reaction is dependent of the substituent and can perform E and/or Z 
isomers. 
 
 
Scheme 33: Basic mechanism of the Wittig reaction. 
 
The phosphorus ylide is generally prepared by using a base and phosphonium salt. 
The salt is obtained by the nucleophilic attack of a phosphine on an alkyl halide, in this case 
a benzyl halide. Triphenylphosphine is the most common phosphine used for this reaction. 
The (4-nitrobenzyl)triphenylphosphonium bromide, shown in Scheme 34, was 
isolated in 88% yield after filtration and washing with acetone.[107] 
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i. PPh3 (2 equiv), toluene, 40 °C, overnight, 88%. 
 
Scheme 34: Synthesis of (4-nitrobenzyl)triphenylphosphonium bromide 46. 
 
 Various aldehydes were coupled with the phosphonium salt 46. The first one was 
prepared as shown in Scheme 35, the others were commercially available such as p-
anisaldehyde or benzaldehyde. The diversity of these aldehydes permits to determine the 
reactivity of the nitro phosphonium salt 46 for the Wittig reaction. The acetyl moiety 
replaced the methyl to ease and increase the yield of the deprotection step. 
 
 
i. AcCl (1.5 equiv), TEA (1.5 equiv), dry CH2Cl2, Ar, 1.25 h, 88%. 
 
Scheme 35: Acetylation of 4-hydroxybenzaldehyde 47. 
 
 Despite several conditions the formation of the stilbene in a practical yield failed 
(see Scheme 36). The crude mixtures were monitored by 1H NMR to confirm the presence 
of the stilbene and the aldehyde. 
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i. n-BuLi (2.5 M in hexane, 2 equiv), 46 (1 equiv), dry toluene, Ar,  r.t.→ 80 °C, overnight; ii. n-
BuLi (2.5 M in hexane, 2 equiv), 46 (1 equiv), dry toluene, Ar, -20 °C→r.t., overnight; iii. n-BuLi 
(2.5 M in hexane, 1.1 equiv), benzaldehyde (1.1 equiv), dry THF, -50 °C→r.t., overnight; iν . n-BuLi 
(2.5 M in hexane, 2 equiv), p-anisaldehyde (1 equiv), dry toluene, Ar, r.t., overnight; ν . NaOMe (2 
equiv), p-anisaldehyde (1 equiv), MeOH, r.t.; ν i. tBuOK (1.1 equiv), p-anisaldehyde (0.8 equiv), dry 
THF, 0 °C→r.t., overnight. 
 
Scheme 36: The Wittig reactions performed with (4-nitrobenzyl)triphenylphosphonium 
bromide 46. 
 
 n-BuLi was added dropwise at different temperatures and stirred for 30 minutes 
before adding the aldehyde. The change of color from yellow to red might be characteristic 
of the formation of the ylide 49. Nevertheless, none of the reactions succeeded in 
synthesising the stilbene. The nitro group placed in para position may interfere in the 
reactivity of the ylide 49 due its conjugate form 50 (see Scheme 37).  
 
 
 
Scheme 37: Possible conjugate form of the ylide made from 46 and the addition of a base. 
 
 Therefore, another organophosphorus compound was prepared to form the desired 
stilbene. It was obtained in three steps in 77% overall yield (see Scheme 38). p-
Anisaldehyde was reduced with LiAlH4 (94% yield) in dry Et2O. After workup, 
PPh3Br
46
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dichloromethane was added in the crude mixture and placed in the dark. The brominating 
agent (PBr3) formed the benzyl bromide 52 in 96% yield.[108] The formation of the 
phosphonium salt 53 with triphenylphosphine occurred quickly after isolation of the halide 
52 to avoid any degradation of the starting material due to exposure to the light. 
 
 
i. LiAlH4 (1 equiv), dry Et2O, Ar, 0 °C→r.t., 2 h, 94%; ii. PBr3 (1 equiv), CH2Cl2, in the dark, r.t., 3 
h, 96%; iii. PPh3 (1 equiv), toluene, reflux, overnight, 86%. 
 
Scheme 38: Preparation of (4-methoxybenzyl)triphenylphosphonium bromide 53. 
 
 The triphenylphosphonium salt 53 was then used with 4-nitrobenzaldehyde to form 
an olefin as shown in Scheme 39.  
 
 
i. tBuOK (1.3 equiv), p-nitrobenzaldehyde (0.9 equiv), dry THF, Ar, r.t., mixture of E/Z (32%, 14:1); 
ii. I2 (1 bead), heptane, reflux, 12 h, E-isomer (30% over 2 steps). 
 
Scheme 39: Formation of (E)-4-nitro-4’-methoxystilbene 37. 
 
 The mixture of E/Z-isomers was isolated with success after purification by flash 
chromatography. The pure E-isomer was obtained by isomerisation of the Z-isomer by 
using a catalytic amount of iodine in heptane under reflux.[109] After removal of iodine with 
a saturated aqueous solution of sodium bisulfite the stilbene 37 was collected in 30% yield. 
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 An alternative procedure to form only the E-isomer was to reflux the Wittig 
reaction in CH2Cl2. The solution was concentrated under reduced pressure and the residual 
mixture was purified by filtration in methanol at low temperature (–40 °C). The pure 
product 37 was obtained as a yellow powder in 16% yield (see Scheme 40). 
 
 
i. p-nitrobenzaldehyde (0.9 equiv), K2CO3 (2.3 equiv), dry CH2Cl2, reflux, overnight, 
16%. 
 
Scheme 40: The Wittig reaction under reflux to synthesize the E-isomer of the stilbene 37. 
 
The compound 37 was synthesised but in low yield (16%). However it was the 
same stilbene than Ono and co-coworkers.[104] A different reaction and/or different substrate 
should permit the synthesis of a more suitable stilbene. 
 Therefore, a precursor for the Heck reaction (styrene 54), shown in section 7.2.2, 
was prepared from the Wittig reaction to form the C—C double bond (see Scheme 41).  
 
 
i. tBuOK (2.5 equiv), MePPh3Br (1.5 equiv), dry THF, N2, 0 °C→r.t., 4 h, 60%. 
 
Scheme 41: Synthesis of 4-vinylphenol 54. 
 
 Obtaining a 60% yield for the Wittig reaction with the presence of a labile 
hydrogen, nitro phosphonium was involved again for the C–C coupling but with 4-hydroxy 
benzaldehyde. The method[110] was carried out in dry CH2Cl2 under reflux with a weak base 
OMe
P(Ph)3Br
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i
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i
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(K2CO3), instead of strong base such as tBuOK used previously in Scheme 39. The reaction 
mixture was purified by flash chromatography to yield the desired E-stilbene 55 in 82% 
yield as shown in Scheme 42. 
 
 
i. 4-hydroxybenzaldehyde (0.8 equiv), K2CO3 (4 equiv), dry CH2Cl2, Ar, reflux, overnight, 82%. 
 
Scheme 42: Formation of 4-nitro-4’-hydroxystilbene 55. 
 
In conclusion, after an intensive experimentation to perform a stilbene via the 
Wittig reaction, two stilbenes were synthesised (37 and 55). The product 55 formed in high 
yield (82%) has the advantage of not having a methoxy moiety and so not requiring its 
deprotection as a further step. 
 The exploration of phosphonates to perform the HEW reaction was abandoned due 
to the difficulty to separate the desired phosphonate from the triethyl phosphite. Even 
though 4-aminobenzylphosphonate was commercially available, its coupling with p-
anisaldehyde in methanol did not offer the desired stilbene. 
 
6.3.2 Investigation of the stilbene formation via the Heck reaction 
 
Based on catalysed C–C bond coupling, Heck, Suzuki and Negishi were awarded 
the Nobel Prize in 2010.[111] The Heck reaction generates a more highly substituted alkene 
from an aryl/vinyl halide or triflate coupled with an olefin. 
The catalytic cycle occurred by the formation of the Pd0 by incorporation of 
monophosphine ligands (L type). The oxidative addition of the aryl halide generates PdII 
complex, which can then incorporate the olefin and form the Csp3–Csp3 bond. Depending on 
the orientation of the alkene attached to the palladium complex, the insertion of the aryl 
group can be achieved at two different positions and so forms two different products (see 
Scheme 43). After C–C rotation, the syn β-hydride elimination occurred and products were 
NO2
PPh3Br
46
(E)
NO2
OH
55
i
82%
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released from the palladium complex. The base, usually TEA, regenerates the Pd0 and the 
catalyst can carry on another catalytic cycle. The number of cycles (turn over) performed 
by the same catalyst can involve more than 150 000 cycles. 
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Scheme 43: Mechanism of the Heck reaction performed with monophosphine ligands.[112] 
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Presented in Scheme 44, the Heck reaction was performed with 4-methoxystyrene 
and two aryl iodides (4-amino-iodo-benzene and 4-nitro-iodo-benzene). Unfortunately none 
of the reactions worked, only starting materials were recovered. 
 
 
i. (R= NH2) 4-iodoaniline 56a (1 equiv), 4-methoxystyrene (2 equiv), Pd(OAc)2 (7 mol%), TEA (63 
equiv), PPh3 (1 equiv), Cu (9 mol%), Ar, dry THF, r.t.→80 °C, overnight; ii. same procedure at r.t.; 
iii. (R= NH2) 4-iodoaniline 56a (1 equiv), 4-methoxystyrene (2 equiv), ), Pd(OAc)2 (7 mol%), 
K2CO3 (2 equiv), TEA (6 equiv PPh3 (1 equiv), iν . (R= NO2) 1-iodo-4-nitrobenzene 56b (1 equiv), 
4-methoxystyrene (1.3 equiv), Pd(OAc)2 (3 mol%), TEA (2.3 equiv), PPh3 (7 mol%), ν . (R= NO2) 1-
iodo-4-nitrobenzene 56b (1 equiv), 4-methoxystyrene (1.3 equiv), Pd(OAc)2 (3 mol%), TEA (63 
equiv), PPh3 (7 mol%). 
 
Scheme 44: Exploration of the Heck reaction to form amino stilbene 58 or nitro stilbene 37. 
 
Recently reported, stilbenes can be synthesised via a tandem reaction 
Heck/decarboxylation/Heck (see Scheme 45).[113] 
 
 
Scheme 45: Formation of stilbenes by using the palladium-catalysed Heck reaction. 
 
 To our knowledge, no method was reported to synthesise 4-nitro or 4-amino 4'-
hydroxystilbenes by using the Heck reaction, this reaction was abandoned. 
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6.3.3 Synthesis of the 4-nitro-4’-hydroxystilbene via the Knoevenagel reaction 
 
The expansion of scope for stilbene formation continued with the Knoevenagel 
condensation as shown in Scheme 46. The selectivity of this reaction induced by the trans-
elimination, forms the E-isomer. 
 
 
Scheme 46: Mechanism for stilbene 55 synthesis via a Knoevenagel reaction. 
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 The advantages of this method were the use of commercially available reagents (4-
hydroxybenzaldehyde and (4-nitrophenyl) acetic acid). Therefore, no preparation of starting 
materials was required for this procedure. As with the Wittig reaction, the synthesis of 4-
nitro-4’hydroxystilbene avoided the deprotection with BBr3 leading to low yield (48%). 
The pure stilbene was isolated in reasonable scale (up to 2 grams) after filtration and 
recrystallisation.  Purification by flash chromatography was not required for this synthesis. 
 
 4-Nitro-4’-hydroxy stilbene 55 was prepared in 72% yield (lit. 75%) by following 
the work of Diemer et al. (see Scheme 47, step i).[114] The workup involved the addition of 
H2O/EtOH (3:1) with glacial acetic acid (0.1 mL) under reflux. The reaction mixture was 
then filtered and recrystallised in iPrOH to give the pure product 55. 
 
 
i. 4-hydroxybenzaldehyde (0.7 equiv), piperidine (1 mL), Ar, 140 °C, 1 h, 72%; ii. 4-
hydroxybenzaldehyde (1 equiv), piperidine (1 equiv), vacuum, 100 →150 °C, 3 h, 85%. 
 
Scheme 47: Formation of 4-nitro-4’-hydroxystilbene 55 following two different methods. 
 
An alternative procedure (see Scheme 47, step ii), proposed by Vangala and co-
workers, produced the stilbene 55 in 85% yield (lit. 90%).[115] The reaction was performed 
under vacuo instead of under an inert atmosphere. Heated to 100 °C for 1 hour, the reaction 
was then heated to higher temperature than the Diemer method for 2 hours (150 °C). The 
workup was carried out with an aqueous solution of NaOH (6 M) and the mixture heated to 
60 °C for 30 minutes. Afterwards a concentrated solution of HCl (36%) was added at room 
temperature to neutralise the reaction. The pure product 55 was collected after filtration.  
The difference between these methods was that the stilbene 55 was obtained in two 
different colors, brown for Diemer method and yellow for Vangala procedure. 
 
Achieving the stilbene 55 in high yields, this method was expanded to the 
formation the 4-nitro-4’-methoxystilbene 37. Described in the literature with low yield 
NO2
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59 55
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(34%)[116] via the Knoevenagel reaction, the synthesis was proceeded following the 
Vangala’s method (see Scheme 44). 
 
i. p-anisaldehyde (1 equiv), piperidine (1 equiv), vacuum, 100 →150 °C, 3 h, 34%; ii. p-
anisaldehyde (1 equiv), piperidine (1 equiv), pyridine (1 equiv), vacuum, 100 →150 °C, 3 h, 52%. 
 
Scheme 48: Formation of the methoxy stilbene 37 by the Knoevenagel reaction. 
 
 The first experiment offered the same yield (34%) than the work of Barnwell[116] 
but the addition of one equivalent of another base, pyridine, increased the yield to 52%. 
Comparing with the HWE reaction carried out by Ono and co-workers,[104] the experiment 
in Scheme 48 offered lower yield of 38% difference. 
 
6.3.4 Investigation into 4-hydroxybenzaldehyde 
 
Prior to incorporate the triethylene chain with the 4-nitro-4’-hydroxy-stilbene 55, 
commercially available 4-hydroxybenzaldehyde was reacted with the 2-(2-(2-
chloroethoxy)ethoxy)ethan-1-ol (see Scheme 49) to develop a suitable method for 
connecting the three ethoxy glycol derivatives to a phenol. 
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Entry 
Ether chain 
Equivalent 
Base (equiv) 
Additive 
(equiv) 
Solvent 
Temperature 
(° C) 
Presence of 
product 
1[117] 3.5 K2CO3 (3.5) _ DMF 100 yesa 
2[118]       1 K2CO3 (3) KI (3) DMFb 120 yesa 
3 1 K2CO3 (3) KI (3) toluene 100 no 
4 1 imidazole (3) TBAI (3) MeCN reflux no 
5 1 DBU (2) DMAP (2) toluene 100 no 
6 1 K2CO3 (2) MSc acetone reflux no 
7 1.1 K2CO3 (2.2) KI (cat.) EtOH reflux 37% 
a. The 1H NMR identified the desired product but the pure product was not obtain after filtration and 
flash chromatography; b. the reaction was proceeded under inert atmosphere; c. molecular sieves 
(MS) 4 Å 
 
Scheme 49: Exploration of several condition reactions of a phenol on chloro-triethylene 
alcohol. 
 The experiments revealed the need of a potassium base for the nucleophilic attack 
of the phenol derivative. The use of strong base (DBU) or nucleophilic base such as 
imidazole and DMAP did not perform SN2 reaction. The 4-hydroxybenzaldehyde was 
identified by 1H NMR after each failed reactions without the presence of the desired 
product. Polar solvents such as DMF or EtOH seemed to promote the reaction. Toluene and 
acetonitrile, which were used for the Kryptofix [2.2.2] synthesis, did not allow the reaction 
to take place.  
 
 An alternative method for the incorporation of the triethylene glycol was performed 
by using the Mitsunobu reaction. The synthesis was carried out for 2 days and offered the 
desired product in 41% yield as shown in Scheme 50. 
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i. triethylene glycol (5 equiv), PPh3 (1 equiv), DIAD (1.1 equiv), CH2Cl2, 0 °C→r.t., 2 days, 41%. 
 
Scheme 50: Incorporation of the triethylene chain via the Mitsunobu reaction. 
 
6.3.5 Investigation into 4-nitro-4’-hydroxystilbene 55 
 
 
i. 2-(2-(2-chloroethoxy)ethoxy)ethan-1-ol (1.2 equiv), K2CO3 (4 equiv), dry DMF, Ar, 90 °C, 
overnight, 34%; ii. 2-(2-(2-chloroethoxy)ethoxy)ethan-1-ol (1 equiv), K2CO3 (2 equiv), dry DMSO, 
Ar, 120 °C, 1.5 h, 71% of E/Z isomers, ratio 15/1; iii. TBSCl (1.2 equiv), imidazole (1.4 equiv), 
DMAP (3 mol%), CH2Cl2, 0 °C →r.t., overnight, 55%. 
 
Scheme 51: Triethylene derivative linked to stilbene 55 via nucleophilic attack. 
 
 The first method (see Scheme 51, step i) was based on Zhang and co-workers.[40] 
The reaction was performed at 90 °C instead of 100 °C and with one less equivalent of the 
base (K2CO3). The yield dropped significantly to 34% (lit. 95%). The use of anhydrous 
DMSO instead of dry DMF accelerates the reaction but also forms the Z-isomer not initially 
present. The second method (see Scheme 51, step ii) was performed at 120 °C and followed 
by TLC monitoring. The enhancement of the nucleophilic attack with a potassium base 
reagent might be explained by the formation of potassium salt of DMSO which acts as a 
superbase.[119] However the presence of potassium base with DMSO can create radicals and 
can explain the formation of the Z-isomer. 
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 Even with the use of a catalyst (DMAP), the silyl protection could only be achieved 
in low yield (55%) compared to the value reported by Zhang and co-workers (95%) for the 
silyl protection of (E)-2-(2-(2-(4-(4-(methylamino)styryl)phenoxy)ethoxy)ethoxy)ethan-1-
ol 41. 
 
 As mentioned in section 6.1.1, tosylate group seemed to be a better leaving group 
and allow a better reactivity to incorporate the triethylene glycol chain. Therefore the chain 
35 prepared in section 6.2.3 was linked to the stilbene 55. This method afforded the 
protected stilbene with ether chain 61 in one step and in 86% yield (see Scheme 52). 
 
 
i. 35 (1 equiv), K2CO3 (2 equiv), DMF, 90 °C, overnight, 86%. 
 
Scheme 52: Formation of the stilbene 61 in one step. 
 
 The 4-nitro-4’-hydroxystilbene 55 was used as limiting reagent (0.9 equiv) and the 
reaction proceeded at 90 °C. Different from the reaction proposed by Ono and co-workers 
(see Scheme 32, step i), anhydrous conditions were not required to synthesise the stilbene 
61 by using the tosylated silylated glycol 35.  
 
6.4 Reduction of the nitro moiety to an amine 
 
To form the desired precursor 7, the nitro group must be reduced to an amine. The 
most common methods to reduce a nitro moiety to amine are palladium on charcoal (Pd/C) 
with hydrogen gas or the use of Raney nickel catalyst. The latter method involves the 
catalyst, a nickel-aluminium alloy, and hydrogen gas or hydrazine. These reactions are also 
known to reduce C—C double bond of the styrene.[110] Nevertheless these conditions were 
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performed at low temperature (down to –40 °C) but several side products were formed, so 
these reactions were not studied further. 
 
6.4.1 Reduction of nitro group via Lewis acid 
 
An alternative method for the reduction of nitro group is the use of Lewis acid as 
reported by Ono and co-workers.[104] Tin chloride or hydrated tin chloride or iron can 
reduce the nitro moiety in EtOH under reflux with or without additives (brønsted acid). The 
reduction of the nitro moiety is generally performed with the absence of labile proton.[40, 104, 
117, 120] The next experiment confirmed the lack of reactivity with the presence of the phenol. 
(see Scheme 53). 
 
 
i. Fe (5 equiv), conc. acetic acid (2 drops), EtOH, reflux, overnight; ii. SnCl2•H2O (5 equiv), EtOH, 
reflux 2 h. 
 
Scheme 53: Reduction of the stilbene 55. 
 
 The desired product was identified in both reactions by 1H NMR but a lot of 
starting material 55 remained with the presence of side products. This reaction was 
performed by Vangala and co-workers[115] and afforded the amino stilbene 62 in 17% yield. 
No explanation was given such as the temperature of the reaction conditions or details 
about the purification step or the amount of hydrated tin chloride used. 
 
 The stilbene 60 was reacted with the same reagent. After purification through silica 
column the pure product 63 was obtained in 34% yield (see Scheme 54). 
 
 
NO2
OH
55
i, ii
NH2
OH
62
Chapter 6   
 
 
94 
 
i. SnCl2•H2O (5 equiv), EtOH, reflux overnight, 34%. 
 
Scheme 54: Reduction of the nitro moiety of the stilbene 60. 
 
The stilbene 61 was also involved by the reduction of the nitro moiety as shown in 
Scheme 55.  
 
 
i. SnCl2•H2O (5 equiv), EtOH, reflux overnight. 
 
Scheme 55: Reduction of the stilbene 61. 
 
However after workup, the 1H NMR spectroscopy of the crude mixture (see Figure 
26) shows the removal of the silyl group. The possible formation of (E)-2-(2-(2-(4-(4-
aminostyryl)phenoxy)ethoxy)ethoxy)ethan-1-ol was not confirmed due to the absence of 
data of this molecule. Therefore another method must be found to perform the reduction of 
the nitro group. 
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Figure 26: 1H NMR of the crude mixture of the stilbene 61 reacting with tin chloride. 
 
 
The reduction was performed with palladium on charcoal (10%) and a large excess 
of NaBH4[121] (see Scheme 56). The reducing agent was added over 30 minutes at –40 °C. 
The reaction must be kept cold to avoid the formation of side products. The use of two 
solvents was necessessary for this reaction. The nitro stilbene 61 is solid in methanol at low 
temperature (below −20 °C) but dissolved in THF at the same temperature. The color of the 
reaction changed from yellow to colorless, signalling the consumtion of the starting 
material 61. After 2 hours the crude mixture was monitored by TLC to confirm the 
completion of the reaction. Even if some traces of starting material remains, a quick 
filtration at –20 °C through celite and washing with cold methanol provided the product 63 
with NaBH4. The mixture was then put inside a ultrasonic bath to degas the solution and an 
aqueous solution of KOH (1 M) was added at 0 °C to neutralise the boron salt. After a 
normal extraction with Et2O, the pure product 63 was isolated in high yield (82%). 
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i. Pd/C (20 mg), NaBH4 (26 equiv), EtOH/MeOH, −40 →−20 °C, 3 h, 69%, ii. Pd/C (20 mg), NaBH4 
(12 equiv), THF/MeOH, −30 →−20 °C, 3 h, 82%. 
 
Scheme 56: Reduction of nitro stilbene 61 by using NaBH4 and Pd/C at low temperature. 
 
 No other stilbenes were reduced by this method. The protected alcohol might offer 
a suitable starting material for the substitution of the aryl amine. 
 
 Another mild method was reported by Crump and co-workers as shown in Scheme 
57, where the catalyst used was an alloy of 1% platinum with 2% vanadium on charcoal.[122] 
 
 
Scheme 57: Nitro reduction by using 1% Pt + 2% V/C. 
 
It was not possible to use this reaction because no supplier was found to buy the 
vanadium on charcoal or any paper to synthesise it. Nevertheless, the authors mentioned a 
supposed mechanism for the hydrogenation of the nitro substrate with catalyst. 
 Indeed within the nitro reduction of 61 with Pd/C and NaBH4, several 
intermediates were formed and monitored by TLC analysis. 
Following this possible mechanism (see Scheme 58),[122, 123] two pathways were 
described to perform the amine product. For each intermediate formed after hydrogenation, 
except for the hydrazo compound, one molecule of water was generated. 
 
61
NH2
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O
H2 (4.5 bar)
1% Pt + 2% V/C
EtOH, 40 °C, 1h
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Scheme 58: Potential pathways of the nitro reduction by using H2 and metal catalyst. 
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6.4.2 N-Monoalkylation of a primary amine 
 
N-Monomethylation under basic conditions 
 
 Originally performed on 4-amino-4’-methoxystilbene 37 by Ono and co-
workers,[104] the N-methylation was performed on the (E)-2,2,3,3-tetramethyl-12-(4-(4-
nitrostyryl)phenoxy)-4,7,10-trioxa-3-siladodecane 63 as shown in Scheme 59. The first step 
was the formylation of the amine via paraformaldehyde in the basic medium under reflux. 
Instead of waiting to receive a commercial solution of sodium methoxide (25% w/w in 
MeOH), the reagent was prepared in situ with sodium metal and MeOH. After one hour the 
solution was cooled to room temperature and NaBH4 added. The reaction mixture was 
stirred for one hour under reflux. The formamide 64 was then reduced to perform the N-
methylamine 65.  
 
 
i. Na (4 equiv, 30% w/w in paraffin), paraformaldehyde (1.4 equiv), MeOH, reflux 1 h; ii. NaBH4 
(1.5 equiv), reflux, 1 h. 
 
Scheme 59: N-methylation following the Ono method.[104] 
 
Unfortunately, the experimental 1H NMR of the crude mixture did not match with 
the NMR data reported by Zhang and co-workers. A doublet at 6.6 ppm was missing. 
Because of the non-elucidation of this missing peak the method was not repeated and other 
procedures were used. 
  
NH2
O O
TBS
NH
O O
TBS
i ii
O
H NH
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63 64 65
3
3
3
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N-Monomethylation under acidic conditions 
 
 The procedure was reported by Andrews and co-workers[124] in 2012. The first step 
was the in situ formation of the acetic formic anhydride reagent from acetic anhydride and 
an excess of formic acid (see Scheme 60). The reaction was stirred at 60 °C for two hours 
and then the amino stilbene 63 was added at 0 °C. After 16 hours the reaction was 
quenched and the crude mixture analysed by 1H NMR spectroscopy. Unfortunately the 
proton of the formamide (around 10 ppm) was not observed. 
 
 
 
i. formic acid (97%, 1.6 equiv), 60 °C, 2 h; ii. 63, 0°C →r.t., 16 h. 
 
Scheme 60: Experimentation of the formylation of an aryl amine under acidic reaction 
conditions. 
 
6.5 Conclusion and possible other strategy 
 
No reliable methods were found for the N-methylation of a stilbene. So the precursor 
of florbetaben has not been synthesised. Nevertheless the amino stilbene 63 was 
synthesised in three steps with an overall yield of 60%. A suitable method using Pd/C and 
NaBH4 allowed the reduction of the nitro moiety with the presence of C–C double bond at 
low temperature. To reach the precursor the key step remains the monomethylation of the 
amine. 
 
A new pathway could be to buy a commercially available N-methyl substrate to form 
the 4-methylamino-4-hydroxystilbene over 3 steps. The 4-(methylamino)benzoic acid or 
O
O O
HO
O O
1.3 equiv
i
HN
O O
TBS
3
O
H
ii
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methyl 4-(methylamino) benzoate might facilitate the synthesis to access the desired 
precursor of florbetaben 7 (see Scheme 61). 
 The process should be to reduce the 4-(methylamino)benzoic acid to the 
corresponding alcohol via a reducing agent such as DIBAL or borane dimethyl sulfide 
complex (BMS) or LiAlH4 (step i or ii). The alcohol would be oxidised with MnO2 to 
perform the aldehyde, the 4-(methylamino)benzaldehyde (step iii).[125] The key step (iν) 
would be the formation of the stilbene via the Knoevenagel reaction by using this aldehyde 
and 4-hydroxyphenylacetic acid, which is commercially available. The following steps 
should be the Boc protection of the amine (step ν) and the use of the tosylated, silylated 
triethylene glycol performed in this work (step ν). The next sequences have been already 
describes by Wang and co-workers[126] to form the precursor 7 in 3 steps (νi to νiii, see 
Scheme 32). 
 
 
Scheme 61: Possible strategy to perform the N-Boc protected mesylate precursor 7. 
 
 
 
 
HN
O OMe
i
HN
OH
iii
HN
O
iν
HN
OH
ν,νi,νii,νiii 7
HN
O OH
ii
Chapter 7   
 
 
 
 
 
 
 
  
Chapter 7:  Experimental 
Chapter 7   
 
 
101 
 
 
 
 
Reagents were obtained from Sigma Aldrich, Alfa Aesar, VWR suppliers and ABX 
(Germany) for the ultra pure mannose triflate and used as received unless otherwise 
specified. Solvents and reagents were purified according to Perrin, Armarego and Perrin’s 
methods.[127] Dichloromethane were dried by refluxing over, and distilling from, calcium 
hydride. Anhydrous tetrahydrofuran was performed by refluxing over sodium with sodium 
benzophenone ketyl as indicator, followed by distillation or directly obtained from an 
MBRAUN Solvent Purification System like dry diethyl ether and dry toluene. Anhydrous 
dimethylformamide was purchased to Alfa Aesar in molecular sieves and dry acetonitrile 
furnished by Sigma Aldrich as well in molecular sieves. “Filtered” designates the removal 
residues by gravity filtration of organic solutions through filter paper. “Evaporated” points 
out the distillation of volatiles using a Büchi rotary heated with a water bath between 20 and 
80 °C. “Degassed” refers to a ventilated solution placed in an ultrasonic bath. 
 All reactions using air/moisture sensitive reagents were performed in oven-vacuum-
dried apparatus under an Argon atmosphere. Solid carbon dioxide and an acetone/EtOH (1:1) 
bath (−78 to −20 °C) or an ice-water bath (−5 to 5 °C) were used to obtain low temperatures 
unless otherwise stated. “m.p.” stands for melting point. Heated batch reactions were 
conducted in a heating block on a magnetically stirred hot plate. Reactions were followed and 
monitored by TLC, 1H NMR, 13C NMR and 19F NMR. The [18F] syntheses were monitored 
by radio-TLC and the level of radioactivity of a sample was detected via a dose calibrator. 
 TLC analysis refers to analytical Thin Layer Chromatography, using aluminium-
backed plates coated with Merck Kieselgel 60 GF254. Chemical spots were viewed either by 
UV fluorescence, or stained with a suitable staining agent. Column chromatography 
designates a flash column chromatography using head pressure by means of compressed air, 
and using Merck Kiesegel 60 F254 silica. 
Melting points were recorded using a GallenKamp Melting Point Apparatus and are 
uncorrected. 
Infrared spectra were recorded in the range 4000-700 cm−1 using a Iraffinity-1 Shimadzu 
FTIR-8400S instrument on a zinc selenide crystals. All absorption are quoted in wave 
numbers (cm−1) 
  
7 General experimental details 
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8.1 [19F]-Fluorination of mannose triflate in batch and microtubing 
 
8.1.1 Procedure in batch 
 
1,2,3,4,6-O-acetyl-β-D-glucose 13[128] 
 
 In a 25 mL round-bottomed flask, mannose triflate 9 (25 mg, 52.0 µmol), K19F (3 
mg, 52.0 µmol) and Kryptofix [2.2.2] (23.5 mg, 62.4 µmol, 1.2 µmol) were dissolved in 
CH3CN (3 mL). After 20 minutes under reflux, the reaction mixture was concentrated and 
then purified by flash chromatography (Petrol/EtOAc, 3:1). The peracetylated D-glucose 13 
was obtained as a colourless solid (3 mg, 7.7 µmol, 15%). 
1H NMR (400 MHz, CDCl3): δ = 5.72 (1 H, d, J = 8.3 Hz), 5.24 (1 H, dd, J = 9.4 Hz), 5.19- 
5.08 (1 H, m), 4.28 (1 H, dd, J = 12.4, 4.4 Hz), 4.11 (1 H, dd, J = 12.4 Hz, 2.4 Hz), 3.84 (1 H, 
ddd, J = 10.0, 4.4, 2.2 Hz), 2.11 (3 H, s), 2.09 (3 H, s), 2.04 (3 H, s), 2.02 (3 H, s) ppm. 
No additional data due to the low amount of product. 
 
 
8.2 Mono and bis-protection of triethylene glycol 24[129] 
 
 
A catalytic amount of DMAP (122 mg, 1 mmol, 5 mol%) and tosyl chloride (11.4 g, 
60.0 mmol, 3 equiv) were added in a stirred solution of triethylene glycol 24 (3.0 g, 20.0 
mmol) and TEA (8.4 mL, 60.0 mmol, 3 equiv) in CH2Cl2 (100 mL). The reaction mixture 
was stirred overnight at room temperature. After addition of water (100 mL), the aqueous 
OAcOAcO
OAc
OAc
OAc
9
OAcOAcO
OTf
OAc
OAc
13
15%
K19F (1 equiv)
K[2.2.2] (1.2 equiv)
CH3CN, reflux, 20 min
HO O OH2
TsCl  (3 equiv)
TEA  (3 equiv)
DMAP (5 mol%)
2524
TsO O OTs2CH2Cl2, r.t., overnight
87%
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layer was extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude solid was purified by 
flash chromatography (Petrol/EtOAc, 1:3) to yield the ditosylate 25 as a white powder (7.56 
g, 16.5 mmol, 82%). 
m.p. 81-82 °C (lit.[129]: 80-81 °C) 
1H NMR (400 MHz, CDCl3): δ = 7.67 (4 H, d, J = 8.1 Hz), 7.26 (4 H, d, J = 8.0 Hz), 4.04 (4 
H, t, J = 4.2 Hz), 3.55 (4 H, t, J = 8.1 Hz), 3.41 (4 H, t, J = 2.3 Hz), 2.34 (6 H, s) ppm. 
13C NMR (101 MHz, CDCl3): δ =145.0 (C), 132.9 (C), 129.9 (CH), 127.9 (CH), 70.6 (CH2), 
69.4 (CH2), 68.7 (CH2), 21.6 (CH3) ppm. 
IR (νmax) = 3059, 2965, 2872, 1593, 1598, 1451, 1355, 1265, 1190, 1176, 1097, 1097, 920, 
886. 
 
 
2-(2-(2-(Benzyloxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate 31[130] 
 
 
To an aqueous solution of NaOH (516 mg, 12.9 mmol in 2.9 mL of distilled water, 
4.3 equiv), triethylene glycol 24 (2 mL, 15.0 mmol, 4 equiv) and benzyl chloride (0.35 mL, 
3.0 mmol) were added. The reaction was heated under reflux for 20 hours. The crude mixture 
was concentrated in vacuo and dissolved in THF (20 mL). p-Toluenesulfonyl chloride (2.38 
g, 12.5 mmol, 1.5 equiv) was added at room temperature followed by an aqueous solution of 
KOH (1.54 g, 27.4 mmol, 3.3 equiv) in deionised water (1.6 mL) poured dropwise at 0 °C 
over 15 min. The reaction was kept at 0 °C for 30 min and a white precipitate appeared. After 
2 hours at room temperature the mixture was neutralised with a saturated solution of 
ammonium chloride and extracted with CH2Cl2 (3 x 20 mL). The combined organic layers 
were dried, filtered and concentrated under reduced pressure. The residue was purified by 
flash chromatography (Petrol/EtOAc, 3:1) to yield the bis-protected glycol 31 (1.79 g, 4.54 
mmol, 40%) as a colourless oil. 
1H NMR (400 MHz, CDCl3): δ = 7.78 (2 H, J = 8.3 Hz, HAr), 7.50- 7.28 (7 H, m, HAr), 4.54 
(2 H, s, CH2Ph), 4.20- 4.04 (4 H, m, OCH2), 3.90- 3.53 (8 H, m, OCH2), 2.42 (3 H, s, CH3) 
ppm. 
1) BnCl
    NaOH (4.3 equiv)
    H2O, reflux, 20 h
2) TsCl (1.5 equiv)
    KOH (3.3 equiv)
    H2O, 0 °C to r.t.,
    2 h
24 31
40%
HO O OH2 BnO
O OTs2
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13C NMR (101 MHz, CDCl3): δ = 144.9 (C), 138.0 (C), 133.1 (C), 129.9 (CH), 128.5 (CH), 
128.0 (CH), 127.8 (CH), 127.6 (CH), 73.3 (CH2), 71.0 (CH2), 70.7 (CH2), 70.6 (CH2), 69.4 
(CH2), 69.3 (CH2), 68.7 (CH2), 21.64 (CH3) ppm. 
IR (νmax) = 2917, 2865, 1597, 1496, 1454, 1352, 1189, 1175, 1120, 1096, 1012, 916, 897, 
814. 
 
 
2-(2-(2-Hydroxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate 34[100] 
 
 
Potassium iodide (276 mg, 1.66 mmol, 0.1 equiv), silver oxide (4.63 g, 16.7 mmol, 
1.2 equiv) and p-toluenesulfonyl chloride (3.17 g, 16.7 mmol) were added to a solution of 
triethylene glycol (2.5 g, 16.7 mmol) in degased CH2Cl2 (75 mL). The reaction mixture was 
stirred at room temperature overnight and then filtered through Celite. The filtrate was 
concentrated and purified by flash chromatography (CH2Cl2/acetone, 7:3) to yield the title 
product 34 (4.33 g, 14.9 mmol, 90%) as a colourless oil. 
1H NMR (400 MHz, CDCl3): δ = 7.78 (2 H, d, J = 8.3 Hz, HAr), 7.33 (2 H, d, J = 8.4 Hz, 
HAr), 4.17- 4.11 (2 H, m, OCH2), 3.72- 3.65 (4 H, m, OCH2), 3.60- 3.51 (6 H, m, OCH2), 2.43 
(3 H, s, CH3), 2.29 (1 H, br, OH) ppm. 
13C NMR (101 MHz, CDCl3): δ = 145.2 (C), 133.2 (C), 130.2 (CH), 128.3 (CH), 72.8 (CH2), 
71.1 (CH2), 70.6 (CH2), 69.5 (CH2), 69.0 (CH2), 62.0 (CH2), 22.0 (CH3) ppm. 
IR (νmax): 3402, 3060, 2918, 2868, 1596, 1452, 1353, 1176, 1120, 1008, 817, 664. 
 
  
HO O OH2
KI (0.1 equiv)
Ag2O (1.2 equiv)
TsCl (1 equiv)
degas DCM, r.t.,
overnight
90%
TsO O OH2
24 34
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2,2,3,3-Tetramethyl-4,7,10-trioxa-3-siladodecan-12-yl 4-methylbenzenesulfonate 35[97] 
 
 
To a solution of mono-protected triethylene glycol 34 (1.61 g, 5.55 mmol), TEA (0.9 
mL, 6.65 mmol, 1.2 equiv) and DMAP (10 mg, 81.9 µmol, 1 mol%) in CH2Cl2 (20 mL) was 
added TBSCl (1.0 g, 6.66 mmol, 1.2 equiv) at 0 °C. After 10 min at 0 °C the reaction mixture 
was allowed to reach room temperature and was stirred overnight. Deionized water was 
added (10 mL) to the solution and the aqueous layers were extracted with CH2Cl2 (3 x 20 
mL). The combined extracts were dried over Na2SO4 and then filtered off. The product 
mixture was concentrated and purify by flash chromatography (Petrol/EtOAc, 2:1) to offer 
the bis-protected triethylene glycol 35 (1.89 g, 4.52 mmol, 90%) as a colourless oil. 
1H NMR (400 MHz, CDCl3): δ = 7.83 (2 H, d, J = 8.3 Hz, HAr), 7.36 (2 H, d, J = 7.9 Hz, 
HAr), 4.18 (2 H, dd, J = 5.4, 4.3 Hz, OCH2), 3.76 (2 H, t, J = 5.4 Hz, OCH2), 3.73- 3.69 (2 H, 
m, OCH2), 3.63- 3.57 (4 H, m, OCH2), 3.54 (2 H, t, J = 5.4 Hz, OCH2), 2.47 (3 H, s, CH3), 
0.90 (9 H, s, tBu), 0.07 (6 H, s, (CH3)2) ppm. 
13C NMR (101 MHz, CDCl3): δ = 145.1 (C), 133.3 (C), 130.1 (CH), 128.3 (CH), 73.0 (CH2), 
71.1 (CH2), 71.0 (CH2), 69.6 (CH2), 69.0 (CH2), 63.0 (CH2), 26.2 (C), 18.7 (CH3), –4.9 (CH3) 
ppm. 
IR (νmax): 2928, 2857, 1738, 1598, 1472, 1463,1359, 1249, 1189 1107, 1097, 1019, 921, 759. 
 
  
TsO O OH2
TBSCl (1.2 equiv)
TEA (1.2 equiv)
DMAP (1 mol%)
DCM, 0 °C → r.t.,
overnight
82%
TsO O OTBS2
34 35
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8.3 Precursor syntheses for the formation of stilbene derivatives via the Wittig 
reaction 
 
(4-Nitrobenzyl)triphenylphosphonium bromide 46[131] 
 
 
Triphenylphosphine (2.43 g, 9.26 mmol, 2.0 equiv) was added to a stirred solution of 
4-nitrobenzyl bromide 45 (1 g, 4.63 mmol) in toluene (50 mL) and heated under reflux 
overnight. Afterwards the reaction mixture was cooled to room temperature and concentrated 
under reduced pressure. After addition of acetone (50 mL), the desired solid 46 was filtered 
using a Büchner funnel and washed with acetone (200 mL). The solid was collected and the 
solvents were evaporated under reduced pressure to offered (4-
nitrobenzyl)triphenylphosphonium bromide 46 as a white powder (1.95 g, 4.08 mmol, 88%). 
m.p. 270 °C (lit.[132] 275 °C). 
1H NMR (400 MHz, CDCl3): δ = 7.87-7.69 (11 H, m, HAr), 7.64-7.53 (6 H, m, HAr), 7.51- 
7.43 (2 H, m, HAr), 6.01 (2 H, d, J = 15.8 Hz, CH2P) ppm. 
13C NMR (101 MHz, CDCl3): δ = 147.5 (C), 136.0 (C), 135.3 (CH), 134.8 (CH), 134.5 
(CH), 134.4 (CH), 132.9 (CH), 132.8 (CH), 130.2 (CH), 130.1 (C), 123.3 (CH), 123.3 (CH), 
117.7 (C), 116.9 (C), 29.6 (CH2) ppm. 
IR (νmax): 2990, 2865, 2773, 1593, 1519, 1348, 1105, 871. 
 
 
4-Acetoxybenzaldehyde 48[133] 
 
 
To a solution of 4-hydroxybenzaldehyde 47 (200 mg, 1.64 mmol) and TEA (0.3 mL, 
2.5 mmol, 1.5 equiv) in anhydrous CH2Cl2 (10 mL), acetyl chloride (0.2 mL, 2.5 mmol, 1.5 
NO2
Br
PPh3 (2 equiv)
toluene, 40 °C, overnight
88%
NO2
PPh3Br
45 46
CHO
OH
acetyl chloride (1.5 equiv)
TEA (1.5 equiv)
dry DCM, r.t., Ar, 1.25 h
88%
CHO
OAc
47 48
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equiv) was added dropwise. The reaction mixture was stirred at room temperature and 
monitored by TLC over 1.25 hours. The aqueous layers were extracted with CH2Cl2 (3 x 20 
mL) and the combined organic layers were dried over Na2SO4 and filtered. The solution was 
concentrated under reduced pressure and then purified by flash chromatography 
(Petrol/EtOAc, 3:1). After removal of solvents, the product 48 was obtained as a colourless 
oil (237 mg, 1.65 mmol, 88%). 
1H NMR (400 MHz, CDCl3): δ = 9.94 (1 H, s, CHO), 7.87 (2 H, d, J = 8.6 Hz, HAr), 7.23 (2 
H, d, J = 8.6 Hz, HAr), 2.29 (3 H, s, CH3) ppm. 
13C NMR (101 MHz, CDCl3): δ = 191.2 (C), 168.9 (C), 155.5 (C), (134.2 (C), 131.4 (CH), 
122.6 (CH), 21.3 (CH3) ppm. 
IR (νmax): 2935, 2862, 1759, 1699, 1594, 1502, 1370, 1201, 1052, 1011, 908, 858. 
 
 
4-Methoxybenzyl alcohol 51[134] 
 
 
In a 50 mL two-neck round-bottomed flask, lithium aluminium hydride (279 mg, 7.34 
mmol, 1 equiv) was added in anhydrous Et2O (10 mL) under an argon atmosphere. Dissolved 
in dry Et2O (5 mL), p-anisaldehyde (1 g, 7.34 mmol) was added dropwise to the flask at 0 °C. 
After that the completion of the reaction was observed by TLC analysis (2 hour), the mixture 
was quenched slowly with ice and an aqueous solution of NaOH (2 M, 2 mL) at 0 °C for 10 
minutes. The resulting mixture was filtered through Celite and washed with Et2O (100 mL). 
The aqueous layer was extracted by Et2O (2 x 50 mL) then washed with brine and dried over 
Na2SO4. The resulting mixture was filtered and the solvents were evaporated under reduced 
pressure. The alcohol 51 was isolated as a colourless oil (943 mg, 6.83 mmol, 94%). 
1H NMR (400 MHz, CDCl3): δ = 7.23 (2 H, d, J = 8.4 Hz, HAr), 6.86 (2 H, d, J = 8.6 Hz, 
HAr), 4.52 (2 H, s, CH2), 3.77 (3 H, s, CH3) ppm. 
13C NMR (101 MHz, CDCl3): δ = 159.2 (C), 133.4 (C), 128.8 (CH), 114.1 (CH), 64.8 (CH2), 
55.5 (CH3) ppm. 
IR (νmax): 3348, 2940, 2836, 1612, 1511, 1302, 1241, 1173, 1031, 813. 
  
CHO
OMe
LiAlH4 (1 equiv)
dry Et2O, Ar, 0 °C  to r.t., 2 h
OMe
HO
51
94%
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4-Methoxybenzyl bromide 52[135] 
 
 
Phosphorus tribromide (0.6 mL, 6.83 mmol) was added in the dark to a solution of 4-
methoxybenzyl alcohol 51 (943 mg, 6.83 mmol) in CH2Cl2 (7 mL). The reaction was 
monitored by TLC and after completion (3 hours), the mixture was quenched with a saturated 
solution of NaHCO3 at 0 °C. The aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The 
combined organic extracts were dried over Na2SO4 and filtered. The residue was 
concentrated in vacuo to yield (1.32 g, 6.57 mmol, 96%) as a yellow oil. 
1H NMR (400 MHz, CDCl3): δ = 7.36 (2 H, d, J = 8.7 Hz, HAr), 6.90 (2 H, d, J = 8.7 Hz, 
HAr), 4.54 (2 H, s, CH2), 3.84 (3 H, s, CH3) ppm. 
13C NMR (63 MHz, CDCl3): δ = 160.0 (C), 130.8 (CH), 130.3(C), 114.5 (CH), 55.7 (CH3), 
34.3 (CH2) ppm. 
IR (νmax): 2959, 2904, 835, 1607, 1511, 1303, 1226, 1111, 1026, 825. 
 
 
(4-Methoxybenzyl)triphenylphosphonium bromide 53[136] 
 
 
To a solution of 4-methoxybenzyl bromide 52 (1.32 g, 6.57 mmol) in toluene (20 mL), 
triphenylphosphine (1.72 g, 6.56 mmol) was added. The reaction mixture was stirred 
overnight under reflux. At room temperature acetone (20 mL) was added and the 
phosphonium salt precipitated. The mixture was filtered using a Büchner funnel and washed 
with acetone (40 mL). The solvents were removed in vacuo to yield the desired 
triphenylphosphonium salt 53 (2.62 g, 5.65 mmol, 86%) as a white powder. 
m.p. 234 °C (lit.[109] 234-235 °C). 
OMe
PBr3 (1 equiv)
DCM, dark,  r.t., 3 h
OMe
Br
51 52
96%
HO
OMe
PPh3 (1 equiv)
toluene, reflux, overnight
52
86%
Br
OMe
P(Ph)3Br
53
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1H NMR (400 MHz, CDCl3): δ = 7.82- 7.71 (9 H, m, HAr), 7.69- 7.62 (6 H, m, HAr), 7.04 (2 
H, dd, J = 8.8, 2.5 Hz, HAr), 6.66 (2 H, d, J = 8.7 Hz, HAr), 5.33 (2 H, d, J = 13.7 Hz, CH2P), 
3.74 (3 H, s) ppm. 
13C NMR (126 MHz, CDCl3): δ = 135.2 (C), 135.2 (C), 134.8 (CH), 134.7 (CH), 133.1 (C), 
133.0 (C), 130.5 (CH), 130.4 (CH), 118.7 (C), 118.0 (C), 114.6 (C), 114.6 (C), 55.6 (CH3), 
30.7 (CH2), 30.3 (CH2) ppm. 
IR (νmax): 3052, 2990, 2860, 2774, 1610, 1585, 1513, 1439, 1264, 1180, 1112, 1031, 997, 
838. 
 
 
8.4 Precursor synthesis for the formation of stilbene derivatives via the Heck reaction 
 
4-Vinylphenol 54[137] 
 
 In a two-necked round-bottomed flask under a nitrogen atmosphere, tBuOK (1.40 g, 
12.5 mmol, 2.5 equiv) was added slowly to a stirred solution of methyltriphenylphosphonium 
bromide (2.68 g, 7.5 mmol, 1.5 equiv) in dry THF (10 mL) at 0 °C for 10 minutes. At room 
temperature, 4-hydroxybenzaldehyde 47 (610.6 mg, 5.0 mmol) dissolved in dry THF (5 mL) 
was added dropwise to the above suspension. The resulting mixture was stirring at room 
temperature and monitored by TLC analysis for 4 hours. The reaction mixture was quenched 
with a saturated solution of NH4Cl and concentrated in vacuo. The aqueous layer was 
extracted with CH2Cl2 (3 x 20 mL). The organic layers were combined and dried over 
Na2SO4. After filtration, the solvents were evaporated under reduced pressure. The residue 
was purified by flash chromatography (Petrol/EtOAc 5:1) to obtain the pure product 54 (361 
mg, 3.0 mmol, 60%) as a colourless oil. 
1H NMR (250 MHz, CDCl3): δ = 7.19 (2 H, d, J = 8.5 Hz, HAr), 6.75 (2 H, d, J = 8.5 Hz, 
HAr), 6.56 (1 H, dd, J = 17.5, 10.9 Hz, Hvinyl), 5.49 (1 H, d, J = 17.5 Hz, Hvinyl), 5.00 (1 H, d, J 
= 10.9 Hz, Hvinyl) ppm. 
13C NMR (126 MHz, CDCl3): δ = 154.0 (C), 136.4 (CH), 127.0 (CH), 124.9 (C), 115.0 
(CH), 110.0 (CH) ppm. 
IR (νmax): 3414, 2963, 1670, 1502, 1303, 1173, 1033, 810. 
OH
O
OH
CH3PPh3Br (1.5 equiv)
tBuOK (2.5 equiv)
dry THF, N2, 0 °C→r.t.
4 h
60%
47 54
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8.5 Formation of stilbene derivatives 
 
4-Nitro-4’-methoxystilbene 37[138] 
 
 
In a 50 mL two-necked round-bottomed flask under inert atmosphere, p-
nitrobenzaldehyde (59 mg, 0.39 mmol, 0.9 equiv) was added at 0 °C to a stirred solution of 
triphenylphosphonium salt 53 (200 mg, 0.43 mmol) with tBuOK (62 mg, 1.3 equiv) in 
anhydrous THF (15 mL) and was stirred for 20 minutes at 0 °C. The reaction mixture was 
stirred at room temperature overnight and concentrated under reduced pressure. After 
quenching with deionised water (5 mL) the resulting aqueous layer were extracted with 
EtOAc (3 x 20 mL). The combined organic layer was washed with brine and dried over 
Na2SO4. After filtration and evaporation of the solvents under reduced pressure, purification 
by flash chromatography (Petrol/EtOAc, 3:1) offered a mixture of the two isomers of 4-nitro-
4’-methoxystilbene (37 mg, 0.14 mmol, 32%, ratio E/Z = 14:1) as a yellow powder. 
1H NMR (400 MHz, CDCl3): E-isomer: δ = 8.21 (2 H, d, J = 8.8 Hz, HAr), 7.60 (2 H, d, J = 
8.8 Hz, HAr), 7.50 (2 H, J = 8.8 Hz, HAr), 7.49 (1 H, d, J = 15 Hz, Hvinyl), 7.26 (1 H, d, J = 
16.4 Hz, Hvinyl), 6.98 (2 H, d, HAr), 3.84 (3 H, s, CH3) ppm. 
Z-isomer: δ = 8.0 (2 H, d, J = 8.9 Hz, HAr), 7.32 (2 H, d, J = 
8.8 Hz, HAr), 7.07 (2 H, d, J = 8.9 Hz, HAr), 6.70 (2 H, d, J = 8.8 Hz, HAr), 6.65 (1 H, d, J = 
12.4 Hz, Hvinyl), 6.45 (1 H, d, J = 12.4 Hz, Hvinyl) ppm. 
 
  
OMe
PPh3Br
53
tBuOK (1.3 equiv)
p-nitrobenzaldehyde (0.9 equiv)
dry THF, Ar, overnight
MeO
NO2
32%
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 In a 50 mL round-bottomed flask fitted with a condenser, the mixture of E/Z isomer 
of the 4-nitro-4'-methoxy stilbene (37 mg, 0.14 mmol) and iodine (1 bead) were added in 
heptane (5 mL). The reaction mixture was heated under reflux for 12 hours. The solution was 
diluted with Et2O (10 mL) and washed with an aqueous saturated solution of sodium bisulfite 
(20 mL). The organic layer was dried over Na2SO4 and filtered. The residue was concentrated 
under reduced pressure to obtain the E-isomer 37 (34 mg, 0.13 mmol) as a yellow powder. 
m.p. 128 °C (lit.[139] 131-132.5 °C). 
1H NMR (400 MHz, d6-acetone): δ = 8.21 (2 H, d, J = 8.8 Hz, HAr), 7.60 (2 H, d, J = 8.8 Hz, 
HAr), 7.50 (2 H, J = 8.8 Hz, HAr), 7.49 (1 H, d, J = 16.4 Hz, Hvinyl), 7.26 (1 H, d, J = 16.4 Hz, 
Hvinyl), 6.98 (2 H, d, J = 8.8 Hz, HAr), 3.84 (3 H, s, CH3) ppm. 
13C NMR (101 MHz, d6-acetone): δ = 162.24 (C), 148.23 (C), 146.56 (C), 134.86 (CH), 
131.07 (C), 130.38 (2 CH), 128.58 (CH), 125.81 (CH), 125.73 (CH), 116.06 (2 CH), 56.60 
(CH3) ppm. 
IR (νmax): 2957, 2831, 1587, 1509, 1336, 1252, 1174, 1108, 1033, 970, 843, 750. 
 
 
 
 In a 50 mL two-necked round-bottomed flask fitted with a condenser under an argon 
atmosphere, was added the phosphonium salt 53 (500 mg, 1.08 mmol), 4-nitrobenzaldehyde 
OMe
NO2
I2 (1 bead)
hepatne, reflux, 12 h
(E)
OMe
NO2
37
93%
(E)
OMe
NO2
37
OMe
PPh3Br
53
4-nitrobenzaldehyde (0.9 equiv)
K2CO3 (2.3 equiv)
dry CH2Cl2, Ar, refux, overnight
16%
Chapter 7   
 
 
112 
(147 mg, 0.97 mmol, 0.9 equiv) and K2CO3 (343 mg, 2.48 mmol, 2.3 equiv) in dry CH2Cl2 
(15 mL). The reaction mixture was heated under reflux overnight. The aqueous phase was 
extracted with CH2Cl2 (3 x 15 mL). The organic phases were combined and dried over 
Na2SO4. The mixture was concentrated under reduced pressure and 20 mL of MeOH was 
added. The product mixture was then cooled at –40 °C and filtered. The title product 37 was 
obtained as a yellow solid (40 mg, 0.16 mmol, 16%). 
 
 
 
 4-Nitrophenylacetic acid 59 (1.81 g, 10.0 mmol), piperidine (1 mL, 10.0 mmol, 1 
equiv) and p-anisaldehyde (1.36 g, 10.0 mmol, 1 equiv) were mixed in a 25 mL two-necked 
round-bottomed flask with a condenser. The reaction was heated at 100 °C under vacuum for 
1 hour and for an additional 2 hours at 150 °C in vacuo. The collected brown solid was was 
crushed and then heated under reflux in a solution of EtOH/H2O (3:1, 20 mL) and 
concentrated AcOH (0.1 mL). At room temperature the yellow solid was filtered an 
recrystalised in iPrOH to yield the desired product 37 (868 mg, 3.4 mmol, 34%). 
 
 
 4-Nitrophenylacetic acid 59 (1.81 g, 10.0 mmol), piperidine (1 mL, 10.0 mmol, 1 
equiv), pyridne (0.8 mL, 10.0 mmol, 1 equiv) and p-anisaldehyde (1.36 g, 10.0 mmol) were 
mixed in a 25 mL two-necked round-bottomed flask with condenser. The reaction was heated 
NO2
(E)
OMe
NO2
p-anisaldehyde (0.7 equiv)
piperidine (1 equiv)
Ar, 100→150 °C, 3 h
34%
59 37
O
OH
NO2
(E)
OMe
NO2
p-anisaldehyde (0.7 equiv)
piperidine (1 equiv)
pyridine (1 equiv)
vacuum, 100→150 °C, 3 h
52%
59 37
O
OH
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at 100 °C under vacuum for 1 hour and for an additional 2 hours at 150 °C in vacuo. The 
collected brown solid was crushed and then heated under reflux in a solution of EtOH/H2O 
(3:1, 20 mL) with 0.1 mL of glacial AcOH. At room temperature the yellow solid was 
filtered and recrystalised in iPrOH to yield the desired product 37 (1.33 g, 5.2 mmol, 52 %). 
 
 
(E)-4-nitro-4’-hydroxystilbene 55[114] 
 
 
 Under inert atmosphere 4-hydroxybenzaldehyde (100 mg, 0.82 mmol, 0.79 equiv), 
the phosphonium salt 46 (470 mg, 0.98 mmol) and K2CO3 (453 mg, 3.28 mmol, 4 equiv) 
were added to a 50 mL two-necked round-bottomed flask with condenser. After addition of 
anhydrous CH2Cl2 (10 mL) the stirred reaction was heated under reflux overnight. The 
resulting mixture was filtered using a Büchner funnel and washed with MeOH (20 mL). The 
corresponding filtrate was concentrated under reduced pressure and purified by flash 
chromatography (CH2Cl2/MeOH, 20:1). After evaporation of the solvents under vacuum, the 
desired stilbene 55 was isolated as a yellow solid (163 mg, 0.68 mmol, 82%). 
1H NMR (500 MHz, CD3OD): δ = 6.81 (2 H, d, J = 8.8 Hz, HAr), 6.32 (2 H, d, J = 8.8 Hz), 
6.09 (2 H, d, J = 8.6 Hz, HAr), 5.94 (1 H, J = 16.3 Hz, Hvinyl), 5.69 (1 H, d, J = 16.3 Hz, 
Hvinyl), 5.45 (2 H, J = 8.6 Hz, HAr) ppm. 
13C NMR (126 MHz, CD3OD): δ = 160.4 (C), 148.4 (C), 147.1 (C), 135.4 (CH), 130.6 (CH), 
130.4 (C), 128.5 (CH), 125.8 (CH), 125.2 (CH), 117.6 (CH) ppm. 
IR (νmax): 3412, 1631, 1583, 1498, 1336, 1315, 1172, 1107, 974, 841, 749. 
 
 
NO2
PPh3Br
46
4-hydroxybenzaldehyde (0.8 equiv)
K2CO3 (4 equiv)
dry DCM, Ar, refux,
overnight
(E)
OH
NO2
82%
55
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 In a 50 mL two-necked round bottomed flask with condenser under inert atmosphere, 
(4-nitrophenyl)acetic acid 59 (4 g, 22 mmol, 1.3 equiv), 4-hydroxybenzaldehyde (2 g, 16.4 
mmol) and piperidine (1 mL, 10.1 mmol, 0.6 equiv) were stirred at 140 °C for 1 hour. The 
obtained brown solid was crushed and then heated under reflux with a solution of EtOH/H2O 
(3:1, 20 mL) and concentrated AcOH (0.1 mL). At room temperature the brown solid was 
filtered and recrystallized with iPrOH to yield the desired stilbene 55 (2.86 g, 11.85 mmol, 
72%) as a brown powder. 
m.p. 203 °C (iPrOH) (lit.[140] 204 °C). 
 
 
 
 4-Nitrophenylacetic acid 59 (1.81 g, 10.0 mmol), piperidine (1 mL, 10.0 mmol) and 
4-hydroxybenzaldehyde (1.22 g, 10.0 mmol) were mixed in a 25 mL two-neck round-
bottomed flask with condenser. The reaction was heated at 100 °C under vacuum for 1 hour 
and for an additional 2 hours at 150 °C. An aqueous solution of NaOH (6 M, 10 mL) was 
added at room temperature. The mixture was heated at 70 °C for 30 minutes and cooled to 0 
°C for the addition of concentrated HCl (36%) to neutralise the pH of the solution. The 
resulting yellow solid 55 was filtered and dry under reduce pressure (2.05 g, 8.5 mmol, 85 
%). 
m.p. 199 °C (water). 
  
NO2
(E)
HO
NO24-hydroxybenzaldehyde (0.7 equiv)
piperidine (0.6 equiv)
Ar, 140 °C, 1 h
72%
59 55
O
OH
NO2
(E)
OH
NO2
4-hydroxybenzaldehyde (1 equiv)
piperidine (1 equiv)
vacuum, 100→150 °C, 3 h
85%
59 55
O
OH
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8.6 Incorporation of derivatives of triethylene glycol into phenols 
 
4-(2-(2-(2-Hydroxyethoxy)ethoxy)ethoxy)benzaldehyde[118] 
 
 
To a stirred solution of 4-hydroxybenzaldehyde 47 (398 mg, 3.26 mmol, 1.1 equiv), 
K2CO3 (902 mg, 6.52 mmol, 2.2 equiv) and potassium iodide (10 mg, 60.2 µmol, 2 mol%) in 
EtOH (5 mL) was added a commercial solution of 2-[2-(2-chloroethoxy)ethoxy]ethanol (0.4 
mL, 2.97 mmol). The reaction was heated under reflux overnight and then concentrated 
under reduced pressure. Deionised water (10 mL) was added to the residual mixture and the 
aqueous phase was extracted with CH2Cl2 (3 x 10 mL). The organic phases were dried over 
Na2SO4 and filtered. The solvents were evaporated under reduced pressure. The mixture was 
purified by flash chromatography (CHCl3/Petrol, 1:1) to yield the desired compound (276 
mg, 1.08 mmol, 37%) as a yellow oil. 
1H NMR (400 MHz, CDCl3): δ =9.80 (1 H, s, HCHO), 7.76 (2 H, d, J = 8.7 Hz, HAr), 6.95 (2 
H, d, J = 8.7 Hz, HAr), 4.23- 4.10 (2 H, m, OCH2), 3.86- 3.77 (2 H, m, OCH2), 3.72- 3.50 (8 
H, m, OCH2) ppm. 
13C NMR (101 MHz, CDCl3): δ = 191.2 (C), 164.0 (C), 132.3 (CH), 130.3 (CH), 115.1 
(CH), 72.8 (CH2), 71.1 (CH2), 70.6 (CH2), 70.0 (CH2) 67.9 (CH2), 61.9 (CH2) ppm. 
IR (νmax): 3015, 2930, 2870, 1682, 1600, 1578, 1509, 1427, 1303, 1355, 1217, 1161, 1109, 
1058, 909, 833, 729. 
 
 
 
To a 1 hour stirred solution of triphenylphosphine (859 mg, 3.28 mmol), 4-
hydroxybenzaldehyde 47 (400 mg, 3.28 mmol) and diol (2.38 mL, 20 mmol, 5 equiv) in dry 
K2CO3 (2.2 equiv)
KI (2 mol%)
EtOH, reflux, overnight
Cl O O OH
37%
OH
O
O
O
O 3
47
H
PPh3 (1 equiv)
DIAD (1.1 equiv)
CH2Cl2, 0 °C→r.t., 2 days
HO O O OH
41%
OH
O
O
O
O 3
47
H
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CH2Cl2 (25 mL) was slowly added DIAD (0.71 mL, 3.60 mmol, 1.1 equiv) at 0 °C. After 2 
days the solvent was evaporated and the residual mixture was neutralised with a dilute 
aqueous solution of NaOH (2 M, 10 mL). The aqueous layer was extracted with EtOAc (3 x 
20 mL). The combined organic extracts were dried over Na2SO4, filtered and evaporated. The 
resulting mixture was then purified by flash chromatography (EtOAc) to afford the desired 
aldehyde (341 mg, 1.34 mmol, 41%) as a yellow oil. 
 
 
 (E)-2-(2-(2-(4-(4-nitrostyryl)phenoxy)ethoxy)ethoxy)ethanol 60 
 
 
In a 50 mL two-necked round-bottomed flask with condenser under inert atmosphere, 
was added a commercial solution of 2-[2-(2-chloroethoxy)ethoxy]ethanol (0.15 mL, 3.3 
mmol, 1.2 equiv) to a mixture of 4’-hydroxy stilbene 55 (200 mg, 0.83 mmol) with K2CO3 
(458 mg, 3.3 mmol, 4 equiv) in dry DMF (10 mL). The reaction was stirred at 90 °C 
overnight and then concentrated in vacuo. Deionised water (10 mL) was added to the reaction 
mixture and the aqueous phase was extracted with CH2Cl2 (3 x 15 mL). The combined 
organic layers were dried over Na2SO4 and filtered. The residue was concentrated under 
reduced pressure and purified by flash chromatography (MeOH/CH2Cl2, 1:24). The collected 
fraction was to obtain the product 60 (104 mg, 0.28 mmol, 34%) as a yellow solid. 
m.p. 35 °C. 
1H NMR (400 MHz, d6-acetone): δ = 8.09 (2 H, d, J = 8.8 Hz, HAr), 7.69 (2 H, d, J = 8.8 Hz, 
HAr), 7.49 (2 H, d, J = 8.7 Hz, HAr), 7.35 (1 H, d, J = 16.4 Hz, Hvinyl), 7.13 (1 H, d, J = 16.4 
Hz, Hvinyl), 6.88 (2 H, d, J = 8.7 Hz, HAr), 4.10- 3.99 (2 H, m, OCH2), 3.74- 3.67 (2 H, m, 
OCH2), 3.57- 3.37 (6 H, m, OCH2), 3.18- 3.09 (2 H, m, OCH2), 2.80 (1 H, br) ppm. 
13C NMR (101 MHz, d6-acetone): δ = 161.3 (C), 148.0 (C), 146.4 (CH), 144.5 (C), 134.7 
(CH), 131.0 (C), 130.2 (CH), 128.4 (CH), 125.7 (CH), 116.5 (CH), 74.3 (CH2), 72.1 (CH2), 
72.0 (CH2), 71.9 (CH2), 71.0 (CH2), 69.2 (CH2) ppm. 
K2CO3 (4 equiv)
dry DMF, Ar, 90 °C, overnight
Cl O O OH
34%
NO2
OH
55
NO2
O O
60
H
3
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IR (νmax): 2963, 2933, 2876, 1588, 1510, 1456, 1338, 1251, 1176, 1108, 1056, 954, 841, 814, 
733. 
HRMS (APCI) calculated for C20H23N1O6Na1 [M + Na]+ 396.1423 found 396.1421. 
 
 
 (E)-2,2,3,3-tetramethyl-12-(4-(4-nitrostyryl)phenoxy)-4,7,10-trioxa-3-siladodecane 61 
 
 
To a stirred solution of stilbene 60 (514 mg, 1.43 mmol), imidazole (132 mg, 1.94 
mmol, 1.4 equiv), DMAP (7 mg, 57 µmol, 4 mol%) in CH2Cl2 (10 mL), TBSCl (175 mg, 
1.16 mmol, 1.2 equiv) was added slowly at 0 °C. The reaction was further stirred at room 
temperature overnight. The resulting yellow solution was filtered leaving a white solid. After 
addition of the deionised water (5 mL), the aqueous layer was extracted with CH2Cl2 (3 x 10 
mL). The combined organic extracts were dried over Na2SO4, filtered and concentrated in 
vacuo. The residual mixture was purified by flash chromatography (EtOAc) to yield the title 
compound 60 (295 mg, 0.79 mmol, 55%) as a yellow solid. 
m.p. 35 °C. 
1H NMR (500 MHz, CDCl3): δ = 8.20 (2 H, d, J = 8.8 Hz, HAr), 7.59 (2 H, d, J = 8.8 Hz, 
HAr), 7.48 (2 H, d, J = 8.7 Hz, HAr), 7.21 (1 H, d, J = 16.3 Hz, Hvinyl), 7.00 (1 H, d, J = 16.3 
Hz), 6.94 (1 H, d, J = 8.7 Hz, HAr), 4.21- 4.10 (2 H, m, OCH2), 3.91- 3.86 (2 H, m, OCH2), 
3.77 (2 H, t, J = 5.4 Hz, OCH2), 3.75-3.65 (4 H, m, OCH2), 3.57 (2 H, t, J = 5.4 Hz, OCH2), 
0.89 (9 H, s, tBu), 0.06 (6 H, s, (CH3)2) ppm. 
13C NMR (126 MHz, CDCl3): δ = 159.9 (C), 146.8 (C), 144.7 (C), 133.3 (CH), 129.5 (C), 
128.7 (CH), 126.9 (CH), 124.5 (CH), 115.4 (CH), 73.1 (CH2), 71.3 (CH2), 71.2 (CH2), 70.0 
(CH2), 67.9 (CH2), 63.1 (CH2), 26.3 (CH3), 18.7 (C), −4.9 (CH3) ppm. 
IR (νmax): 3052, 2953, 2926, 2857, 1607, 1588, 1511, 1338, 1249, 1176, 1108, 954, 836, 814. 
 
 
  
TBDMSCl (1.2 equiv)
imidazole (2 equiv)
DMAP (3 mol%)
CH2Cl2, 0 °C→r.t., overnight
55%
NO2
O O
NO2
O O
60 61
H TBS
3 3
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The stilbene 55 (115 mg, 4.77 mmol), the ether chain (1.62 mmol, 4.77 mmol) and 
K2CO3 (1.32 g, 9.52 mmol, 2 equiv) were added to a two-necked round-bottomed flask fitted 
with a condenser under an inert atmosphere. The mixture was stirred in DMSO (5 mL) at 120 
°C for 1.5 hours. After addition of an aqueous solution of HCl (2 M, 5 mL) the aqueous layer 
was extracted with EtOAc (3 x 5 mL). The combined organic layers were dried over Na2SO4 
and filtered. The solvents were evaporated in vacuo to obtain the three ethoxy stilbene as a 
yellow solid, as an inseparable 15:1 mixture of E/Z isomers. 
1H NMR (400 MHz, CDCl3): E-isomer: δ = 8.18 (2 H, d, J = 8.8 Hz, HAr), 7.58 (2 H, d, J = 
8.8 Hz, HAr), 7.47 (2 H, d, J = 8.8 Hz, HAr), 7.20 (1 H, d, J = 16.4 Hz, Hvinyl), 6.99 (1 H, d, J = 
16.4 Hz, Hvinyl), 6.93 (2 H, d, J = 8.8 Hz, HAr), 4.19- 4.14 (2 H, m), 3.90- 3.84 (2 H, m), 3.78- 
3.58 (8 H, m), 2.96 (1 H, br) ppm. 
Z-isomer: δ = 7.4 (2 H, d, J = 8.8 Hz, HAr), 7.18 (1 H, d, J = 
16.4 Hz, Hvinyl), 6.85 (2 H, d, J = 8.8 Hz, HAr), 4.27- 4.19 (2 H, m) ppm, only 4 distinct peaks. 
 
 
 (E)-2,2,3,3-tetramethyl-12-(4-(4-nitrostyryl)phenoxy)-4,7,10-trioxa-3-siladodecane 61 
 
 
To a solution of stilbene 55 (858 mg, 4.06 mmol) and K2CO3 (1.25 g, 9.02 mmol, 2 
equiv) in dry DMF (20 mL) was added bis-protected diols 35 (1.89 g, 4.51 mmol, 1.1 equiv). 
K2CO3 (2 equiv)
dry DMSO, Ar,120 °C, 1.5 h
Cl O O OH
71%
NO2
OH
55
NO2
O O
H
3
35 (1.1 equiv)
K2CO3 (2 equiv)
DMF, 90 °C, overnight
86%
NO2
OH
55
NO2
O O
61
TBS
3
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The reaction was stirred at 90 °C overnight and quenched at room temperature with deionised 
water (30 mL). The aqueous layer was extracted with EtOAc (3 x 10 mL) and the resulting 
combined organic phases were dried, filtered and concentrated in vacuo. The residual was 
purified by flash chromatography (Petrol/EtOAc, 2:1) to yield 61 (1.71 g, 3.51 mmol, 86%) 
as a yellow solid. 
1H NMR (500 MHz, d6-acetone): δ = 8.23 (2 H, d, J = 8.8 Hz), 7.83 (2 H, d, J = 8.8 Hz), 
7.63 (2 H, d, J = 8.8), 7.49 (1 H, d, J = 16.4 Hz), 7.27 (1 H, d, J = 16.4 Hz), 7.01 (2 H, d, J = 
8.8), 4.18 (2 H, t, J = 4.8 Hz), 3.84 (2 H, t, J = 4.8 Hz), 3.75 (2 H, t, J = 5.2 Hz), 3.65 (m, 4 
H), 3.52 (2 H, t, J = 5.6 Hz), 0.89 (9 H, s), 0.07 (6 H, s) ppm. 
13C NMR (126 MHz, d6-acetone): δ = 161.4 (C), 148.1 (C), 146.4 (C), 134.7 (CH), 131.0 
(C), 130.2 (CH), 128.5 (CH), 125.7 (CH), 125.6 (CH), 116.6 (CH), 74.2 (CH2), 72.3 (CH2), 
72.2 (CH2), 71.1 (CH2) 69.3 (CH2), 64.3 (CH2), 27.1 (CH3), 19.6 (C), -4.3 (CH3) ppm. 
IR (νmax): 2953, 2926, 2858, 1607, 1588, 1511, 1338, 1249, 1176, 1108, 955, 836, 832 
HRMS (APCI) calculated for C26H37N1O6Na1Si1 [M + Na]+ 510.2288 found 510.2275 
 
8.7 Reduction of the nitro moiety 
 
General procedure: To a mixture of nitrostilbene 61 in MeOH, a co-solvent was added with a 
catalytic amount of palladium on charcoal and an excess of NaBH4 at low temperature. The 
reaction was monitored by TLC analysis. After completion (3 hours), the solution was 
degased with an ultrasonic bath for 5 minutes. The residual mixture was cooled in liquid 
nitrogen and filtered through Celite and then concentrated under reduced pressure. After 
quenching with an aqueous solution of KOH (1 M, 5 mL), the aqueous phase was extracted 
with Et2O (3 x 20 mL). The combined organic layers were dried over Na2SO4 and filtered. 
The solvents were evaporated in vacuo to obtain the desired aniline derivative 63. 
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(E)-4-(4-((2,2,3,3-tetramethyl-4,7,10-trioxa-3-siladodecan-12-yl)oxy)styryl)aniline 63 
 
 
In a 50 mL round-bottomed flask cooled at −40 °C, the stilbene 61 (200 mg, 0.41 
mmol) and Pd/C (20 mg) were added to a MeOH/EtOH mixture (25 mL, 4:1). The NaBH4 
(400 mg, 10.57 mmol, 26 equiv) was added slowly for 10 minutes at −40 °C. After 2 hours, 
the reaction mixture was stirred at −20 °C for 1 hour. Following the general procedure the 
title product was obtained (130 mg, 0.28 mmol, 69%) as a yellow solid. 
m.p. 68 °C. 
1H NMR (400 MHz, d6-acetone): δ = 7.48 (2 H, d, J = 8.7 Hz, HAr), 7.32 (2 H, J = 8.5 Hz, 
HAr), 7.03- 6.89 (4 H, m, HAr and (Hvinyl)2), 6.70 (2 H, d, J = 8.5 Hz), 4.82 (1 H, br), 4.19- 
4.14 (2 H, m), 3.88- 3.84 (2 H, m), 3.79 (2 H, t, J = 5.2 Hz), 3.72- 3.64 (4 H, m), 3.56 (2 H, t, 
J = 5.2 Hz), 2.91 (1 H, br), 0.93 (9 H, s, tBu), 0.11 (6 H, s, (CH3)2) ppm. 
13C NMR (101 MHz, d6-acetone): δ = 159.7 (C), 149.8 (C), 132.8 (C), 128.9 (CH), 128.6 
(CH), 128.1 (CH), 124.8 (C), 116.3 (CH), 116.0 (CH), 74.1 (CH2), 72.2 (CH2), 72.2 (CH2), 
71.12 (CH2), 69.1 (CH2), 64.3 (CH2), 27.0 (CH3), 19.61 (CH3) ppm. 
IR (νmax): 3019, 2930, 2865, 1601, 1511, 1251, 1215, 1161, 1125, 1097, 1036, 935, 834. 
HRMS (APCI) calculated for C26H39N1O4Na1Si1 [M + Na]+ 480.246 found 480.246. 
 
 
 
 
MeOH/EtOH, −40→−20 °C, 
3 h
69%
NO2
O O
NH2
O O
61 63
TBS TBS
3 3
Pd/C (20 mg)
NaBH4 (26 equiv)
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In a 25 mL round-bottomed flask cooled at −30 °C, the stilbene 61 (400 mg, 0.82 
mmol) and Pd/C (20 mg) were added to a MeOH/THF mixture (11 mL, 5:6). The NaBH4 
(300 mg, 7.9 mmol, 12 equiv) was added slowly for 10 minutes at −40 °C. A balloon of 
argon was connected to the flask. After 2 hours, the reaction mixture was stirred at −20 °C 
for 1 hour under an argon atmosphere. Following the general procedure the title product was 
obtained (130 mg, 0.28 mmol, 69%) as a yellow solid. 
 
  
THF/MeOH, Ar,
 −30→−20 °C, 3 h
82%
NO2
O O
NH2
O O
61 63
TBS TBS
3 3
Pd/C (20 mg)
NaBH4 (12 equiv)
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9.1 Production of [18F]-fluoride with no-carrier-added (nca) 
 
The [18F]-fluoride was produced from an onsite cyclotron (cyclone® 18/9, IBA, 
Belgium). It was obtained by the bombardment of enriched [18O]-water (>98%, Nukem 
GmbH, Germany) by following the 18O(p,n)18F nuclear reaction.  
 
9.2 General procedure for microfluidic [18F]-fluorination 
 
The QMA cartridge was preconditioned with an aqueous solution of NaHCO3 (1 M, 5 
mL, ABX) and washed with deionised water (10 mL). The Kryptofix solution used was 
purchased from ABX (K[2.2.2] (22.6 mg, 60.0 µmol) and K2CO3 (4.2 mg, 30.4 µmol) in 
acetonitrile (300 µL) and deionised water (300 µL)) or unless otherwise stated. The 
radiolabeling process was described in several steps. The final step of the synthesis was the 
measurement of the radioactivity by the dose calibrator and the analysis of the radioactive 
mixture by radio-TLC. The [18F]-fluorination occurred in a PEEK loop tubing (length = 3 m, 
∅ = 0.5 mm, Vici, Switzerland) unless otherwise mentioned. Each reaction was performed 
by using the same amount of mannose triflate 9 (25 mg, 52 µmol). 
 
9.3 Procedure for formation of peracetylated [18F]-deoxy-glucose 14 using loop 
system 
 
 
  
OAcOAcO OAc
OAc
OTf
CH3CN, Δ
  [K+⊂2.2.2]18F−
OAcOAcO OAc
OAc
18F
9 14
CH3CN/H2O
Δ
9 Radiosyntheses 
Chapter 7   
 
 
123 
 
 
Experiment 1 to 3 
Entry 
Activity received 
(GBq) 
Process time  
(min) 
Recovery of activity, decay-
corrected (%) 
1 1.5 34 19 
2 1.5 30 27 
3 1.5 30 23 
 
Procedure A: 
Step 1: The aqueous [18F]-fluoride was delivered from the cyclotron to the synthesiser at the 
intersection 6 by following the path 6, 7, 8, 9. The aqueous mixture passed through a QMA 
cartridge to trap the [18F]-fluoride and transferred the [18O]-water to the waste vial (O18 
water). A flow of nitrogen from the intersection 1 was applied to dry the [18F]-Fluoride for 80 
seconds. 
Step 2: The ABX Kryptofix solution passed through the QMA cartridge to form the 
[K+⊂2.2.2]18F− complex. This complex was then eluted into the V-shape reactor vial for 35 
seconds at room temperature (switching valves 5, 7, 8, 10, 11, 12). 
Step 3: The drying process occurred at 90 °C for 2 minutes in the Peltier reactor module. The 
azeotropic distillation was performed with 2 vials of MeCN (2 x 1 mL). One vial of MeCN 
(MeCN 1) was eluted to the reaction mixture heated at 55 °C. The mixture was maintained at 
55 °C for 30 seconds and for an additional 90 seconds at 95 °C under reduced pressure and 
nitrogen flow. This sequence was repeated once with another 1 mL of acetonitrile (MeCN 2). 
QMA$
6" 5" 4"
7" 9" 13"12"11"10"
3" 2" 1"
8" 14" 15"
loop$
reactor$
mannose$$
triﬂate$$
in$MeCN$
MeCN$3$
pressure$
ac6vity$
Kryptoﬁx$
solu6on$
MeCN$1$ MeCN$2$ sA$ sB$
liquid$$
trap$
vacuum$$
pump$
CA18$
pel6er$
reactor$module$
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Step 4: Syringe A transferred the acetonitrile (2 mL, MeCN 3) to the reactor vial heated at 35 
°C. The [K+⊂2.2.2]18F− complex dissolved in acetonitrile was transferred into syringe A. The 
mannose triflate 9 in MeCN (2 mL) was transferred to syringe B. 
Step 5: Both solutions were mixed together via a T-mixer (ETFE). The reaction took place in 
the loop (double helix, length = 3 m, ∅ = 0.5 mm) heated at 80 °C in the loop reactor. The 
overall flow rate of the radiolabeling occurred at 14 µL/s (7 µL/s per syringe).  
 
Experiments 4 and 5 
Entry 
Activity received 
(GBq) 
Process time  
(min) 
Recovery of activity, decay-
corrected (%) 
4 1.8 34 30 
5 1.5 30 37 
 
Procedure B: based on the procedure A, the reactions 4 and 5 were performed with a different 
Step 3. 
Step 3: The drying process occurred at 90 °C for 2 minutes in the Peltier reactor module. The 
azeotropic distillation was performed with 2 vials of MeCN (2 x 1 mL). One vial of MeCN 
(MeCN 1) was eluted to the reaction mixture heated at 55 °C. The mixture was heated at 55 
°C for 30 seconds and for an additional 90 seconds at 90 °C under reduced pressure and 
nitrogen flow. This sequence was repeated once with another 1 mL of acetonitrile (MeCN 2). 
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9.4 Procedure using microfluidic technology for the [18F]-FDG 1 in continuous flow 
 
 
 
 
Experiment 6 to 8 
Entry 
Activity received 
(GBq) 
Process time  
(min) 
Recovery of activity, decay-
corrected (%) 
6 3.0 38                   10 
7 2.4        34 18 
8 1.5        36 14 
 
 
 
 
OAcOAcO OAc
OAc
OTf
1. CH3CN, Δ
2. NaOHaq, Δ
  [K+⊂2.2.2]18F−
OHOHO OH
OH
18F
9 1
CH3CN/H2O
Δ
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7" 9"
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12"11"10"
3" 2" 1"
8"
14" 15"
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triﬂate$$
in$MeCN$
MeCN$2$
pressure$
ac6vity$
Kryptoﬁx$
solu6on$
MeCN$1$ NaOH$ dis6lled$water$
sA$ sB$
liquid$$
trap$
vacuum$$
pump$
alumina$
CC18$
16" 17" 18"
pel6er$
reactor$module$
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Procedure C: 
Step 1: The aqueous [18F]-fluoride was delivered from the cyclotron to the QMA cartridge by 
following the path 6, 7, 16, 17. The [18O]water was collected in a vial at the intersection 17. 
The [18F]-fluoride was dried for 80 seconds under nitrogen pressure. 
Step 2: The commercial Kryptofix solution (ABX) was eluted through the QMA cartridge 
and then transferred to the Peltier module in a V-shape glass vial at room temperature for 35 
seconds under reduced pressure (switching valves 5, 7, 16, 8, 9, 10, 12). 
Step 3: The Peltier module heated the reaction mixture at 70 °C for 50 seconds under 
negative pressure and for an additional 70 seconds under reduced and nitrogen pressure 
(switching valves 10, 12). The azeotropic distillation occurred at 55 °C with the elution of the 
dry acetonitrile (MeCN 1) under reduced pressure (switching valve 4, 9, 10, 12). The reaction 
mixture was heated at 95 °C for 50 seconds under negative pressure and for an additional 20 
seconds under reduced pressure and nitrogen flow (switching valves 1, 9, 10, 12). 
Step 4: The heated [K+⊂2.2.2]18F− complex (39 °C) was transferred to syringe A via the dry 
acetonitrile (1.5 mL) present in the MeCN 2 vial (switching valves 13, 14, 9). The mannose 
triflate dissolved in dry MeCN (1.5 mL) was transferred to syringe B (switching valve 15). 
Step 5: Both solutions were mixed together via a T-mixer. The reaction took place in the loop  
heated at 85 °C in the loop reactor. The overall flow rate of the radiolabeling was 14 µL/s 
(switching valves 14 and 15). The resulting mixture was transported into the reactor vial 
(switching valves 18, 16, 8, 9, 10, 12). 
Step 6: The deprotection step occurred at 50 °C in the Peltier module after the addition of the 
NaOH solution (1 M, 1 mL) for 50 seconds under reduced pressure (switching valves 3, 9, 
10, 12). The addition of distilled water (4 mL) to the crude mixture was performed by syringe 
A. The purification of this mixture through the alumina and C-18 cartridges was provided by 
using syringe A (switching valves 2, 9, 14).  
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Experiment 9 to 11 
Entry 
Activity received 
(GBq) 
Process time  
(min) 
Recovery of activity, decay-
corrected (%) 
9 1.1 30 68 
10 1.85 33 52 
11 1.1 30 64 
 
The 5 mL V-shape vial was replaced by a 7 mL flat PEEK vial. 
 
Procedure D: based on the procedure C, the reactions 9 to 11 were performed with a different 
Step 2. 
Step 2: The commercial Kryptofix solution (ABX) was eluted through the QMA cartridge 
and then transferred to the Peltier module in a flat bottom PEEK vial at room temperature for 
35 seconds under reduced pressure (switching valves 5, 7, 16, 8, 9, 10, 12). 
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9.5 Procedure for synthesis of peracetylated [18F]-deoxy-glucose 14 in segmented flow 
with presence of an ionic liquid. 
 
 
Entry 
Activity 
received 
(GBq) 
Process time  
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
12 3.3 38 69 5 
13 1.3 30 — 54 
 
Experiment 12 
 
Procedure E: 
Step 1: The aqueous [18F]-fluoride was introduced to the system via the F18 in path to the 
QMA cartridge (switching valves 6, 7, 8 and 9). At the end of the delivery the cartridge was 
dried over nitrogen flow for 50 seconds (switching valves 6, 1, 7, 8 and 9). 
Step 2: The commercial Kryptofix solution was withdrawn through the QMA cartridge and 
then to the reactor vessel under reduced pressure for 1 minute (switching valve 5, 7, 8, 10, 11 
and 12). 
 
QMA$
6" 5" 4"
7" 9"
13"
12"11"10"
3" 2" 1"
8"
14" 15"
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in$MeCN$
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Kryptoﬁx$
solu7on$
MeCN$1$
sA$ sB$
liquid$$
trap$
vacuum$$
pump$
pel7er$
reactor$module$
Product$
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Step 3: The [K+⊂2.2.2]18F− complex was heated at 100 °C under reduced pressure for 50 
seconds (switching valves 11 and 12). The drying process continued with the addition of a 
nitrogen pressure into the reactor vial for 70 seconds (switching valves 1, 10, 11 and 12). 
Step 4: The acetonitrile was driven into the 50 °C reactor vial by using a negative pressure 
(switching valves 4, 10, 11 and 12). The reaction mixture was then heated at 110 °C under 
reduced pressure for 80 seconds (switching valves 11 and 12). The temperature was 
increased to 120 °C for 1 minute. An additional 80 seconds of drying was performed under 
negative and nitrogen flow (switching valves 1, 10, 11 and 12). 
Step 5: The mannose triflate solution in dry acetonitrile (1.5 mL) with BMI(OTf) (300 µL, 
1.6 mmol) was added into the reactor vessel heated at 43 °C by syringe A. The reaction 
mixture was then withdrawn into syringe A (switching valves 13, 14 and 10). Syringe B was 
filled with nitrogen gas (switching valves 1 and 15). 
Step 6: The two phases were injected simultaneously to the loop heated at 95 °C with an 
overall flow rate of 14 µL/s. 
 
 
Experiment 13 
 
Procedure F: based on the procedure E, the reaction 13 was performed with a different Step 
4. 
Step 4: The acetonitrile was driven into the 50 °C reactor vial by using a negative pressure 
(switching valves 4, 10, 11 and 12). The reaction mixture was then heated at 110 °C under 
reduced pressure for 80 seconds (switching valves 11 and 12). The temperature was 
increased to 125 °C for 1 minute. An additional 80 seconds of drying was performed under 
negative and nitrogen flow (switching valves 1, 10, 11 and 12). 
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9.6 Segmented technique used for [18F]-fluorination of mannose triflate 9 performed 
in different loop sizes. 
 
 
Entry 
Activity 
received 
(GBq) 
Process time  
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
14 1.2 35 40 54 
 
Procedure F: 
Step 1: The aqueous [18F]-fluoride was introduced to the system via the "F18 in" path to the 
QMA cartridge (switching valves 6, 7, 16, and 17). At the end of the delivery, the cartridge 
was dried over nitrogen flow for 50 seconds (switching valves 6, 1, 7, 16 and 17). 
Step 2: The Kryptofix solution was withdrawn through the QMA cartridge and then to the 
reactor vessel under reduced pressure for 1 minute (switching valve 5, 7, 16, 8, 10, 11 and 
12). 
 
QMA$
6" 5" 4"
7" 9"
13"
12"11"10"
3" 2" 1"
8"
14" 15"
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mannose$$
triﬂate$
$in$MeCN$
pressure$
ac5vity$
Kryptoﬁx$
solu5on$ MeCN$1$
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vacuum$$
pump$
pel5er$
reactor$module$
Product$
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Step 3: The [K+⊂2.2.2]18F− complex was heated at 120 °C under reduced pressure for 50 
seconds (switching valves 10 and 12) and for an additional 70 seconds under negative and 
nitrogen pressure (switching valves 10, 12, 1 and 10). The dry acetonitrile (1 mL, MeCN 1) 
placed above the intersection 4 was driven into the reactor vial heated at 80 °C for 15 seconds 
under negative pressure (switching valves 5, 9, 10 and 12). The reaction mixture was heated 
at 110 °C over 80 seconds and for an additional 1 minute at 130 °C under reduced pressure 
(switching valves 10 and 12). The azeotropic distillation carried on at the same temperature 
for 80 seconds under reduced pressure and nitrogen flow (switching valves 1, 9, 10, 11 and 
12). 
Step 4: The mannose triflate solution in dry acetonitrile (1.5 mL) was added into the reactor 
vessel heated at 43 °C by syringe A. The reaction mixture was then withdrawn into syringe A 
(switching valves 13, 14 and 10). Syringe B was filled with nitrogen gas (switching valves 1 
and 15). 
Step 5: The two phases were injected simultaneously into the PEEK loop (length = 3 m, ∅ = 
0.5 mm) heated at 100 °C with an overall flow rate of 14 µL/s. 
 
 
Experiment 15 
Entry 
Activity 
received 
(GBq) 
Process time  
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
15 1.2 102 21 74 
 
Procedure G: based on the procedure F, the reaction 15 was performed with a different Step 
5. 
Step 5: The two phases were injected simultaneously into the first PEEK loop (length = 3 m, 
∅ = 0.5 mm) heated at 100 °C. Then the reaction mixture passed through the second PEEK 
loop (length = 3 m, ∅ = 0.5 mm) directly connected at one edge of the first loop and heated 
at 75 °C in a water bath. The overall flow rate of the reaction was 14 µL/s.  
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Experiment 16 
 
Entry 
Activity 
received 
(GBq) 
Process time  
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
16 1.2 36 27 62 
 
Procedure H: based on the procedure G, the reaction 16 was performed with a different Step 
5. 
Step 5: The two phases were injected simultaneously into a longer and smaller PEEK loop 
(length = 5 m, ∅ = 0.01 mm) heated at 100 °C. The overall flow rate of the reaction was 14 
µL/s. 
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9.7 Semi-automated radiosynthesis performed with the minimum of check valves  
 
c  
The configuration of the synthesiser was modified by using one new module (Hamilton 
device), check valves (C V) and luer connectors. 
 
 
Experiment 17 
Entry 
Activity 
received 
(GBq) 
Process time  
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
17 1.5 36 67 36 
 
Procedure I: 
Step 1: The aqueous [18F]-fluoride was eluted through the QMA cartridge via a nitrogen 
stream applied on the top of the vial having the radioactivity (F18 in). The [18O]-water was 
OAcOAcO OAc
OAc
OTf
CH3CN, Δ
  [K+⊂2.2.2]18F−
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OAc
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9 14
CH3CN/H2O
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driven to the waste vial by using a nitrogen flow (e). This sequence was performed over 105 
seconds. The QMA cartridge was dried over a nitrogen (K222 and e) flow for 270 seconds. 
Step 2: The Kryptofix solution was driven through the QMA cartridge and into the reactor 
vial (5 mL, PP) under nitrogen flow and reduced pressure directly applied from the K222 vial 
and from the reactor vial, respectively. This elution took place for 15 seconds and the reactor 
vial was heated to 50 °C. 
Step 3: The azeotropic distillation started with the addition of 1 mL of dry acetonitrile to the 
reactor vial under reduced pressure and nitrogen flow (a) for 15 seconds. The reaction 
mixture was heated to 95 °C over 105 seconds under nitrogen (c) and reduced pressure. 
Another 1 mL of acetonitrile was added into the reactor vessel still heated at 95 °C. The 
solvents were evaporated for 150 seconds under reduced pressure and nitrogen (b and c) 
flow. 
Step 4: The mannose triflate solution in dry acetonitrile (1.2 mL) was added into the reactor 
vessel heated at 85 °C under reduced pressure and nitrogen (d) stream for 20 seconds. The 
reaction mixture was heated at 90 °C over 180 seconds under both reduced and nitrogen (c) 
pressure. 
 
 
Experiments 18 and 19 
 
 Some luer connectors were replaced by a 1-way cassette to drive away the [18O]-
water and to perform the elution of [K+⊂2.2.2]18F− complex into the reactor vial. Two 
Tefzel® tees were connected to the mannose triflate vial and the aqueous solution of NaOH 
by replacement of luer connectors. 
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1. CH3CN, Δ
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  [K+⊂2.2.2]18F−
OHOHO OH
OH
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Entry 
Activity 
received 
(GBq) 
Process time  
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
18 1.5 109 85 19 
19 0.9 32 44 91 
 
Procedure J: 
Step 1: The aqueous [18F]-fluoride was eluted through the QMA cartridge via a nitrogen 
stream applied on the top of the vial containing the radioactivity (F18 in). The [18O]-water 
was driven to the waste vial by using a nitrogen flow (e). This sequence was performed over 
105 seconds. The QMA cartridge was dried over a nitrogen (K222 and e) flow for 270 
seconds. 
Step 2: The Kryptofix solution was driven to the QMA cartridge and into the reactor vial (5 
mL, glass and flat) under nitrogen flow and reduced pressure directly applied from the K222 
vial and from the reactor vial, respectively. This elution took place for 15 seconds and the 
reactor vial was heated to 50 °C. 
Step 3: The azeotropic distillation started with the addition of 1 mL of dry acetonitrile to the 
reactor vial under reduced pressure and nitrogen flow (a) for 15 seconds. The reaction 
mixture was heated to 105 °C over 240 seconds under nitrogen (c) and reduced pressure. 
Another 1 mL of acetonitrile was added into the reactor vessel and the solvents were 
evaporated for 1 minute under reduced and nitrogen (b and c) flow at 90 °C. 
Step 4: The mannose triflate solution in dry acetonitrile (1 mL) was added to the reactor 
vessel heated at 85 °C under reduced pressure and nitrogen (d) stream for 20 seconds. The 
reaction mixture was heated at 100 °C for 300 seconds under both reduced and nitrogen (c) 
pressure. 
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Experiment 20 
 
 
 
Entry 
Activity 
received 
(GBq) 
Process time  
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
20 1.4 26 37 74 
 
Procedure K: based on the procedure J, the reaction 20 was performed with a different Step 
3. 
Step 3: The evaporation of the solvents occured at 105 °C for 390 seconds under reduced and 
nitrogen (e) flow and for an additional 210 seconds at 110 °C.  
 
 
Experiment 21  
 
 The 5 mL flat glass reactor vial was replaced by a 5 mL flat plastic vial (PP). 
 
Entry 
Activity 
received 
(GBq) 
Process time  
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
21 1.2 29 20 26 
 
[18F]$in$
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N2$
[18O]3water$$
N2$
IC3H$$
cartridge$NaOH$$
(3$M,$5$mL)$
mannose$
triﬂate$
Kryptoﬁx$
soluMon$
tefzel®$cross$
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Procedure L: based on the procedure K, the reaction 21 was performed with a 5 mL plastic 
flat vial (PP) instead of a 5 mL glass vial. 
 
Experiment 22 and 24  
Entry 
Activity 
received 
(GBq) 
Process time  
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
22 1.1 32 59 20 
23 1.0 27 57 32 
24 1.2 28 35 72 
 
Procedure M: based on the procedure K, the reactions 22 to 24 were performed with the 
nitrogen input c directly connected through the seal of the reactor vial. 
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9.8 Radiolabeling syntheses performed with a Kryptofix solution prepared with 100 
µL of deionised water 
 
 
 
Entry 
Activity 
received 
(GBq) 
Process time  
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
25 1.1 32 50 66 
26 1.5 32 59 70 
27 1.6 30 59 79 
28 0.9 29 54 50 
 
Experiments 25 to 27 
Procedure N: 
Step 1: The elution of the aqueous [18F] proceeded at room temperature for 2 minutes. Two 
flows of nitrogen (g and f) were applied to guide the [18F]-fluoride and the [18O]-water to the 
QMA cartridge. The [18O]-water continued to the [18O]-water waste vial. 
Step 2: The elution of the [18F]-fluoride was performed by the prepared Kryptofix solution to 
the heated reactor vial (65 °C). A nitrogen flow (K[222]) and negative pressure (vacuum) 
were used. 
Step 3: The azeotropic distillation started with the addition of 500 µL of dry acetonitrile to 
the reactor vial under reduced pressure and nitrogen flow (a) for 15 seconds. The reaction 
mixture was heated to 105 °C over 360 seconds under reduced pressure. The [K+⊂2.2.2]18F− 
complex was dried for an additional 240 seconds under both reduced and nitrogen (c) 
pressure. 
Step 4: The radiolabelling occurred at 50 °C with the transfer of the mannose triflate solution 
in dry MeCN (1.2 mL) to the reactor vessel by flows of nitrogen (d and c). The reactor vessel 
was then heated at 105 °C for 240 seconds under nitrogen pressure (e). At similar 
OAcOAcO OAc
OAc
OTf
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2. NaOHaq, Δ
  [K+⊂2.2.2]18F−
OHOHO OH
OH
18F
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CH3CN/H2O
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temperature, the procedure continued with negative (vacuum) and positive (e) pressure for 
180 seconds. 
Step 5: The aqueous solution of NaOH (3 M, 3 mL) was transported to the reactor vessel 
heated at 55 °C by nitrogen flow (b and c). The hydrolysis took place over 3 minutes. The 
elution of the crude mixture to the IC-H cartridge and then to the product vial was performed 
via nitrogen flow (e). 
 
Experiment 28 
 
Procedure O: based on the procedure K, the drying process of the reactions 28 was performed 
without addition of dry acetonitrile (500 µL). 
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9.9 Semi-automated E&Z platform using anhydrous Kryptofix solution 
 
The Kryptofix solution was prepared with K[2.2.2] (24 mg, 63.7 µmol), K2CO3 (4 mg, 
28.9 µmol) in anhydrous MeOH (600 µL). The mannose triflate (25 mg, µmol) in dry 
CH3CN (1.1 mL).  
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Entry 
Activity 
received 
(GBq) 
Process time 
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
31 1.6 28 33 73 
32 1.2 30 39 50 
33 1.6 34 55 32 
 
Experiment 31 
 
Procedure P: 
Step 1: The elution of the aqueous [18F] proceeded at room temperature for 2 minutes. Two 
flows of nitrogen (g and f) were applied to guide the [18F]-fluoride and the [18O]-water to the 
QMA cartridge. The [18O]-water continued to the to the [18O]-water waste vial. 
Step 2: The elution of the [18F]-fluoride was performed by the Kryptofix solution to the 
heated reactor vial (65 °C). A nitrogen flow (K[222]) and negative pressure (vacuum) were 
used. 
Step 3: The drying process commenced at 105 °C for 200 seconds under flow of nitrogen (e). 
The sequence carried on at 110 °C under reduced pressure (vacuum) for 90 seconds and 
finished at 110 °C under flow of nitrogen (e) and reduced pressure (vacuum) for 130 seconds. 
Step 4: The radiolabelling occurred at 50 °C with the transfer of the mannose triflate solution 
in dry MeCN (1 mL) to the reactor vessel by flows of nitrogen (d and c). The reactor vessel 
was then heated at 105 °C for 100 seconds under nitrogen pressure (e). At similar 
temperature, the procedure continued with negative (vacuum) and positive (e) pressure for 2 
minutes seconds. 
Step 5: The aqueous solution of NaOH (3 M, 3 mL) was transported to the reactor vessel 
heated at 65 °C by nitrogen flows (b and c). The elution of the crude mixture to the IC-H 
cartridge and then to the product vial was performed via nitrogen flow (e).  
Experiment 32 
Procedure Q: based on the procedure M, the reaction 32 was performed with different steps 3 
and 4. 
Step 3: The drying process was commenced at 105 °C for 3 minutes under flow of nitrogen 
(e). The sequence carried on at 110 °C under reduced pressure (vacuum) for 100 seconds and 
finished at 110 °C under flow of nitrogen (e) and reduced pressure (vacuum) for 100 seconds. 
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Step 4: The radiolabelling occurred at 50 °C with the transfer of the mannose triflate solution 
in dry MeCN (1 mL) to the reactor vessel by flows of nitrogen (d and c). The reactor vessel 
was then heated at 95 °C for 160 seconds under nitrogen pressure (e). At similar temperature, 
the procedure continued with negative (vacuum) and positive (c) pressure for 100 seconds 
and the input of nitrogen pressure was replaced by the one placed on the top of the reactor 
vessel (e) for 2 minutes. 
 
Experiment 33 
Procedure R: based on the procedure M, the reaction 33 was performed with different steps 3 
and 4. 
Step 3: The drying process commenced at 105 °C for 3 minutes under flow of nitrogen (e). 
The sequence carried on at 110 °C under reduced pressure (vacuum) for 100 seconds and 
finished at 110 °C under flow of nitrogen (e) and reduced pressure (vacuum) for 2 minutes. 
Step 4: The radiolabelling occurred at 50 °C with the transfer of the mannose triflate solution 
in dry MeCN (1 mL) to the reactor vessel by flows of nitrogen (d and c). The reactor vessel 
was then heated at 95 °C for 160 seconds under nitrogen pressure (e). At 105 °C, the 
procedure continued with negative (vacuum) and positive (c) pressure for 2 minutes and the 
input of nitrogen pressure switched by the one placed on the top of the reactor vessel (e) for 2 
minutes. 
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11 Low concentration of water for Kryptofix solution 
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Entry 
Activity 
received 
(GBq) 
Process time  
(min) 
Recovery of 
activity, decay-
corrected (%) 
Radiochemical 
conversion 
(%) 
34 1.6 32 ⎯ 82 
35 1.5 28 48 8 
36 1.7 29 53 67 
37 0.4 26 20 84 
38 2.0 28 56 77 
39 1.5 33 89 25 
 
Experiment 34 
 
Procedure S: 
Step 1: The aqueous [18F-fluoride] was eluted from the "F18 in" vial to the QMA cartridge 
via nitrogen flow applied directly to the "F18 in" vial (activity) for 1 minute. The [18F] was 
loaded in the QMA cartridge and the [18O]-water was collected in the [18O]-water waste vial 
by nitrogen pressure (f) for 1 minute. 
Step 2: The Kryptofix solution was transferred through the QMA cartridge to unload the 
[18F]-fluoride and to the reactor vessel heated at 65 °C (30 seconds). 
Step 3: The drying process commenced at 105 °C under nitrogen flow (e) for 250 seconds. At 
90 °C the dry acetonitrile (500 µL) was transported to the reactor vial for 15 seconds. The 
reaction mixture was then heated at 105 °C under vacuum for 100 seconds and for an 
additional 2 minutes under vacuum and nitrogen flow (e). 
Step 4: The mannose triflate in 1 mL of acetonitrile replaced the empty acetonitrile vial used 
in Step 3. The mannose triflate was then transferred to the reactor vial heated at 65 °C. The 
crude mixture was heated at 95 °C under nitrogen flow (e) for 200 seconds. An additional 
140 seconds was performed at 105 °C under negative pressure and nitrogen flow (c). 
Step 5: Cooled at 55 °C, the NaOH solution (3 M, 3 mL) was added to the reaction mixture 
(40 seconds) by an applied nitrogen pressure (d). Afterwards the solution was mixed under 
nitrogen pressure (e) for 1 minute. The reaction was eluted through the IC-H cartridge and to 
the product vial via nitrogen pressure (e). The empty NaOH vial was replaced by a 4 mL 
distilled water vial. The water was injected to the reactor vial by using nitrogen pressure (d 
and c) for 80 seconds. The water was collected to the product vial by an applied nitrogen 
pressure (e). 
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Step 6: The product mixture was placed in the sleeve of the dose calibrator to detect the level 
of radioactivity. The reaction was monitored by radio-TLC to obtain the conversion of the 
[18F]-FDG 1. 
 
 
Experiment 35 
 
Procedure T: based on the procedure P, the reaction 35 was performed with a different step 5. 
Step 5: Cooled at 55 °C, the NaOH solution (3 M, 3 mL) was added to the reaction mixture 
(35 seconds) by an applied nitrogen pressure (d). Afterwards the solution was mixed under 
nitrogen pressure (e) for 50 seconds. The reaction was eluted through the IC-H cartridge and 
to the product vial via nitrogen pressure (e). The empty NaOH vial was replaced by a 4 mL 
distilled water vial. The water was injected in the reactor vial by using nitrogen pressure (d 
and c) for 1 minute. The water was collected to the product vial by using an applied nitrogen 
pressure (e) for 80 seconds. 
 
 
Experiment 36 
 
Procedure U: based on the procedure Q, the reaction 36 was performed with different steps 1, 
4 and 5. 
Step 1: The aqueous [18F-fluoride] was eluted from the "F18 in" vial to the QMA cartridge 
via nitrogen flow applied directly to the "F18 in" vial (activity) for 1 minute. The [18F] was 
loaded in the QMA cartridge and the [18O]-water was collected in the [18O]-water waste vial 
by nitrogen pressure (f) for 2 minutes. 
Step 4: The mannose triflate solution (1 mL acetonitrile) was connected to the system to be 
flowed to the reactor vial heated at 65 °C by nitrogen flows (c and d). Once transferred, the 
mixture was heated at 70 °C for 1 minute under nitrogen pressure (e). An additional 100 
seconds at 95 °C was performed under nitrogen flow (e). The solution mixture was then 
heated at 105 °C with both vacuum and nitrogen pressure (c) for 100 seconds. 
Step 5: Cooled at 55 °C, the NaOH solution (3 M, 3 mL) was added to the reaction mixture 
(35 seconds) via a nitrogen pressure (d). Afterwards the solution was mixed under nitrogen 
pressure (e) for 40 seconds. The reaction was eluted through the IC-H cartridge and to the 
product vial via nitrogen pressure (e). The empty NaOH vial was replaced by a 4 mL distilled 
water vial. The water was injected to the reactor vial by using nitrogen pressure (d and c) for 
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40 seconds. Afterwards, the water was collected to the product vial via an applied nitrogen 
pressure (e) for 40 seconds. 
 
 
Experiment 37: 
 
Procedure V: based on the procedure R, the reaction 37 was performed with a different step 
4. 
Step 4: The mannose triflate solution (1 mL acetonitrile) was connected to the system to be 
flowed to the reactor vial heated at 65 °C by nitrogen flows (c and d). Once transferred, the 
mixture was heated at 90 °C for 1 minute under nitrogen pressure (e). An additional 100 
seconds at 95 °C was performed under nitrogen flow (e). The solution mixture was then 
heated at 105 °C with both vacuum and nitrogen pressure (c) for 100 seconds. 
 
 
Experiment 38 and 39 
 
Procedure W: based on the procedure S, the reaction 38 and 39 were performed with 
different steps 1 to 3. 
Step 1: The aqueous [18F-fluoride] was eluted from the "F18 in" vial to the QMA cartridge 
via nitrogen flow applied directly to the "F18 in" vial (activity) for 1 minute. The [18F] was 
loaded in the QMA cartridge and the [18O]-water was collected in the [18O]-water waste vial 
by nitrogen pressure (f) for 3 minutes. 
Step 2: The Kryptofix solution was transferred through the QMA cartridge by using a 
nitrogen pressure (K222) and vacuum. The nitrogen pressure was stopped after 1 second and 
the [K+⊂2.2.2]18F− complex was transported to the heated reactor vial (65 °C) by the applied 
reduced pressure (vacuum) for 30 seconds. 
Step 3: The drying process commenced at 105 °C under nitrogen flow (e) for 250 seconds. 
The dry acetonitrile (500 µL) was transported to the reactor vial heated at 90 °C for 15 
seconds. The reaction mixture was then heated at 105 °C under vacuum for 1 minutes and 40 
seconds and for an additional 1 minute and 40 seconds under vacuum and nitrogen flow (e).  
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